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Abstract 
New chemical scaffolds are needed to inspire the development of new chemotherapeutics to treat 
evolving pathogens. Despite hurdles facing natural product biodiscovery paradigms, recent advances 
in microbial genomics showed their potential to produce diverse metabolites more than estimated. 
This thesis is focused on exploration of the chemical diversity of microorganisms obtained from 
animal (sheep and fish) gastrointestinal tract content and in-house Australian Collection of 
Microorganisms (ACM) through applying two strategies (i) bioassay-guided biodiscovery, and (ii) 
variation of culture conditions. Microbial metabolites were purified using different chromatographic 
techniques such as SPE fractionation, size exclusion chromatography, semi-preparative, and 
preparative HPLC. In addition, different spectroscopic methods (UV-vis, HRMS, [a]D, circular 
dichroism (CD), 1D and 2D NMR), total synthesis, semi-synthesis, and chemical derivatization (C3 
Marfey’s method) were utilized for structure elucidation of isolated metabolites. 
 
Chapter 1 highlights the importance of natural products especially the microbial natural products to 
enrich the chemical space with high hit-to-lead ratio. The chapter also gives an overview of the 
common challenges encountering microbial biodiscovery and selected opportunities to overcome 
them and access new chemical diversity. 
 
Chapter 2 outlines the construction of (i) microbial libraries from faecal samples of sheep infected 
with Haemonchus contortus nematode and gastrointestinal tract (GIT) content of Mugil mullet fish 
obtained from local commercial market and (ii) an extract library obtained from solid vs liquid-based 
cultivations. It also describes the chemical and biological profiling of the obtained crude extract 
library, and strains prioritization. This chapter also discusses bioassay-guided approach through the 
isolation and characterization of bioactive metabolites of three strains prioritized for the biological 
properties of their crude extracts. 
 
Chapter 3 describes an example of the chemical diversity of fish gastrointestinal tract microbiota. It 
illustrates the chemical investigation of Evlachovaea sp. CMB-F563 sourced from gastrointestinal 
tract of mullet fish leading to the isolation of thirteen metabolites belonging to different chemical 
classes. The structures were assigned on the basis of detailed spectroscopic analysis, total synthesis, 
semi-synthesis, analytical studies, and biosynthetic considerations. 
 
Chapter 4 describes the method development for the detection of the putative biosynthetic precursors 
of prolinimines A and B, N-amino-L-Pro hydrazinyl Schiff bases isolated from CMB-F563 in Chapter 
  iii 
3, that revealed N-amino-L-Pro methyl ester as the genuine natural product. This chapter discusses 
our concerns about the definition of natural products and artefacts. Additionally, it describes the 
synthesis, hydrolytic stability, and biological properties of a series of N-amino-L-Pro methyl ester 
Schiff bases. 
 
Chapter 5 demonstrates the effect of varying culture conditions (MATRIX) on the secondary 
metabolism of a fungus isolated from the gastrointestinal tract of mullet fish, Metarhizium sp. CMB-
F624. Scale-up cultivation of CMB-F624 on rice solid medium afforded seven metabolites including 
three new macrocycles, metarhizolides A–C, together with two new 4'-O-methyl glucosides, 
metarhizides A and B. The structures were assigned on the basis of detailed spectroscopic analysis, 
and chemical derivatization (C3 Marfey’s analysis). The isolated metabolites were evaluated for 
cytotoxic properties against cancer cell lines and none showed cytotoxic activity. 
 
Chapter 6 illustrates the efficiency of varying culture conditions (MATRIX) in inducing the 
production of new antibacterial biantharyl atropisomers, lincolnenins, in Streptomyces lincolnensis 
ACM-4234. Analytical scale cultivations (under 34 different culture conditions) identified ISP2 broth 
shaken and oatmeal agar as the only conditions for production of lincolnenins with the latter as the 
optimum culture condition for scale-up cultivation. The planar structures of four biantharyl 
atropisomers, lincolnenins A and C–E, were elucidated by extensive analysis NMR spectroscopic 
data. The absolute configuration of lincolnenin A was fully assigned by ECD calculation. Lincolnenin 
A and C displayed good antibacterial activity against Gram-positive bacteria (IC50 1.3-4.1 µM) with 
no cytotoxic properties against cancer cell lines. 
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Chapter 1 Microbial Biodiscovery: challenges and opportunities 
1.1 Natural products (NPs) as a source of drugs and drug leads 
Nature has played a vital role to address the basic requirements of humans especially in providing 
medicines for the treatment of a range of diseases such as bacterial and parasite diseases and cancers. 
The reliance on nature as a source of medicinal products has passed through several stages of 
development from the use of raw drugs, especially plant-derived materials, in ancient era as in 
Mesopotamia and old Egypt, to drug formulations of bioactive pure compounds these days.1  
Nowadays, there is a massive need for novel and effective drugs to combat diseases in humans, 
animals and plants. There are three sources of drugs and drug leads: natural products, natural product 
derivatives (semisynthetic) and synthetic compounds. Natural products are biosynthesized by living 
cells of plants, microorganisms (fungi and bacteria), or marine organisms either as primary 
metabolites or as specialized (secondary) metabolites.2 Most of these metabolites have specialized 
roles and are physiologically bioactive.3 Moreover, there is a common agreement that the chemical 
diversity offered by synthetic and combinatorial chemical libraries is not sufficient to provide the 
required number of quality hits for hit-to-lead 
programs in drug discovery due to the lack of 
biocompatibility compared to natural 
products.4  
In 2016, a review noted that 50 % of new 
small-molecule drugs approved from 1981 to 
2014 by FDA were either natural products or 
compounds related to them (Figure 1.1).5 This 
provides an evidence that natural products still 
play a major role in the discovery of drugs and 
drug leads. Thus, connecting Nature to 
combinatorial synthetic techniques is vital to 
surge the number of developed drugs. 
 
1.2 Microbial natural products (MNPs) 
Plants and microorganisms are considered the main sources of natural products. One of the 
advantages of microbes is their remarkable adaptability to survive in diverse ecological 
environments, from terrestrial to marine habitats, and their unique chemical diversity. Another 
advantage is that of being renewable. Microbes can be cultured and scaled-up in the 
laboratory/factory which gives them an advantage over plants that need field collection and are 
protected under the Convention on Biological Diversity.6 In 2012, Bérdy showed that the percentage 
Figure 1.1. Sources of small molecule drugs approved by 
FDA from 1981 to 2014.5 N; an unmodified natural product, 
NB; a natural product botanical, S; a synthetic compound with 
no natural product conception, S*, S*/NM; a synthetic 
compound with a natural product pharmacophore (/NM 
indicates competitive inhibition), and S/NM; a synthetic 
compound showing competitive inhibition of natural product 
substrate 
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of bioactive microbial metabolites comprises about 47% of the total number of known microbial 
metabolites.7 Most importantly, many of these metabolites showed potent and highly selective 
biological properties that have inspired and fueled a revolution in modern healthcare and agriculture. 
Reviews have been published showing the significance of microbial metabolites as a reliable source 
of medicines including, but not limited to, antibiotics (e.g. penicillin, erythromycin and daptomycin 
(1.01)), antitumor drugs (e.g. calicheamicins), hypocholesterolemics (e.g. lovastatin (1.02)), 
immunosuppressants (e.g. rapamycin (1.03)), antiparasitics (e.g. avermectins (1.04)), insecticides 
(e.g. pogonins) and herbicides (e.g. bialaphos).1,8 
 
 
Despite the aforementioned impact of microbes as a valuable source of drugs and drug leads, the 
biodiscovery process has been confronted by various challenges that led to a decline in the discovery 
of new chemical scaffolds. 
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1.3 Challenges facing microbial biodiscovery 
The late 20th century and early current century witnessed the abandonment of major pharmaceutical 
companies of their natural product discovery programs and their switch to combinatorial chemistry 
(CombiChem).9,10 In 2015, a survey conducted on representatives from industry and academia 
attributed this switch to cost and/or funding, structural complexity of NPs, and limited supply of 
natural sources. Respondents from industry also pointed high-throughput screening (HTS) to be their 
preferred drug discovery strategy because it facilitates the screening of large number of pure synthetic 
libraries and is cost-effective leading to a reduced cost/risk ratio compared to biodiscovery paradigm 
from natural sources.11 
Other challenges include the recurrent isolation of well-known metabolites,12 the inability to culture 
all microbial isolates from an environmental sample (it is estimated that less than 1% of microbes are 
culturable under laboratory conditions),13-16 and the presence of cryptic “silent” biosynthetic gene 
clusters (BGCs) that was determined by the recent advances in whole-genome sequencing of 
microbes.17-23 These gene clusters are cryptic under standard cultivation conditions and remain 
dormant until an apt signal induces their expression and the corresponding metabolites are produced. 
It is now obvious that most of the microbes have the ability to produce a far greater number of 
metabolites than have been explored previously.17-23 
 
1.4 Opportunities to hustle microbial biodiscovery 
The re-isolation of commonly identified metabolites and hurdles to access new chemical diversity 
are observed as major issues facing microbial biodiscovery.24 A number of reviews25-28 discussed the 
possible approaches for induction of microbial secondary metabolites which could be subdivided into 
approaches that do require prior knowledge of genetic material of microorganism (e.g. genome 
mining and heterologous expression) and others do not (Figure 1.2). A number of selected 
opportunities that do not necessarily require previous knowledge of genetic sequences are discussed 
with examples below (Figure 1.3). 
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Figure 1.2. Possible methods to access chemodiversity of microorganisms29 
 
 
 
Figure 1.3. A diagram of selected opportunities to avoid re-isolation of known metabolites and access new chemistry 
 
1.4.1 Opportunity 1: Chemical dereplication 
Dereplication has become a matter of great interest in recent years to prevent spending efforts on 
isolation of known metabolites as well as to focus resources on the new metabolites. Advances in 
technology offered hyphenated techniques that can be used as dereplication tools.30-32 The commonly 
followed techniques compose of a detection technique coupled to liquid chromatography (HPLC or 
UHPLC) such as LC-DAD, LC-MS, LC-NMR, or LC-NMR-MS linked to multivariate statistical 
data analysis tools as principal component analysis (PCA) and cluster analysis. The aforementioned 
techniques relied on the fact that similar molecules share similar physical characteristics as UV-vis 
spectra, retention times or NMR chemical shifts. LC-HRMS-PCA has been a successful application 
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in microbial grouping based on the chemical diversity of their metabolites for prioritizing microbial 
isolates for drug biodiscovery.33,34 Lately, MS/MS-based dereplication has been regarded as more 
accurate method for identification of known metabolites as similar metabolites share similar MS/MS 
fragmentation pattern. Molecular networking such as The Global Natural Product Social Molecular 
Networking (GNPS) has also emerged as a tool to cluster structurally-related molecules together 
based on their MS/MS profiles.35,36 As a result, chemical dereplication is relying on advances in 
instrumentation to create high quality data that can be manipulated to a visual representation to detect 
known metabolites. 
1.4.2 Opportunity 2: Animal gastrointestinal microbiota 
In search for chemical diversity of microorganisms, special attention should be given to their 
environmental source. In competitive environments, the microorganisms have to edit their metabolic 
pathways to accommodate with the surrounding ecosystem in order to survive. In addition to their 
ability to replace a part of their genomes leading to the production of chemically diverse secondary 
metabolites.37  
For many years, microbiologists and natural product chemists worked on exploring various 
environmental sources, especially under-represented sites, as sources of potential microbes and 
subsequently new compounds. Examples of microbial sources include but are not limited to terrestrial 
soil, marine (e.g. Arctic and Anataractic waters, deep-sea sediment, sponge, tunicates, corals, 
mangroves, mollusc, and snails), insects (e.g. termite, spiders, wasp, and bee), and plants. However, 
it is important to declare the cosmopolitan nature of the majority of microbes, being able to survive 
in different environments, with few exceptions such as the genus Salinospora which is limited to 
marine environment.38 Animal gastrointestinal tract (GIT) have emerged as a new environment to 
harbor microbes.39,40 Here we list examples of secondary metabolites derived from fish GIT. 
Examples of secondary metabolites isolated from bacteria sourced from fish GIT included three 2,5-
diketopiperazines 1.05–1.07 from Streptomyces sp. isolated from Katsuwonus sp. fish,33 an 
antibacterial lipid sebastenoic acid (1.08),39 and halichomycin (1.09)41 from Streptomyces 
hygroscopicus from Halichoeres bleekeri fish. While, secondary metabolites isolated from fungi 
sourced from fish GIT included fumiquinazolines A–G (1.10–1.16) isolated from Aspergillus 
fumigatus sourced from Pseudolabrus japonicus fish,42,43 perinadine A (1.17),44 and scalusamides A–
C (1.18–1.20)45 from Penicillium citrinum isolated from parrot fish, twenty seven chaetomugilin 
azaphilones46-53 (e.g. chaetomugilin A (1.21)) isolated from Chaetomium globosum from Mugil 
cephalus, and fellutamides A (1.22) and B (1.23) from Penicillium fellutanum from Apogon 
endekataenia. 
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1.4.3 Opportunity 3: Variation of media composition 
Culture conditions have a dramatic effect on secondary metabolism in microbes. Consequently, it is 
a challenge to find the optimal conditions for the production of secondary metabolites, which is 
unnecessary to be the prime conditions required for microbial growth. As the ecology of microbial 
community is still not well known, the optimal conditions have been based on trial and error. 
However, ‘OSMAC (One Strain Many Compounds) approach’ hypothesized by Bode et al54 has 
proved its success in inducing or maximizing the production titers of secondary metabolites. OSMAC 
approach has considered different culture parameters involving media composition (e.g. carbon or 
nitrogen source, salts, and amino acids), pH, aeration, and temperature with a recent review55 adding 
other approaches as chemical elicitation, epigenetic modification and co-culture under the umbrella 
of OSMAC approach. We found a fair number of applications of this approach and selected examples 
related to varying media composition factor are summarized below. 
The fungus Sphaeropsidales sp. was known to produce cladospirone bisepoxide, a 
spirobisnaphthalene compound. However, Bode et al56 described that culturing the same strain on 
altered cultivation conditions, different media, and cultivation vessels led to the isolation of additional 
fourteen compounds including eight new cladospirones B–I (1.24–1.31). Notably, the highest number 
of metabolites was produced when this strain was subjected to solid-phase cultivation in P flasks with 
wet oat grains as a single substrate.  
 
A study conducted by Hemphill et al57 on Fusarium tricinctum has found that replacing water of solid 
rice medium with different types of commercially available juices (banana, apple, and carrot) 
enhanced the production of new fusarielin J (1.32) (14-80 fold) and induced the production of known 
fusarielins A (1.33) and B (1.34) and new fusarielins K (1.35) and L (1.36). 
O O
O
OH
OH
OH
OOO
HOO
O
H
O O
O O
OO
OH
O
O OO
OH
OH
O
O O
OH
OH
OOO
HOHO
OH
H
OO
HOO OH
OH
OH
H
OO
HOO OH
OH
OH
cladospirone B (1.24) cladospirone C (1.25) cladospirone D (1.26) cladospirone E (1.27)
cladospirone F (1.28) cladospirone G (1.29) cladospirone H (1.30) cladospirone I (1.31)
 Chapter 1: Microbial Biodiscovery: challenges and opportunities 
 
8 
  
A study on the strictly anaerobic bacterium Clostridium cellulolyticum has indicated that imitating 
the natural cultural environment through addition of soil extract to the fermentation culture has 
induced the production of closthioamide (1.37), an exceptional polythioamide antibiotic with activity 
against methicillin-resistant Staphylococcus aureus (MRSA).58 
 
Although OSMAC approach showed its applicability without previous knowledge of genomic 
information, a study conducted on Aspergillus nidulans showed an example for the effectiveness of 
combining OSMAC and genomic approaches. The genome mining of Aspergillus nidulans has 
revealed the presence of a number of putative biosynthetic gene clusters. Aspergillus nidulans 
cultivated under diverse culture conditions such as rice medium led to the discovery of the novel 
alkaloids, aspoquinolones A–D (1.38–1.41) as well as aspernidines A (1.42) and B (1.43) when 
cultivated on malt medium.59 Another example was the isolation of coelichelin (1.44), a tris-
hydroxamate tetrapeptide iron siderophore, from Streptomyces coelicolor. Using genome mining 
approach, the structure of coelichelin (1.44) was proposed to be a tripeptide iron siderophore. 
Consequently, an iron depleted medium was chosen to induce the siderophore production was 
successful to isolate enough quantity. However, the isolated structure revealed to be a tetrapeptide 
which illustrates imperfections of genome mining approach.21 
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1.4.4 Opportunity 4: Biological elicitation 
Some biosynthetic gene clusters (cryptic) are expressed weakly, or not at all, when microbes are 
cultivated in pure monoculture, this may happen because many of the activating signals are absent, 
and the expression of corresponding metabolites is thus downregulated. There are many reports 
supporting the concept of biological elicitation of microbial secondary metabolism including co-
cultures, microbial cell lysates or biotic cell components.28,29 Selected examples of different 
biological elicitation are discussed below. 
Co-culture mimics the ecological situation where microorganisms exist within complex microbial 
communities. The structural diversity of secondary metabolites is believed to be the result of 
interspecies crosstalk between organisms occupying the same environment. In 2015, a review by 
Bertrand et al summarized different types and strategies of co-culture studies including bacterial-
bacterial, fungal-fungal and bacterial-fungal interactions with a fair number of examples of induced 
secondary metabolites during co-culture or mixed fermentation.29 
In 2013, a study conducted by Luti and Mavituna used a microbial cell lysate as biotic elicitor. This 
study indicated the production of undecylprodigiosin (1.45), an antibiotic with immunosuppressive 
characteristics, from Streptomyces coelicolor A3 was enhanced upon treatment with heat killed cells 
of either Bacillus subtilis or Staphylococcus aureus. However, this enhancement was not attributed 
to a specific elicitor as neither N-acetyl glucosamine nor peptidoglycan (cell wall components) 
induced the production of 1.45.60 
In 2014, Khalil et al reported the effect of the Gram-negative bacterial cell wall component 
lipopolysaccharide (LPS) as a natural chemical/biotic cue on the fungal secondary metabolism. For 
instance, treatment of Penicillium sp. ACM-4616 with LPS (0.6 ng/mL) enhanced the production of 
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pseurotin A (1.46) and activated the biosynthesis of both pseurotin A1 (1.47) and pseurotin A2 
(1.48).61 
 
 
1.4.5 Opportunity 5: Chemical reactivity of natural products 
Another opportunity to augment chemodiversity is the chemical transformation of natural products 
to artefacts. The chemical transformation may happen due to the high reactivity of the natural product 
during handling or purification. Selected examples of microbial artefacts experienced by the Capon 
group, along with elaboration of conditions responsible for their chemical transformation, are 
summarized below. 
Heronamides A–C (1.49–1.51) are unusual polyketides isolated from an Australian marine sediment-
derived Streptomyces sp. CMB-0406.62 Further study conducted by Booth et al63 to understand the 
biosynthesis of these metabolites proved that heronamides A (1.49) and B (1.50) could be obtained 
from their precursor heronamide C (1.51) through thermal [6p+4p] or photochemical [6p+6p] 
cycloadditions, respectively, without the involvement of biological catalysts (Figure 1.4).  
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Figure 1.4. Proposed mechanism for conversion of heronamide C (1.51) to heronamides A (1.49) and B (1.50) 
 
Quinolactacins are a rare class of N-methyl quinolone lactams derived from fungi. Quinlactacins A2 
(1.52), B2 (1.53), C2 (1.54) and A1 (1.55) were reisolated, together with the first-time isolation of 
quinolactacins B1 (1.56), C1 (1.57), D1 (1.58) and D2 (1.59), and the derivatives quinolonimide 
(1.60) and quinolonic acid (1.61) from an Australian soil-derived Penicillium citrinum MST-F10130. 
A series of decomposition experiments conducted by Clark et al64 found that quinolactacins A2 (1.52) 
and B2 (1.53) were the genuine natural products with all other co-metabolites being artefacts. A 
mechanism of this finding was explained by C-3 epimerization of quinolactacins A2 (1.52) and B2 
(1.53) to A1 (1.55) and B1 (1.56), respectively, under neutral or basic conditions. While C2 (1.54) 
and C1 (1.57) epimers, the oxidation products of A2 (1.52) and A1 (1.55), were tentatively proposed 
to undergo acid-mediated hydrolysis to quinolonimide (1.60) which in turn hydrolysed to quinolonic 
acid (1.61) under acidic conditions. Likewise, D1 (1.58) and D2 (1.59) were suggested to be the 
oxidation artefacts of undetected precursors (Figure 1.5). 
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Figure 1.5. Structures of isolated quinolactacins and their decomposition products. Overall scheme for decomposition of 
quinolactacin A2 (1.52) (green dashed box) 
 
Cytochalasins are hybrid polyketide synthase-non-ribosomal peptide synthase (PKS-NRPS) fungal 
metabolites. Shang et al65 isolated two known cytochalasins J (1.62) and H (1.63) together with the 
new analogues J1–J3 (1.64−1.66), H1 (1.67) and H2 (1.68) from an Australian marine sediment-
derived Phomopsis sp. CMB-M0042F. Cytochalasin J (1.62) was found to afford J1−J3 (1.64−1.66) 
by exposure to mild acidic conditions. A mechanism for this conversion was explained to occur either 
by dehydration of 1.62 at C-18-3oOH followed by SN1 addition of MeOH to afford 1.64 or non-
reversible elimination of C-18-3oOH to yield 1.65 which is prone to acid-mediated intramolecular 
cycloaddition to afford 1.66. Similarly, cytochalasin H (1.63) was found to undergo acid-mediated 
transformation to 1.67 and 1.68 (Figure 1.6). The metabolites 1.62, 1.63, 1.65, and 1.66 were 
considered natural products, being detected in the crude extracts, while 1.64, 1.67 and 1.68 were 
handling artefacts. 
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Figure 1.6. Proposed mechanism for acid-mediated transformation of cytochalasin J (1.62) to cytochalasins J1–J3 
(1.64−1.66) and of cytochalasin H (1.63) to H1 (1.67) and H2 (1.68). 
 
Reveromycins are spiroketal polyketides isolated from Streptomyces sp. with cytotoxic properties 
against fungal (Candia albicans) and mammalian cancer cell lines (KB and K562). Fremlin et al66 
isolated four known (1.69–1.72) and twelve new members of this class from Australian marine 
sediment derived and soil-derived Streptomyces sp. MST-MA568 and MST-RA7781, respectively. 
The isolated metabolites were categorized into (i) 6,6-spiroketals including hemi-succinate (1.69, 
1.71–1.73), 4¢-methyl esters of A, D, and E (1.76–1.78), hemi-fumarates H–J, and hemi-furanoates 
K–M, and (ii) 5,6-spiroketal hemi-succinate B, F and G (1.70, 1.74, and 1.75). The hemi-succinate 
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moiety of 6,6-spiroketal hemi-succinate reveromycins A, C–E (1.69, 1.71–1.73) was found to 
undergo intramolecular cyclization upon storage at 30 oC in HPLC eluate for 24 h after purification 
giving rise to ketal-succinyl species explaining the presence of minor contaminant peak. The authors 
proposed the uniqueness of this equilibrium, being limited to 6,6 spiroketals hemi-succinates, to the 
formation of a 7 membered ring linking the ketal-succinyl 1o-OH and the 6,6-spiroketal. 
Understanding the hemi-succinyl:ketal-succinyl equilibrium, the authors proposed that 4¢-methyl 
esters of A, D, and E (1.76–1.78) and 5,6-spiroketal hemi-succinate (1.70, 1.74, and 1.75) were indeed 
artefacts. The methyl esters were suggested to be formed by nucleophilic attack of MeOH solvent on 
the activated ketal-succinyl moiety while, 5,6-spiroketal hemi-succinate was attributed to the rotation 
of ketal-succinyl moiety bringing the primed carbonyl close to 6,6-spirketal system followed by ring 
opening (Figures 1.7 and 1.8). 
 
 
Figure 1.7. Structures of reveromycins A, C–E (1.69, 1.71–1.73) and proposed mechanism for the formation of 4'-methyl 
ester artefacts (1.76–1.78) 
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Figure 1.8. Proposed mechanism for the formation of 5,6-spiroketal artefacts (1.70, 1.74, and 1.75) 
 
Kibdelones are heterocyclic polyketides isolated from an Australian soil- derived Kibdelosporangium 
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proposed to start with air oxidation of kibdelone C (1.81) to kibdelone B (1.80) which undergo 
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Figure 1.9. Structures of kibdelones A–C (1.79–1.81) 
 
 
Figure 1.10. Proposed mechanism for equilibration of kibdelones A–C (1.79–1.81) 
 
 
Figure 1.11. Proposed mechanism for solvolysis of kibdelone B (1.80) to 25-methoxy-24-oxokibdelone C (1.82) 
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Shornephine A (1.83), belonging to the naturally uncommon diketomorpholine class, was isolated 
together with other diketopiperazines from an Australian marine sediment-derived Aspergillus sp. 
CMB-M081F.68 The use of MeOH in the fractionation process led to isolation of seco-shornephine 
A methyl ester (1.84), a methanolysis product of shornephine A whereas, the change of isolation 
strategy by replacing using MeOH with MeCN afforded shornephine A. The proposed mechanism 
includes auto acid-catalysed (C-9 phenol) dehydration to afford a C-4 carbocation, which undergo a 
1,2-sigmatropic rearrangement and H2O addition to yield seco-shornephine A intermediate. The latter 
intermediate was very unstable transforming quickly to the methyl ester (1.84) (Figure 1.12). Khalil 
et al observed the resistance of shornephine A (1.83) to direct solvolysis which was attributed to N-
alkylation based on solvolysis studies conducted on synthesized model compounds. 
 
Figure 1.12. Proposed mechanism of solvolysis of shornephine A (1.83) to seco-shorenephine A (1.84) 
 
1.5 Summary 
In conclusion, the microbial biodiscovery is facing challenges responsible for a decline in number of 
new chemical scaffolds such as rediscovery problem of known molecules. Continuous advances in 
instrumentation improved dereplication approach to solve the problem of redundant metabolites. 
Chemical diversity is needed to inspire the development of new chemotherapeutics to treat evolving 
pathogens. On the other hand, the recent discoveries of cryptic biosynthetic gene clusters in microbes 
revealed their potential to have a hidden reservoir of secondary metabolites. Several approaches were 
reported to exploit the maximum capacity of the biosynthetic machinery process of the microbial 
metabolism with or without previous knowledge of the microbial genetic material. Examples of 
approaches that do not require previous knowledge of genetic sequences of microbes include 
variation of media composition and biological elicitation. Another opportunity which is undervalued 
by many chemists is the chemical reactivity of natural products and their transformation to artefacts, 
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being considered a negative result caused by mistakes and mishandling. To us, understanding the 
mechanism and reasons behind the chemical transformation to an artefact is equally important as the 
discovery of the original natural product as this could provide a chemical diversity without genetic 
manipulation, or pro-drugs such as roseopurpurins H and I undergo in situ quantitative reverse 
Michael addition in the presence of cancers cells to the cytotoxic Michael acceptor, 15S-a,b-
dehydrocurvularin, making H and I as rare examples of natural Michael adduct pro-drugs.69 
 
1.6 Focus of this thesis 
This thesis focuses on investigation of the chemical diversity of Australian microorganisms sourced 
from animal (sheep and fish) gastrointestinal tract (GIT) content and in-house Australian Collection 
of Microorganisms (ACM) through application of bioassay-guided and variation of culture conditions 
approaches. For this investigation, two microbial libraries were created from less commonly explored 
ecological sources, namely faecal samples of sheep infected with Haemonchus contortus nematode 
and GIT content of Mugil mullet fish obtained from local commercial market. Microbial isolates were 
cultivated on solid vs liquid-based media creating an extract library that was subjected to both 
chemical profiling using UHPLC-DAD and HPLC-DAD-MS, and biological profiling for 
nematocidal (larval development assay), antibacterial (against Gram-positive and Gram-negative 
bacteria, and Mycobacterium bovis (BCG)), and cytotoxicity properties. Chemical profiles of the 
crude extracts were compared through constructing a UV-vis based library by extracting the UV-vis 
spectra from the DAD data at each peak. Microbial strains were prioritized based on chemical and/or 
biological profiling. Chapter 2 reports the results of aforementioned objectives along with the 
chemical investigation of three case studies for strains chosen for the biological properties of their 
crude extracts. Chapter 3 illustrates the chemical diversity of a fungal strain obtained from GIT of 
mullet fish. Chapter 4 includes analytical and synthetic studies as an expansion for the discovery of 
an unprecedented N-amino-L-proline hydrazinyl Schiff bases (prolinimines) in Chapter 3 and 
introduces new definition about natural products and artefacts. The last two chapters (Chapter 5 and 
6) shows the impact of varying the culture conditions on expression of microbial secondary 
metabolites qualitatively and quantitatively. 
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Figure 1.13. General flowchart for the thesis 
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Chapter 2 : Microbial diversity, dereplication, prioritization, and bioactivity-guided studies 
2.1 Introduction 
This chapter describes the preliminary work conducted at the start of my PhD. It starts with the 
construction of microbial libraries from the gastrointestinal tract (GIT) of two animals: sheep (a 
terrestrial animal), and mullet fish (a marine animal). Afterwards, an extract library was prepared and 
subjected to chemical and biological profiling for prioritization of microbial isolates. Chemical 
profiling was performed using ultra high-performance liquid chromatography (UHPLC) equipped 
with a diode array detector (DAD), and high-performance liquid chromatography (HPLC) equipped 
with a diode array detector (DAD) and an electrospray ionization mass spectrometer (ESIMS). The 
data generated by UHPLC-DAD chemical profiling was compiled as a library facilitating the 
dereplication of strains and metabolites. The biological properties of the crude extracts were also 
evaluated with an array of biological (antibacterial, nematocidal, and cytotoxicity) assays. A list of 
prioritized strains was established based on the collective data obtained from the chemical and 
biological profiling. This chapter also discusses the chemical investigation of three strains prioritized 
based on their biological properties, including the isolation and characterization of bioactive 
secondary metabolite(s). Structure identification was based on comparison of spectral data (UV, MS, 
and NMR) with those reported in literature. This chapter highlights a bioactivity-guided approach to 
microbial biodiscovery. 
 
2.2 Assembly of microbial libraries 
A total of ´59 microbes, including ´30 fungi and ´29 bacteria, were isolated from faecal samples 
obtained from sheep infected with the gastrointestinal parasite Haemonchus contortus using M1 and 
ISP2 solid-based media. A former trainee student in the Capon group had previously isolated ~750 
fungal isolates (gross number before morphological and chemical dereplication) from the 
gastrointestinal tract of fresh mullet fish sourced from local fish market, using four solid-based media, 
M1, ISP2, M1-salt and ISP2 salt. All microbial isolates were photographed, cryopreserved from both 
agar and broth-based media and archived at –80 °C. 
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Figure 2.1. Morphology of selected fungal isolates 
 
2.3 Analytical scale cultivation and extraction 
All pure microbial isolates were cultured in both liquid (Micro-bioreactor (MBR)) and solid media 
(10 cm Petri dishes). Extracts of both liquid and solid-based cultures were prepared for chemical 
profiling. A portion of each extract from agar-based media was archived in deep 96-well plates at 1 
mg/mL in DMSO. 
2.4 Chemical profiling and UHPLC-DAD library 
Aliquots (1 µL) of each microbial extract (5 mg/mL) were subjected to UHPLC-DAD analysis. A 
UHPLC-DAD based library was constructed through extracting the UV-vis spectrum from the DAD 
data at each retention time (tR). Extracts with interesting profiles were prioritized for further analysis 
by HPLD-DAD-MS to detect the molecular weight for further evaluation (i.e. Scifinder). This library 
facilitated the identification of strain replicates (Figure 2.2), common metabolites (e.g. media 
components) (Figure 2.3), and metabolites with unique chromophores. 
 
Figure 2.2. Screenshot showing ability of UHPLC-DAD based library in detection of microbial replicates 
 
Figure 2.3. Screenshot showing ability of UHPLC-DAD based library in detection of common metabolites 
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2.5 Biological profiling 
Extracts were evaluated (50 µg/mL) for antibacterial activity against Gram-positive bacteria 
(Staphylococcus aureus ATCC25923 and Bacillus subtilis ATCC6633), Gram-negative bacteria 
(Escherichia coli ATCC25922) and Mycobacterium bovis (Bacille Calemette-Guerin), nematocidal 
activity (Larval development assay), and cytotoxicity against multiple human cancer cell lines (lung 
cancer cell line NCIH460 and colon cancer cell line SW620). The crude extracts showing 
antibacterial activity against Gram-positive bacteria in the primary screening were evaluated against 
multi-drug resistant strains, methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-
resistant Enterococci (VRE). Three microbial crude extracts showed significant activity against drug-
resistant Gram-positive bacteria (Table 2.1). 
Table 2.1. List of microbial isolates with antibacterial activity against MDR bacteria 
Isolate no. Isolate code MRSA VRE 
1 CMB-NB095 98% 94% 
2 CMB-NB092 94% 97% 
3 CMB-F718 --- 95% 
2.6 Strain prioritization  
In order to achieve the main objective of the thesis, we have proposed a strategy to select favoured 
strains for further study. Prioritization was based on the data obtained from biological profiling and 
chemical profiling. The first priority was given to strains whose crude extract showed antibacterial 
activity (>50% inhibition at 50 µg/mL) but not toxic to mammalian cell lines (i.e. <50% inhibition at 
50 µg/mL). The second priority was for strains whose crude extracts exhibited a promising chemical 
profile, in other words uncommon UV-vis spectra, while at the same time being not toxic to 
mammalian cell lines (i.e. <50% inhibition at 50 µg/mL). A list of prioritized microbial strains is 
tabulated in Table 2.2. 
Table 2.2. List of prioritized microbial isolates 
Isolate no. Isolate code Prioritization reason Cytotoxicity(% of inhibition)  
1 CMB-NF055 BCG (> 90%) 
Anti G+ve bacteria (> 90%) 
<50% 
2 CMB-F731 BCG (> 90%) <50% 
3 CMB-F511 BCG (> 50%) <50% 
4 CMB-F629 BCG (> 50%) <50% 
5 CMB-NF072 BCG (> 75%) <50% 
6 CMB-NF052 LDA (100%) <50% 
7 CMB-F448 LDA (100%) <50% 
8 CMB-F158 LDA (100%) <50% 
9 CMB-F451 LDA (100%) <50% 
10 CMB-NB174 LDA (100%) <50% 
11 CMB-NB095 MRSA and VRE (> 90%) <50% 
12 CMB-F718 VRE (> 90%) <50% 
13 CMB-NB092 MRSA and VRE (> 90%) <50% 
14 CMB-F563 Chemical profile <50% 
15 CMB-F624 Chemical profile <50% 
16 CMB-F713 Chemical profile <50% 
17 CMB-F294 Chemical profile <50% 
18 CMB-NB106 Chemical profile <50% 
19 CMB-F504 Chemical profile <50% 
BCG, Bacillus Calmette-Guérin; LDA, larval development assay 
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2.7 Case study 1: chemical investigation of Aspergillus sp. CMB-NF052 
2.7.1 Isolation and morphology 
The fungus Aspergillus sp. CMB-NF052 was isolated from a faecal sample sourced from a sheep 
infected with Haemonchus contortus, cultured on ISP2 agar medium at 30 °C for 7 days. The strain 
was subjected to cryopreservation from both solid and liquid media and archived at –80 °C. Colonies 
of CMB-NF052 grown on ISP2 agar are approximately 10 to 20 mm in diameter, and appear grainy, 
brown in colour and produce yellow secretions into the agar (Figure 2.4a). Microscopic examinations 
suggested that CMB-NF052 belongs to the genus Aspergillus. (Figure 2.4b). 
 
Figure 2.4. (a) Morphology of CMB-NF052 cultured on ISP2 agar plate (b) 40X resolution images of CMB-NF052 
showing phialides with conidia 
 
2.7.2 Analytical cultivation and chemical analysis 
Aspergillus sp. CMB-NF052 was inoculated on ISP2 agar and incubated for 7 days at 30 °C. After 
incubation, the agar was extracted with EtOAc (20 mL) for 30 min, decanted and concentrated to 
dryness in vacuo to yield a crude extract (8.9 mg). The crude extract was redissolved in MeOH (5 
mg/mL) and subjected to UHPLC-DAD and HPLC-DAD-MS analyses (Figure 2.5). The crude 
extract of CMB-NF052 exhibited pronounced nematocidal activity against Haemonchus contortus 
Kirby, prompting scale-up cultivation. 
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Figure 2.5. UHPLC-DAD (210 nm) chromatograms of (a) ISP2 agar extract (blank) and (b) CMB-NF052 ISP2 agar 
extract 
2.7.3 Scale-up cultivation 
A seed culture of CMB-NF052 was prepared by inoculating a 250 mL flask containing ISP2 broth 
medium (80 mL) with a single colony of the fungus and shaking at 190 rpm at 26.5 °C for 7 days. 
Aliquots of the seed culture (50 µL) were transferred to individual ISP2 agar plates (´200) which 
were incubated at 26.5 °C for 14 days. After the incubation period, the agar was diced (~ 1.5 cm ´ 
1.5 cm), transferred to 2 L flasks and extracted with EtOAc (2 ´ 400 mL) by shaking at 150 rpm 
overnight. The decanted organic layer was then concentrated in vacuo to yield a crude extract (2 g). 
The crude extract was subjected to sequential trituration using solvents of increasing polarities viz., 
n-hexane (2 ´ 20 mL), DCM (2 ´ 20 mL), and MeOH (2 ´ 20 mL), which were concentrated under 
nitrogen at 40 °C to afford, after drying in vacuo, 37.4 mg, 1.95 g and 4.1 mg, respectively (Scheme 
2.1). Triturated fractions were evaluated for activity in the larval development assay against 
Haemonchus contortus. The n-hexane fraction showed >90% inhibition of larvae development. 
 
Scheme 2.1. Trituration scheme for CMB-NF052 ISP2 agar extract. (a) Trituration. 
 
1H NMR (DMSO-d6) analysis of the n-hexane fraction showed the presence of linoleic acid as 
principal component, a well-known nematocide (Figure 2.6).70  
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Figure 2.6. Comparison of 1H NMR (600 MHz, DMSO-d6) spectra of (a) n-hexane fraction of CMB-NF052 ISP2 agar extract, and 
(b) standard linoleic acid. 
 
Having experienced the challenge of scale-up cultivation with CMB-NF052, including the 
consumption of the resources (e.g. media, solvents and consumables) and time, the strategy of 
bioactivity guided approach was modified. This modification included fractionation of the crude 
extract obtained from medium scale cultivation of a prioritized isolate on either solid-based media 
(´10 plates), or liquid-based media (80 mL broth). The modified workflow is summarized by the 
flow chart (Figure 2.7). 
 
Figure 2.7. Flow chart of modified workflow for bioactivity-guided strategy 
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2.8 Case study 2: chemical investigation of Leucosphaerina arxii CMB-NF055 
2.8.1 Isolation and morphology 
The fungus Leucosphaerina arxii CMB-NF055 was isolated from a faecal sample sourced from a 
sheep infected with Haemonchus contortus, cultured on ISP2 agar incubated at 30 °C for 7 days. The 
strain was subjected to cryopreservation from both solid and liquid media and archived at –80 °C. 
 
Figure 2.8. Morphology of CMB-NF055 cultured on ISP2 agar plate 
 
2.8.2 DNA taxonomy and phylogenetic analysis of Leucosphaerina sp. CMB-NF055 
BLAST analysis (NCBI database) showed that the amplified ITS sequence of CMB-NF055 has the 
closest identity with Leucosphaerina arxii (99% identity). A phylogenetic tree obtained by PhyML 
Maximum Likelihood analysis was constructed using the top similar 18S rRNA sequences (>92% 
identity) displayed after BLAST on NCBI database, using CMB-NF055 18S rRNA as the query 
(Figure 2.9). 
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Figure 2.9. Phylogenetic analysis of CMB-NF055 using PhyML Maximum likelihood analysis of ITS DNA sequences 
using the optimal nucleotide substitution model determined by jModeltest271 using UGENE72 software. Phylogenetic 
relationship of CMB-NF055 with selected strains (nucleotide collection Genbank) shown with their accession numbers 
indicated in brackets, highlighted in blue. 
 
2.8.3 Analytical cultivation, chemical analysis, and biological profiling 
CMB-NF055 was inoculated on ISP2 agar and incubated for 7 days at 30 °C. After incubation, the 
agar was extracted with EtOAc (20 mL) by shaking for 30 min at 150 rpm, decanted, and concentrated 
to dryness in vacuo to yield a crude extract (2.2 mg). The crude extract was redissolved in MeOH (5 
mg/mL) and subjected to UHPLC-DAD and HPLC-DAD-MS analyses. The crude extract showed a 
strong antibacterial activity against Gram-positive bacteria (>90% inhibition), S. aureus ATCC25923 
and B. subtilis ATCC6633, and Mycobacterium bovis, Bacille Calmette-Guerin (BCG) (>90% 
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inhibition), at a concentration of 50 µg/mL with no toxic effect (i.e. less than 50% inhibition) against 
human cancer cell lines. Hence, CMB-NF055 was chosen for further investigation. 
 
Figure 2.10. UHPLC-DAD (254 nm) chromatograms of (a) ISP2 agar extract (blank) and (b) CMB-NF055 ISP2 agar 
extract 
2.8.4 Medium-scale cultivation 
Spores of CMB-NF055 were cultured on ISP2 agar plates (´10), incubated for 7 days at 30 °C. After 
incubation, the agar was diced (~ 1.5 cm ´  1.5 cm) and transferred to 1 L flasks where it was extracted 
with EtOAc (2 ´ 200 mL) by shaking at 150 rpm overnight. The decanted EtOAc was concentrated 
to dryness in vacuo to yield a crude extract (52 mg). The crude extract was subjected to liquid-liquid 
partitioning between n-hexane and MeOH, with individual phases concentrated under nitrogen at 40 
°C to afford, after drying in vacuo, 23 mg and 26 mg, respectively (Scheme 2.2). The MeOH fraction 
was chosen for further study as it showed activity (>90%) against Mycobacterium tuberculosis (Mtb 
H37Rv). 
 
Scheme 2.2. Fractionation scheme for CMB-NF055 ISP2 agar extract. (a) liquid-liquid partitioning, and (b) preparative 
HPLC 
 
The MeOH fraction was redissolved in MeOH (1 mL) and subjected to chromatographic fractionation 
(Figure 2.11) using preparative reversed phase HPLC (Agilent SB-C8, 21.2 mm ´ 15 cm. 5 µm, 20 
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mL/min, gradient elution from 90% H2O/MeCN to 100% MeCN over 20 min including 0.01% TFA 
as modifier) to yield 22 fractions. The preparative HPLC fractions F1-22 (at concentration of 25 
µg/mL) were tested against Mycobacterium tuberculosis (Mtb H37Rv) with F12 and F13 showed > 
90% inhibition. Moreover, HPLC-DAD-MS analysis revealed fractions F12 and F17 were relatively 
pure. NMR (CDCl3) analysis identified the two known metabolites viridominic acid B (2.1) and LL-
Z1272z (2.2), respectively. 
 
Figure 2.11. Preparative HPLC (210 nm) chromatogram of CMB-NF055 MeOH fraction. (BCG active fractions 
highlighted in green). 
 
Meanwhile, HPLC-DAD-MS analysis of F13 showed a mixture of at least four metabolites, believed 
to include viridominic acid A (2.3) and B (2.1) (Figure 2.12, Table 2.3). 
 
Figure 2.12. HPLC-DAD (210 nm) chromatograms of BCG active fractions of CMB-NF055 MeOH fraction a) F12, and 
b) F13 
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Table 2.3. LC-MS data and tentative identification of peaks of F13 
Peak no. tR (min) 
m/z tentative identification 
ESI(+)MS ESI(-)MS 
1 10.7 545 603 viridominic acid B (2.1) 
2 10.9 529.2 587 viridominic acid A (2.3) 
3 11.2 ND ND unknown 
4 11.4 701 699 unknown 
ND, not detected 
 
2.8.5 Viridominic acid B (2.1) 
 
HRESI(+)MS analysis of 2.1 revealed a sodium adduct ion ([M+Na]+) indicative of the molecular 
formula C33H48O10 (Dmmu –0.3) requiring ten double bond equivalents (DBE). Analysis of 1H NMR 
(CDCl3) data for 2.1 revealed resonances for five 3o methyls (dH 0.89, s, H3-29; dH 1.31, s, H3-19; dH 
1.54, s, H3-18; dH 1.57, s, H3-26 and dH 1.64, s, H3-27), one 2o methyl (dH 0.90, s, H3-28) and two 
acetoxy groups (δH 1.99, 16-OAc, s; dH 2.04, s, 6-OAc). Online searching in Scifinder suggested that 
2.1 was viridominic acid B, a chlorosis-inducing metabolite isolated from Cladosporium sp.73 The 
relative stereochemistry of stereogenic centres C-3, C-6, C-7, C12, and C-16 of viridominic acid B 
were reported in literature based on spin-spin coupling constant values. The structure elucidation of 
2.1 was further supported by comparing the 1D NMR (CDCl3) data with published data and by 
comparison of the [a]22D +65.7 (c 0.05, MeOH) with that reported for viridominic acid B ([a]17D +64 
(c 0.37, MeOH)) (Table 2.4).73 It’s noteworthy that 2.1 is closely related to the well-known antibiotic 
fusidic acid (2.4) which is active against numerous pathogenic bacteria including Nocardia sp., 
Staphylococci sp., Mycobacterium sp., and Clostridia sp.74-77  
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Figure 2.13. Structures of viridominic acid A (2.3) and fusidic acid (2.4) 
 
 
 
Figure 2.14. 1H NMR (600 MHz, CDCl3) and UV-vis (HPLC-DAD, H2O/MeCN plus HCO2H) (inset) spectra for 
viridominic acid B (2.1) 
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Table 2.4. 1H NMR (CDCl3) data comparison of viridominic acid (2.1) with published data  
Pos. * dH, mult (J in Hz) experimental a  * δH, mult (J in Hz) b literature 73 
3 3.73, br. s 3.73, br. s 
6 4.42, d (9.4) 4.45, d (10.0) 
7 3.49, s 3.50, s 
9 3.38, s 3.39, s 
12 4.27, d (10.5) 4.28, d (11.0) 
16 5.74, d (8.7) 5.73, d (8.0) 
18 1.54, s 1.56, s 
19 1.31, s 1.32, s 
24 5.11, br t (7.0) 5.12, br. t (7.5) 
26 1.57, s 1.58, s 
27 1.64, s 1.65, s 
28 0.90, d (6.8) 0.92, d (6.5) 
29 0.89, s 0.90, s 
*1H NMR measured in (a) 600 MHz, CDCl3 (b) CDCl3 
 
2.8.6 LL-Z1272z (2.2) 
 
HRESI(+)MS analysis of 2.2 revealed a sodium adduct ion ([M+Na]+) indicative of the molecular 
formula C25H31ClO6 (Dmmu 0.5) requiring ten double bond equivalents (DBE). Analysis of 1H and 
HSQC NMR (CDCl3) data for 2.2 revealed resonances for an aldehyde (dH 10.12, s), an acetoxy (dH 
2.04, s), two phenolic moieties (dH 12.69, s; dH 6.36, br s), two trans coupled olefinic protons (dH 
5.90, d, J= 15.9 Hz; dH 5.30, d, J= 15.9 Hz), two 2o methyls (dH 0.84, d, J= 6.7 Hz; dH 0.84, d, J= 6.7 
Hz) and three 3o methyls, two of which were deshielded (dH 2.59, s; dH 1.89, s; dH 0.71, s). Online 
searching in Scifinder suggested that 2.2 was LL-Z1272z, known from different fungal species such 
as Fusarium sp., Cylindrocladium ilicicolia, Verticillium sp., and Nectria galligena and reported to 
have antibacterial activity against Gram-positive bacteria (S. aureus).78-82 The double bond 
geometries and the relative stereochemistry of cyclohexanone moiety of LL-Z1272z were reported 
in literature based on spin-spin coupling constant values. The structure elucidation of 2.2 was further 
supported by comparing the 1D NMR data with published data and by comparison of the [a]22D –
17.7 (c 0.1, MeOH) with that reported for LL-Z1272z ([a]17D –15 (c 1.0, MeOH)).79,81 
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Figure 2.15. 1H NMR (600 MHz, CDCl3) and UV-vis (HPLC-DAD, H2O/MeCN plus HCO2H) (inset) spectra for LL-
Z1272z (2.2) 
 
Table 2.5. 1H NMR (CDCl3) data comparison of LL-Z1272z (2.2) with published data  
Pos. * dH, mult (J in Hz) experimental a * δH, mult (J in Hz) b literature 81 
1-CHO 10.12, s 10.14, s 
2-OH 12.69, s 12.71, s 
4-OH 6.36, br s --- 
6-Me 2.59, s 2.61, s 
1' 3.52, d (7.4) 3.54, d (7.6) 
2' 5.53, t (7.4) 5.54, t (7.6) 
3'-Me 1.89, s 1.92, s 
4' 5.90, d (15.9) 5.92, d (16.0) 
5' 5.30, d (15.9) 5.32, d (16.0) 
6'-Me 0.71, s 0.73, s 
7' 1.97, dq (11.0, 11.0, 6.7) 2.01, m 
7'-Me 0.84, d (6.7) c 0.86, d (6.6)  
8' 4.87, ddd (11.0, 5.7) 4.89, m 
9' a 2.40, md 2.42-2.38, m 
 b 2.85, dd (13.3, 5.7)  
11' 2.39, md 2.42-2.38, m 
11'-Me 0.84, d (6.7) c 0.86, d (6.6) 
Ac-Me 2.04, s 2.06, s 
*1H NMR measured in (a) 600 MHz, CDCl3 (b) 270.05 MHz, CDCl3, c-d Overlapping signals 
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2.9 Case study 3: chemical investigation of Streptomyces sp. CMB-NB095 
2.9.1 Isolation and morphology of Streptomyces sp. CMB-NB095 
Streptomyces sp. CMB-NB095 was isolated from a faecal sample sourced from a sheep infected with 
Haemonchus contortus, cultured on M1 agar incubated at 30 °C for 7 days. The strain was subjected 
to cryopreservation from both solid and liquid media and archived in –80 °C freezer. Preliminary 
morphological examination colonies of CMB-NB095 grown on M1 agar suggested to be a 
Streptomyces (Figure 2.16). 
 
Figure 2.16. Morphology of CMB-NB095 cultured on M1 agar plate 
 
2.9.2 DNA taxonomy and phylogenetic analysis of Streptomyces sp. CMB-NB095 
BLAST analysis (NCBI database) showed that the amplified 16S rRNA sequence of CMB-NB095 
has the closest identity with the genus Streptomyces (98% identity). A phylogenetic tree obtained by 
PhyML Maximum Likelihood analysis was constructed using the top similar 16S rRNA sequences 
(>96% identity) displayed after BLAST on NCBI database using CMB-NB095 16S rRNA as the 
query. 
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Figure 2.17. Phylogenetic analysis of CMB-NB095 using PhyML Maximum likelihood analysis of ITS DNA sequences 
using the optimal nucleotide substitution model determined by jModeltest271 using UGENE72 software. Phylogenetic 
relationship of CMB-NB095 with selected strains (16S ribosomal RNA Bacteria and Archaea GenBank) shown with their 
accession numbers indicated in brackets, highlighted in blue. 
2.9.3 Analytical cultivation, chemical analysis, and biological profiling 
CMB-NB095 was inoculated on M1 agar and incubated for 7 days at 30 °C. After incubation, the 
agar was extracted with EtOAc (20 mL) by shaking for 30 min, then decanted and concentrated to 
dryness in vacuo to yield a crude extract (2.7 mg). The crude extract was redissolved in MeOH (5 
mg/mL) and subjected to UHPLC-DAD and HPLC-DAD-MS analyses. The crude extract of CMB-
NB095 also showed antibacterial activity against Gram-positive bacteria, S. aureus ATCC25923, B. 
subtilis ATCC6633, methicillin-resistant S. aureus (MRSA), and vancomycin-resistant Enterococci 
(VRE) (>90% inhibition) at a concentration of 50 µg/mL with no toxic effect (i.e. less than 50% 
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inhibition) against human cancer cell lines. UHPLC-DAD based library detected another replicate, 
CMB-NB109, of this strain that was cultured on ISP2 agar and possessed a similar antibacterial 
activity. Comparing the chemical profiles of their crude extracts, it was speculated that the 
antibacterial activity is attributed to a common metabolite (tR=2.8 min) (Figure 2.18). 
 
Figure 2.18. UHPLC-DAD (210 nm) chromatograms of (a) CMB-NB095 extract cultured on M1 agar and (b) CMB-
NB109 extract cultured on ISP2 agar 
2.9.4 Medium-scale cultivation 
A 250 mL shake flask containing M1 broth medium (80 mL) inoculated with a single colony of CMB-
NB095 was shaken at 190 rpm at 26.5 oC for 7 days. After the incubation, the broth culture was 
extracted with EtOAc (2 ´ 50 mL), and the decanted EtOAc was concentrated to dryness in vacuo to 
yield a crude extract (2.3 mg). The crude extract was redissolved in MeOH (100 µL) and subjected 
to chromatographic fractionation (Figure 2.19) using semi-preparative reversed phase HPLC 
(Zorbax SB-C8, 9.4 mm ´ 25 cm. 5 µm, 3 mL/min, gradient elution from 90% H2O/MeCN to 100% 
MeCN over 30 min including 10% isocratic 0.01% TFA as modifier) to yield 22 fractions, with 
fraction 19 being a pure compound identified as 16-deethylindanomycin (2.5). 
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Figure 2.19. Semi-preparative HPLC (210 nm) chromatogram of CMB-NB095 crude extract 
 
2.9.5 16-Deethylindanonmycin (2.5) 
 
HRESI(+)MS analysis of 2.5 revealed a sodium adduct ion ([M+Na]+) indicative of the molecular 
formula C29H39NO4 (Dmmu –1.1) requiring eleven double bond equivalents (DBE). Analysis of 1H 
and HSQC NMR (DMSO-d6) data for 2.5 revealed resonances for two exchangeable protons (dH 
11.69, s; dH 12.01, br s), two 2o methyls (dH 0.69, d, J= 6.9 Hz; dH 0.95, d, J= 6.8 Hz), one 3o methyl 
(dH 0.76, t, J= 7.5 Hz) and three coupled olefinic protons (dH 5.67, d, J= 11.2 Hz; dH 5.92, dd, J= 14.9 
Hz and 11.2 Hz; dH 5.32, dd, J= 14.9 and 8.5 Hz). Online searching in Scifinder suggested that 2.5 
was either 16-deethylindanomycin or its C-7 epimer iso-16-deethylindanomycin. The 1H NMR data 
for 2.5 was consistent with 16-deethylindanomycin with H-7 (dH 4.19, br s) compared to that of the 
C-7 epimer (dH 3.24, d, J= 9.8 Hz). The stereochemistry of 16-deethylindanomycin was suggested in 
literature based on matching the 1D NMR data (1H and 13C) with indanmoycin (2.6) whose absolute 
stereochemistry was determined by X-ray analysis.83,84 As a result, 2.5 was confirmed to be 16-
deethylindanomycin, an antibacterial metabolite known from the genus Streptomyces.83,85 The 
structure elucidation was further supported by comparing the 13C NMR (DMSO-d6) data with the 
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reported data (Table 2.6).85 comparison of specific optical rotation of 2.5 [a]22D –130.7 (c 0.1, 
MeOH) was not applicable because it was not reported in literature. 
 
 
Figure 2.20. Structure of indanomycin (2.6) 
 
 
 
Figure 2.21. 1H NMR (600 MHz, DMSO-d6) and UV/vis (HPLC-DAD, H2O/MeCN plus TFA) (inset) spectra for 16-
deethylindanomycin (2.5) 
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Table 2.6. 13C NMR (DMSO-d6) data comparison of 16-deethylindanomycin (2.5) with published data  
Pos. * dC experimental a * δC literature b85 
1 175.9 175.9 
2 39.5 39.5 
3 75.4 75.4 
4 19.3 19.3 
5 25.3 25.3 
6 29.1 29.2 
7 72.5 72.5 
8 141.5 141.5 
9 122.5 122.6 
10 126.1 126.1 
11 131.9 131.9 
12 44.1 44.1 
13 129.4 129.4 
14 129.9 129.9 
15 44.0 44.0 
16 28.5 28.5 
17 21.8 21.8 
18 27.3 27.3 
19 40.5 40.5 
20 50.9 50.9 
21 189.9 189.9 
22 132.0 132.0 
23 116.0 116.0 
24 109.7 109.7 
25 125.1 125.1 
26 21.1 21.2 
27 13.4 13.5 
28 12.5 12.5 
29 14.4 14.4 
*13C NMR measured in (a) 150 MHz, DMSO-d6 (b) 125 MHz, DMSO-d6 
 
16-deethylindanomycin (2.5) was reported to possess antibacterial activity against Gram-positive 
strains with MIC range 2-6 µg/mL with no reports against multidrug-resistant (MDR) strains.83,85 The 
antibacterial activity of 2.5 was evaluated against MDR Gram positive bacteria, vancomycin-resistant 
Enterococci (VRE) and methicillin-resistant Staphylococcus aureus (MRSA). 2.5 showed potent 
activity against both strains with IC50= 94-97 nM. 
 
Figure 2.22. Antibacterial activity of 16-deethylindanomycin (2.5) against (a) VRE, and (b) MRSA 
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2.10 Conclusion 
This chapter summarizes the isolation, chemical profiling, and biological profiling of (´194) 
microbial isolates from the gastrointestinal tracts of sheep (´59) and mullet fish (´135). The chemical 
profiling was conducted by UHPLC-DAD analysis of the microbial extract library, which was 
effectively compiled into a UHPLC-DAD based library. On the other hand, biological profiling of 
the extract library for antibacterial (against Gram-positive, Gram-negative, and Mycobacterium 
bovis), nematocidal (against Haemonchus contortus sheep nematode), and cytotoxic (against human 
cancer cell lines) properties was implemented as a prioritization tool. This chapter also described 
three chemical investigation case studies, Aspergillus sp. CMB-NF052, Leucosphaerina arxii CMB-
NF055, and Streptomyces sp. CMB-NB095, that were prioritized for their biological properties. The 
use of NMR and HPLC-DAD-ESIMS in the chemical investigation of aforementioned strains helped 
to address the bioactive metabolite(s) responsible for the biological activity. While, the prioritization 
by biological assay did not lead to isolation of active new metabolites, the potent antibacterial activity 
of 16-deethylindanomycin (IC50= 94-97 nM) against MDR Gram-positive bacteria is encouraging. 
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2.11 Experimental 
2.11.1 General experimental details   
Refer to Appendix 
2.11.2 Acquisition of samples  
A total of twenty eight (~ 1 g) faecal samples from sheep infected with Haemonchus contortus 
nematode, including five collected at Gatton campus, University of Queensland in September 2014 
in sterile 50 mL falcon tubes, and twenty three provided by DAWBUTS company in faecal collection 
trays. Debris/plant residues were removed by manual inspection. 
2.11.3 Construction of microbial libraries 
2.11.3.1 Sheep library  
The faecal samples were processed using two different methods, stamping and heat shock, and were 
inoculated into two agar-based isolation media (M1 and ISP2). Each microbial isolate was 
photographed and assigned a unique code. The code format is CMB-NB001- where NB stands for 
“Nematode Bacteria” and the “001” represents a sequential code number per sample, or CMB-
NF001- where NF stands for “Nematode Fungi” and the “001” represents a sequential code number 
per sample. 
Table 2.7. Different types and compositions of culture media used for growing microorganisms 
Media Composition (per Litre) 
M1 agar yeast extract (4.0 g), peptone (2.0 g), starch (10.0 g), and agar (18.0 g) 
ISP2 agar yeast extract (4.0 g), malt extract (10.0 g), glucose (4.0 g), and agar (18.0 g) 
 
All the isolation media were autoclaved at 121 oC, 20 min, after which were cooled (~50 oC) and 
supplemented with the antifungal cycloheximide (100 µg/mL) and the antibacterial rifampin (5 
µg/mL) using a sterile syringe with a 0.22 µm millipore sterile filter, and media were poured into 
Petri dishes under sterile conditions. After solidification, petri dishes were sealed with parafilm and 
labelled clearly with the media name and the date prepared on the bottom of each plate. When not 
used, plates were stored in a sealed bag and kept at 4°C. 
a) Stamping method: 
1 g sample of sheep faecal material was aseptically inoculated onto agar media by stamping eight or 
nine times in a circular fashion, to achieve a serial dilution effect. After sealing the agar plates with 
parafilm, and labelling, plates incubated set at 30 °C for 7-21 days. 
 
 
b) Dilution-and-heat-shock method: 
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A 1 g sample of sheep faecal material was added to sterile water (8 mL) and heated for 30 min at 55 
°C in a water bath, with vigorous shaking. The cooled solution was serially diluted (10-1, 10-2, 10-3) 
by transferring 100 µL into 900 µL sterile water by means of sterile micro-titre pipette. Aliquots of 
each dilution (50 µL) were applied to agar-based isolation media spread evenly with a sterile rod. 
After sealing the agar plates with parafilm, and labelling, plates were incubated set at 30 °C for 7-21 
days.  
2.11.3.2 Fish library  
A total of ´116 M1 agar plates inoculated with fungal isolates were provided by Pamela Abdala, a 
visiting research student in the Capon group, in order to be subjected to purification of pure fungal 
strains (if required). Each fungal culture plate was photographed and the cryopreserved isolates (see 
below) assigned a unique code. The code format is CMB-F001- where F stands for “Fish” and the 
“001” represents a sequential code number per sample. 
2.11.4 Primary cultivation and cryopreservation of pure strains   
2.11.4.1 Preparation of liquid vs solid cultures 
Liquid vs solid cultures were prepared for the purpose of both cryopreservation and extraction for 
chemical and biological profiling. 
a) Liquid culture  
The spores of microbial strains were individually transferred from agar plate cultures to a sterile 24-
well micro-bioreactor (containing 1.5 mL broth media) using inoculation loops under sterile 
conditions. The micro-bioreactor plate was then incubated on an orbital platform shaker at 190 rpm 
under 26.5 °C for 7 days.  
b) Solid culture  
Each isolate was inoculated on agar-based medium. All the plates were incubated at 30 °C for at least 
7 days with periodic inspection, with the incubation time for slow growing microbes extended to 21 
days.  
2.11.4.2 Preparation of microbial glycerol suspension  
Aliquots (500 µL) of sterile 30% aqueous glycerol and medium broth (ISP2 or M1) were transferred 
to screw-cap cryovials (2 mL) labelled with the date and the codes of the microbes. Either an aliquot 
(100 µL) of the culture broth or few spores/ mycelia of microbial isolate growing on solid medium 
was transferred to the cryovial. The vial content was mixed thoroughly by capping and inverting 
several times. Four cryovials were prepared for each viable isolate, two from liquid-based medium 
and two from solid-based medium. Microbial stock was cooled to -30°C freezer for 1 h then archived 
at -80°C for long-term cryopreservation. 
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2.11.5 Preliminary chemical analysis    
2.11.5.1 Preparation of crude extracts: 
a) Liquid culture: 
After the incubation, micro-bioreactor liquid cultures were extracted with EtOAc (2 mL) in situ at 
150 rpm for 30 min. The organic layer was filtered through 0.45 µm millipore sterile filter into 2 mL 
vials and dried under N2 at 40 °C. All the microbial crude extracts were preserved at –30 °C. 
b) Solid culture: 
After the incubation, the agar with mycelium was chopped into small pieces and transferred to a 
Falcon tube (50 mL) and extracted with EtOAc (20 mL) at 150 rpm for 30 min. The decanted organic 
layer was dried in vacuo at 40 °C, weighed, and archived at –30 °C. 
2.11.5.2 Chemical profiling  
a) Sample preparation  
Crude extracts from micro-bioreactor broth cultivation were dissolved in MeOH (20 µL). Crude 
extracts from agar plate cultivation were redissolved in MeOH (5 mg/mL). 
b) UHPLC-DAD and HPLC-DAD-ESIMS analysis of crude extracts 
Refer to Appendix 
c) Analysis and comparison of chemical profiles  
A UV-vis library was constructed by electronically extracting the UV-vis spectra from the UHPLC-
DAD, for each peak with a unique retention time. This data was assembled into a database using 
Agilent Open Lab CDS (Chromatography Data System) Rev. C.01.03 ChemStation Software. 
The acquired HPLC-DAD-MS data were processed by LC-MS ChemStation software. The HPLC 
profiles and ion extraction of crude extracts from both liquid and solid media were overlaid and 
compared at the same scale. 
2.11.6 Biological profiling: 
A portion of each crude extract obtained from agar-based cultures was archived in deep 96-well plates 
at 1 mg/mL in DMSO at – 20 °C. 
2.11.6.1 Antibacterial assay against drug-susceptible bacteria 
The bacterium to be tested was streaked onto a tryptic soy agar plate and was incubated at 37 °C for 
24 h. One colony was then transferred to fresh lysogeny broth (15 mL), and the cell density was 
adjusted to 104−105 cfu/mL. Aliquots of crude extracts (100 µL) to be tested were dried to give a 
final weight of 0.1 mg. This was dissolved in DMSO (20 µL) and 80 µL of sterile water was added. 
An aliquot (10 µL) was transferred to sterile 96-well microtiter plate. From LB culture media, 190 µL 
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were transferred to each well making the final concentrations of the crude extracts 50 µg/mL. The 
plates were incubated at 37 °C for 24 h, and the optical density of each well was measured 
spectrophotometrically at 600 nm using a POLARstar Omega plate (BMG LABTECH, Offenburg, 
Germany). Each crude extract was screened against the Gram-negative bacteria Escherichia coli 
(ATCC25922) and the Gram-positive bacteria Staphylococcus aureus ATCC25923 and Bacillus 
subtilis ATCC6633. Ampicillin was used as a positive control (30 μM in 20% DMSO). All 
experiments were performed in duplicate. 
 
2.11.6.2 Antibacterial assay against drug-resistant bacteria 
Antibacterial activities were measured against two clinical isolates of drug-resistant Gram-positive 
bacteria by the broth micro-dilution method. The bacterium to be tested was streaked onto a Muller 
Hinton (MH) agar plate and was incubated at 37 °C for 24 h. One colony was then transferred to fresh 
MH broth (5 mL) and incubated for 37 °C for 24 h after which the cell density was adjusted to 7 x 
105 cfu/mL. 16-deethylindanomycin (2.5) was dissolved in DMSO and diluted with H2O to give 600 
µM stock solution (20% DMSO), which was serially diluted with 20% DMSO to give concentrations 
from 600 µM to 0.2 µM in 20% DMSO. An aliquot (10 µL) of each dilution was transferred to a 96-
well microtiter plate and freshly prepared microbial broth (190 µL) was added to each well to give 
final concentrations of 30 – 0.01 µM in 1% DMSO. An aliquot (10 µL) of each dilution was 
transferred to a 96-well microtiter plate and freshly prepared microbial broth (190 µL) was added to 
each well. The plates were incubated at 37 °C for 24 h and the optical density of each well was 
measured spectrophotometrically at 600 nm using POLARstar Omega plate (BMG LABTECH, 
Offenburg, Germany). MICs were determined visually, as the lowest concentration showing no 
visible growth, while IC50 values were calculated as the concentration of the compound or antibiotic 
required for 50% inhibition of the bacterial cells using Prism 5.0 from GraphPad Software Inc. (La 
Jolla, CA). 
 
2.11.6.3 Mycobacterium bovis (BCG) assay 
Mycobacterium bovis, Bacille Calmette Guerin (BCG) was grown until early-mid log phase in 7H9 
liquid medium (Difco) containing 0.2% glycerol, 0.05% Tween80, 0.5% bovine serum albumin 
(BSA), 0.2% dextrose, and 0.085% sodium chloride. Single cell suspensions of independent cultures 
were prepared by centrifuging the bacterial cultures for 10 min, at room temperature, 130 Å~ g and 
then diluted to an optical density (OD; 600 nm) of 0.02. An aliquot (10 µL) of crude extracts dissolved 
in 20 % DMSO (1 mg/mL) was added to bacterial growth mixture (190 µL) and monitored by OD 
measurements. To analyse bacterial survival, serial dilutions of culture material were plated on 
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Middlebrook 7H10 plates supplemented with 10% oleic acid/albumin/dextrose catalase (OADC; 
Middlebrook) and 0.5% glycerol. Isoniazid (INH) was used as a positive control (20 μg/ml in H2O). 
 
2.11.7 Larval development assay (LDA)  
The larval development assay (LDA) was performed according to the previously established 
methods86-88 with sight modifications. Nematode eggs were recovered from faecal samples of sheep 
infected with Haemonchus contortus Kirby by adapting previously described protocols86-88 by Dr Léa 
Indjein.  
 
2.11.8 Cytotoxicity assay (MTT assay) 
The MTT assay was modified from that previously described89 using adherent cell lines SW620 
(adherent epithelial like, human colorectal carcinoma) and NCIH460 (adherent epithelial like, human 
lung carcinoma) were cultured in RPMI medium 164090in flasks supplemented with 10% foetal 
bovine serum, 2 mM L-glutamine, 100 unit/mL penicillin and 100 µg/mL streptomycin in a 
humidified 37 °C incubator supplied with 5% CO2. Briefly, cells were harvested with trypsin and 
dispensed into 96-well microtiter assay plates at 2,000 cells/well for SW620, and NCIH460, then 
incubated for 18 h at 37 °C with 5% CO2 (to allow cells to attach). Crude extracts were dissolved in 
20% DMSO in PBS (v/v) and aliquots (10 µL) tested at a concentration of 50 µg/mL. Control wells 
were treated with 1% aqueous DMSO. After 48 h incubation at 37 °C with 5% CO2 an aliquot (20 
µL) of MTT in PBS (5 mg/mL) was added to each well (final concentration of 0.5 mg/mL), and the 
microtiter plates incubated for a further 4 h at 37 °C with 5% CO2. After this final incubation the 
medium was aspirated, and precipitated formazan crystals dissolved in DMSO (100 µL/well). The 
absorbance of each well was measured at 580 nm with a PowerWave XS Microplate Reader from 
Bio-Tek Instruments Inc. (Vinooski, VT). IC50 values were calculated using Prism 5.0 (GraphPad 
Software Inc., La Jolla, CA), as the concentration of analyte required for 50% inhibition of cancer 
cell growth (compared to negative controls). Vinblastine (20 µg/mL) and 1% DMSO served as 
positive and negative controls, respectively.  All experiments were performed in duplicate. 
 
2.11.9 Collection and Taxonomy of Leucosphaerina arxii CMB-NF055 
The fungus Leucosphaerina arxii CMB-NF055 was isolated from faecal material sourced from a 
sheep infected with Haemonchus contortus, by cultivation on ISP2 agar plates at 30 °C for 7 days. 
Genomic DNA was extracted from the mycelia using the DNeasy Plant Mini Kit (Qiagen) as per the 
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manufacturer’s protocol. The 18S rRNA genes were amplified by PCR using the universal primers 
ITS 1 (5"-TCCGTAGGTGAACCTGCGG-3") and ITS 4 (5"TCCTCCGCTTATTGATATGC-3") 
purchased from Sigma-Aldrich. The PCR mixture (50 μL) contained genomic DNA (2 μL, 20–40 
ng), EmeraldAmpn GT PCR Master Mix (2X Premix) (25 μL), primer (0.2 μM, each), and H2O (up 
to 50 μL). PCR was performed using the following conditions: initial denaturation at 95 °C for 2 min, 
40 cycles in series of 95 °C for 20 s (denaturation), 56 °C for 20 s (annealing) and 72 °C for 30 s 
(extension), followed by one cycle at 72 °C for 5 min. The PCR products were purified with PCR 
purification kit (Qiagen) and sequenced. BLAST analysis (NCBI database) showed that the amplified 
ITS sequence has the closest identity with Leucosphaerina arxii.  
18S rRNA sequence  
TTGTGACATATCATGTTGCTTCGGCGGGTTGCGGGCTGGCCTAGCGCCTAACGCACCGCCCGCCGG
AGGCCAAACTCTTGTTTTCTAGCGGAATCTTCTGAGTTTTTACCAATAAGCAATCAAAACTTTCAG
CAACGGATCTCTTGGCTCTGGCATCGATGAAGAACGCAGCGAAATGCGATAAGTAATGTGAATTGC
AGAATTCAGTGAATCATCGAATCTTTGAACGCACATTGCGCCCGCCAGCACTCTGGCGGGCATGCC
TGTTCGAGCGTCATTTCAACCCTCAGAACCCCTCGCGGGATCTGGCGTTGGGGATTGGCAGCCAGC
CAGCCCCTAAATCTAGTGGCGGTCCCTCCGCGACCTCCCCTGTGCAGTAGTGATACCTCGCAGCGG
GATAGCGGTCTGACCACGCCGTAAAACCCCCTACTTCTCAAGGTTGACCTCGGATCAGGTAGGAAT
ACCCGCTGAACTTAAGCATATCAATAAGCGGAGG (496 bp) 
BLAST search (closet match) 
An NCBI-BLAST database search of 18S rRNA sequence established a 99% similarity for CMB-
NF055 with Leucosphaerina arxii. (Figure 2.23) 
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Figure 2.23. BLAST search (closest match) for CMB-NF055 
2.11.10 Collection and Taxonomy of Streptomyces sp CMB-NB095 
The bacterium Streptomyces CMB-NB095 was isolated from faecal material sourced from a sheep 
infected with Haemonchus contortus, by culturing on ISP2 agar plates at 30 °C for 7 days. Genomic 
DNA was extracted from the mycelia using the DNeasy blood and tissue Kit (Qiagen) as per the 
manufacturer’s protocol. The 16S rRNA genes were amplified by PCR using the universal primers 
27F (5"-AGAGTTTGATCCTGGCTCAG-3") and RC-1494 
(5"-  TACGGCTACCTTGTTACGACTT-3") purchased from Sigma-Aldrich. The PCR mixture (50 
μL) contained genomic DNA (2 μL, 20–40 ng), EmeraldAmpn GT PCR Master Mix (2X Premix) 
(25 μL), primer (0.2 μM, each), and H2O (up to 50 μL). PCR was performed using the following 
conditions: initial denaturation at 95 °C for 2 min, 40 cycles in series of 95 °C for 20 s (denaturation), 
56 °C for 20 s (annealing) and 72 °C for 30 s (extension), followed by one cycle at 72 °C for 5 min. 
The PCR products were purified with PCR purification kit (Qiagen) and sequenced. BLAST analysis 
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(NCBI database) showed that the amplified ITS sequence has the closest identity with Streptomyces 
sp. 
16S rRNA sequence 
TGCAAGTCGAACGATGAACCTCCTTCGGGAGGGGATTAGTGGCGAACGGGTGAGTAACACGTGGGC
AATCTGCCCTGCACTCTGGGACAAGCCCTGGAAACGGGGTCTAATACCGGATAACACCTTCCCTCG
CATGGGGGAGGGTTCAAAGCTCCGGCGGTGCAGGATGAGCCCGCGGCCTATCAGCTTGTTGGTGAG
GTAGTGGCTCACCAAGGCGACGACGGGTAGCCGGCCTGAGAGGGCGACCGGCCACACTGGGACTGA
GACACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGAATATTGCACAATGGGCGAAAGCCTGATG
CAGCGACGCCGCGTGAGGGATGACGGCCTTCGGGTTGTAAACCTCTTTCAGCAGGGAAGAAGCGAA
AGTGACGGTACCTGCAGAAGAAGCGCCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGC
GCAAGCGTTGTCCGGAATTATTGGGCGTAAAGAGCTCGTAGGCGGCTTGTCACGTCGGTTGTGAAA
GCCCGGGGCTTAACCCCGGGTCTGCAGTCGATACGGGCAGGCTAGAGTTCGGTAGGGGAGATCGGG
AATTCCCGGTGTAGCGGTGAAAATGCGCA (623 bp) 
BLAST search (closet match) 
An NCBI-BLAST database search of 16S rRNA sequence established a 98% similarity for CMB-
NB095 with Streptomyces sp.(Figure 2.24) 
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Figure 2.24. BLAST search (closest match) for CMB-NB095 
 
2.11.11 Phylogenetic analysis 
Phylogenetic tree obtained by PhyML Maximum Likelihood analysis was constructed using the top 
similar 18S and 16S rRNA sequences displayed after BLAST on NCBI database using CMB-NF055 
18S rRNA and CMB-NB095 16S rRNA as queries, respectively. The JC69 model was used to infer 
phylogeny sequences. Sequences alignments were produced with the MUSCLE program. 
Phylogenetic tree was constructed using the UGENE program using the aforementioned models and 
visualized using Ugene’s tree view. 
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2.11.12 Scale-up cultivation of CMB-NF052 
A seed culture of CMB-NF052 was prepared by inoculating a 250 mL flask containing ISP2 broth 
medium (80 mL) with a single colony of the fungus and shaking at 190 rpm at 26.5 °C for 7 days. 
Aliquots of the seed culture (50 µL) were transferred to individual ISP2 agar plates (´200) and 
incubated at 26.5 °C for 14 days. After the incubation period, the agar was diced (~ 1.5 cm ´ 1.5 cm), 
transferred to 2 L flasks and extracted with EtOAc (2 ´ 400 mL), by shaking, at 150 rpm overnight. 
The decanted organic layer was concentrated in vacuo to yield a crude extract (2 g). The crude extract 
was subjected to sequential trituration using solvents of increasing polarities viz., n-hexane (2 ´ 20 
mL), DCM (2 ´ 20 mL) and MeOH (2 ´ 20 mL), which were concentrated under nitrogen at 40 °C 
to afford, after drying in vacuo, 37.4 mg, 1.95 g and 4.1 mg, respectively. 
2.11.13 Medium-scale cultivation of CMB-NF055 
The spores of CMB-NF055 were individually transferred from ISP2 agar culture to ISP2 agar plates 
(´10, 20 g each) and incubated at 30 oC for 7 days. After incubation, the agar was diced (~ 1.5 cm ´ 
1.5 cm), transferred to 1L flasks and extracted with EtOAc (2 ´ 200 mL) by shaking at 150 rpm 
overnight. The decanted and filtered organic layer was concentrated in vacuo at 40 oC to yield a crude 
extract (52 mg). The crude extract was partitioned between n-hexane (3 ´ 5 mL) and MeOH (5 mL), 
and both fractions were concentrated in vacuo to afford n-hexane (23 mg) and MeOH (26 mg) 
fractions. The MeOH fraction was further purified by preparative reversed phase HPLC (Agilent SB-
C8, 21.2 mm x 15 cm. 5 µm, 20 mL/min, gradient elution from 90% H2O/MeCN to 100% MeCN 
over 20 min including 0.01% TFA as modifier) to yield viridominic acid B (2.1) (1.8 mg, 3.4%) and 
LL-Z1272z (2.2) (1.7 mg, 3.2%). 
Viridominic acid B (2.1): colourless oil; [a]22D +65.7 (c 0.05, MeOH); 1H NMR (600 MHZ, CDCl3) 
see Table 2.4; HRESI(+)MS m/z 627.3137 [M+Na]+ (calculated for C33H48O10Na 627.3140). 
LL-Z1272z (2.2): pale yellow oil; [a]22D –17.7 (c 0.1, MeOH); 1H NMR (600 MHZ, CDCl3) see 
Table 2.5; HRESI(+)MS m/z 485.1696 [M+Na]+ (calculated for C25H31ClO6Na 485.1701). 
2.11.14 Medium-scale cultivation of CMB-NB095 
A 250 mL shake flask containing M1 broth medium (80 mL) inoculated with a single colony of CMB-
NB095 was shaken at 190 rpm at 26.5 oC for 7 days. After incubation, the broth was extracted with 
EtOAc (2 ´ 50 mL), decanted, and concentrated to dryness in vacuo to yield a crude extract (2.3 mg). 
The crude extract was subjected to fractionation by semi-preparative reversed phase HPLC (Zorbax 
SB-C8, 9.4 mm ´ 25 cm. 5 µm, 3 mL/min, gradient elution from 90% H2O/MeCN to 100% MeCN 
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over 30 min including 10% isocratic 0.01% TFA as modifier) to yield 16-deethylindanomycin (2.5) 
(0.4 mg, 17.4%). 
16-deethylindanomycin (2.5): pale yellow oil; [a]22D –130.7 (c 0.1, MeOH); 13C NMR (600 MHZ, 
CDCl3) see Table 2.6; HRESI(+)MS m/z 488.2782 [M+Na]+ (calculated for C29H39NO4Na 
488.2771).
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Chapter 3 : Chemically diverse fungal metabolites isolated from a fish GIT associated 
fungus Evlachovaea sp. CMB-F563 
3.1 Declaration 
This chapter is a part of my research project on exploration of secondary metabolites from 
Evlachovaea sp. fungus sourced from the gastrointestinal tract (GIT) of a mullet fish. Chemical 
investigation of this fungus led to the identification and/or isolation of fifteen metabolites (3.01–3.14 
and 3.21) belonging to different classes. An article describing the discovery of four Schiff bases, 
prolinimines A–D (3.14 and 3.07–3.09), was published in Organic letters in 2018 (Mohamed O. G.; 
Khalil, Z. G.; Capon, R. J. Prolinimines: N-Amino-L-Pro-methyl Ester (Hydrazine) Schiff Bases from 
a Fish Gastrointestinal Tract-Derived Fungus, Trichoderma sp. CMB-F563. Org. lett. 2018, 20(2), 
377–380). Prolinimines are only the second reported natural products incorporating an N-amino-Pro 
residue, the first to include L-Pro, the first to occur as Schiff bases, and the first to be isolated from a 
microorganism. Structures inclusive of absolute configurations were assigned to prolinimines A–D 
on the basis of detailed spectroscopic and C3 Marfey's analysis, as well as biosynthetic considerations, 
biomimetic total synthesis, and chemical transformations. Of note, the taxonomy of the fungus has 
been revisited and corrected from Trichoderma sp. to Evlachovaea sp. after publishing the article. 
This chapter is slightly modified from the published article mentioned above. Contribution of each 
co-author in this article is listed below. The first author and the author of this dissertation (Mr. Osama 
G. Mohamed) conducted the experimental design, the identification and the scale-up cultivation of 
the fungus Evlachovaea sp., the purification and characterization of the metabolites 3.14 and 3.07–
3.09, total synthesis of 3.14 and 3.07–3.09, and the supplementary information drafting. My associate 
supervisor Dr. Zeinab Khalil edited the manuscript and provided valuable suggestions for the draft. 
My supervisor Prof. Rob Capon provided critical and invaluable advice for this project and the 
manuscript drafting. 
  
 Chapter 3: Chemically diverse fungal metabolites from CMB-F563 
 
 
53 
3.2 Introduction 
This chapter reveals the importance of microbes sourced from the gastrointestinal tract of a mullet 
fish as a rich source of structurally fascinating natural products. We propose that bottom-feeding fish 
such as mullet acts as biosamplers and accumulators. The fungus Evlachovaea sp. CMB-F563 
afforded thirteen metabolites (3.01–3.13) belonging to different chemical classes viz., N-amino-L-
proline hydrazinyl Schiff bases, alkyl nucleosides, bianthraquinones, diketopiperazine, and 4'-O-
methylglucoside. In addition, two extract co-metabolites (3.14 and 3.21) were detected and identified 
in the crude extract. The structures were assigned on the basis of detailed analysis of spectroscopic 
data, semi-synthesis, biomimetic total synthesis, and analytical studies. 
3.3 Isolation, morphology and microscopic analysis of Evlachovaea sp. CMB-F563 
The fungus Evlachovaea sp. CMB-F563 was isolated from the gastrointestinal tract of a specimen of 
Mugil mullet fish on M1 agar and subjected to cryopreservation from both solid and liquid media in 
15% aqueous glycerol and archived at –80 °C. CMB-F563 grows quickly and forms white cottony 
filamentous segments after 3 days, which turn pale pink on day 7 (Figure 3.1a). A thin ultra-clear 
film for 96 well PCR plates was gently applied to the fungal mycelia of 3 d CMB-F563 culture on 
M1 agar then placed on a slide, treated with lactophenol blue (10 µL) and examined using a 
microscope (60X) (Figure 3.1b). 
  
Figure 3.1. (a) Morphology of CMB-F563 cultured on M1 agar plate (b) 60X resolution images of CMB-F563 showing 
phialides with conidia 
 
3.4 DNA taxonomy and phylogenetic analysis of Evlachovaea sp. CMB-F563 
BLAST analysis (NCBI database) showed that the amplified ITS sequence of CMB-F563 has the 
closest identity with the genus Evlachovaea sp. (99% identity). A phylogenetic tree obtained by 
PhyML Maximum Likelihood analysis was constructed using the top similar 18S rRNA sequences 
(>93% identity) displayed after BLAST on NCBI database using CMB-F563 18S rRNA as the query 
(Figure 3.2). 
(a) (b)
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Figure 3.2. Phylogenetic analysis of CMB-F563 using PhyML Maximum likelihood analysis of ITS DNA sequences 
using the optimal nucleotide substitution model determined by jModeltest271 using UGENE72 software. Phylogenetic 
relationship of CMB-F563 with selected strains (nucleotide collection Genbank) shown with their accession numbers 
indicated in brackets, highlighted in blue. 
3.5 Analytical cultivation and chemical analysis 
CMB-F563 was inoculated on an M1 agar plate and incubated for 7 days at 30 °C. After incubation, 
the agar was extracted with EtOAc (20 mL) for 30 min at 150 rpm, and the decanted EtOAc was 
concentrated in vacuo to yield a crude extract (0.4 mg). The crude extract was redissolved in MeOH 
(5 mg/mL) and subjected to UHPLC-DAD analysis which revealed two peaks (tR 2.33 and 2.35 min) 
with interesting UV-vis profiles (Figure 3.3). Molecular weights were assigned to these peaks on the 
basis of HPLC-DAD-ESIMS analysis (Table 3.1). 
Cordyceps pruinosa HMIGD 20930 [DQ342253.1]
Cordyceps pruinosa [AB044635.1]
Ophiocordyceps caloceroides TSJ871 [KF937319.1]
Simplicillium sp. AMVP-2014 [KF937365.1]
Isaria fumosorosea ARSEF 1576 [EU553296.1]
Evlachovaea sp. IP 304 [GU734765.1] 
CMB-F563
Evlachovaea sp. 126 [EU553279.1]
Cordyceps sp. BCMU CN03 [AB233335.1]
Hypocreales sp. NWHC 24746-01-01-02 [KX148701.1]
Evlachovaea sp. AB-2016 1[KU983517.1]
Verticillium sp. [EF513024.1]
Akanthomyces websteri BCC02113 [GQ250008.1]
Isaria javanica CHE-CNRCB 305 [KM234214.1]
Isaria javanica CHE-CNRCB 303/2 [KM234213.1]
Isaria javanica RCEF5495 [KP644423.1]
Isaria javanica CM1 [EF990131.1]
Paecilomyces sp. ZLY-2010 isolate M26 [HM595502.1]
Paecilomyces sp. CICR-RSS-0089 [MG976232.1]
Isaria fumosorosea IfTS02 [KX057373.1]
Isaria fumosorosea NBAII Pfu-8 [KC147667.1]
Isaria javanica CHE-CNRCB 303 [KM234212.1]
Isaria javanica RCEF5499 [KP644424.1]
Isaria javanica CHE-CNRCB 307 [KM234217.1]
Isaria javanica CHE-CNRCB 307/7 [KM234218.1]
Isaria fumosorosea FAFU-1 [MG837716.1]
Isaria javanica CHE-CNRCB 305/1 [KM234215.1]
Isaria javanica ACP [MG837718.1]
Isaria fumosorosea NLAG [FJ765016.1]
Isaria fumosorosea NLUC [FJ765015.1]
Isaria fumosorosea SKCH-1 [FJ765017.1]
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Figure 3.3. UHPLC-DAD (254 nm) chromatograms of (a) M1 agar extract (blank), and (b) CMB-F563 M1 agar extract, 
with UV-vis spectra for 3.01 and 3.02 (inset) 
 
Table 3.1. LC-MS data for 3.01 and 3.02 
Metabolite UHPLC tR (min) 
m/z MW ESI(+)MS ESI(–)MS 
3.01 2.33 587 585 586 
3.02 2.35 571 569 570 
 
A literature analysis indicated that 3.01 and 3.02 correspond closely to two bianthraquinones, YM-
187781 and YM-187787, reported in 2000 from Verticillium lecanii in a Japanese patent.91 Of note, 
YM-187787 was also reported in 2006 as 1,1¢-bislunatin from an endophytic fungus Diaporthe sp.92 
 
Figure 3.4. Bianthraquinones isolated from Verticillium lecanii 
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Having established the agar cultivation procedures, CMB-F563 was cultivated in liquid medium M1 
broth (1.5 mL) in a micro-bioreactor format under static and shaken conditions, to study the effect of 
culture conditions on the production of 3.01 and 3.02. After the incubation for 7 days at 30 °C, each 
culture was extracted with EtOAc (2 mL), and the filtered EtOAc was concentrated to dryness under 
nitrogen at 40 °C to yield crude extracts. The crude extracts were redissolved in MeOH (40 µL) and 
analysed via UHPLC-DAD (Figure 3.5).  
 
Figure 3.5. UHPLC-DAD (254 nm) chromatograms of (a) M1 broth extract (control), (b) CMB-F563 M1 broth static 
extract, and (c) CMB-F563 M1 broth shaken extract 
 
From Figure 3.5, it can be concluded that 3.01 and 3.02 were not produced under shaken culture 
conditions. These outcomes revealed that static condition was crucial for the production of 3.01 and 
3.02. 
3.5.1 Scale-up cultivation on M1 agar 
A seed culture of CMB-F563 was prepared by inoculating a 250 mL shake flask containing M1 broth 
medium (80 mL) with a single colony of the fungus. The flask was shaken at 190 rpm at 26.5 °C for 
7 days. Aliquots of the seed culture (50 µL) were transferred to M1 agar plates (´64) and incubated 
at 30 °C for 14 days. After the incubation period, the agar was chopped into pieces (approximately 
1.5 cm ´ 1.5 cm) and transferred to 2 L flasks and extracted with EtOAc (2 ´ 400 mL), shaken at 150 
rpm overnight, decanted, and the organic layer concentrated in vacuo to yield a crude extract (104 
mg). The crude extract was subjected to successive trituration using solvents of increasing polarities 
viz., n-hexane, DCM and MeOH, which were concentrated under nitrogen at 40 °C. The triturated 
fractions were weighed and kept for further investigation (Scheme 3.1). An aliquot of each triturated 
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fraction was redissolved in MeOH for UHPLC-DAD analysis. Based on the chemical profiles of the 
triturated fractions, the DCM fraction was chosen for further purification. 
 
Scheme 3.1. Fractionation scheme for CMB-F563 M1 agar plate extract 
 
The DCM solubles were subjected to chromatographic separation using semi-preparative reversed 
phase HPLC (Zorbax Eclipse XDB-C8, 9.4 mm ´ 25 cm, 5 µm, 3 mL/min, gradient elution 90% 
H2O/MeCN to 43% H2O/MeCN over 15.8 min, then isocratic elution with 43% H2O/MeCN for 15.2 
min, followed by gradient elution 43% H2O/MeCN to 100 % MeCN over 14 min, including 10 % 
isocratic 0.01 % TFA as modifier) to yield (3.01-3.04). Although the yield of 3.01 and 3.02 was 
insufficient for detailed spectroscopic characterization and structure elucidation, 3.03 was identified 
as the known diketopiperazine cyclo-(L-Leu-4-hydroxy-L-Pro)93 and 3.04 was identified as the known 
metabolite (–)–pestalotin.94  
3.5.2 Scale-up cultivation on medium grain rice 
Due to the low yield obtained from M1 agar culture and the capability of single substrate solid-phase 
cultivation in producing a high number of metabolites56, medium grain rice was chosen as a promising 
alternate culture medium. A seed culture of CMB-F563 was prepared by inoculating a 250 mL flask 
containing M1 broth medium (80 mL) with a single colony of the fungus, followed by shaking at 190 
rpm at 26.5 °C for 7 days. Aliquots of the seed culture (5 mL) were transferred to 2 L flasks (´2) 
containing medium grain rice (200 g), and the flasks were incubated at room temperature for 45 days. 
The resulting cultures were extracted with EtOAc (2 ´ 400 mL), shaken at 150 rpm overnight, 
followed by filtration, and the organic layer concentrated in vacuo to yield a crude extract (1.4 g) 
which was sequentially triturated with solvents of increasing polarities viz., n-hexane (2 ´ 50 mL), 
DCM (2 ´ 50 mL), and MeOH (2 ´ 50 mL) to afford, after concentration in vacuo, 573, 530, and 120 
mg, respectively (Scheme 3.2).  
M1 agar plate extract
CMB-F563
(104 mg)
DCM
(30.2 mg)
n-hexane
(66.7 mg)
MeOH
(1.1 mg)
3.01
(0.7 mg)
3.02
(0.5 mg)
3.04
(1.5 mg)
a
b
3.03
(1.8 mg)
(a) Trituration
(b) Semi-preparative HPLC
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Based on UHPLC-DAD analysis of each of the triturated fractions, the two target metabolites 3.01 
and 3.02 were detected in the DCM soluble fraction. As a consequence, the DCM fraction was chosen 
for further purification. 
 
Scheme 3.2. Fractionation scheme for CMB-F563 medium grain rice extract 
 
The DCM fraction was not completely soluble in MeOH. As a result, the DCM fraction (530 mg) 
was triturated with MeOH (6 mL), centrifuged (2000 rpm, 5 min) and the supernatant was 
concentrated in vacuo to yield F2 (417.1 mg). F2 was subjected to Gel chromatographic purification 
on Sephadex LH-20 (2.5 cm ´ 86 cm, 0.6 mL/min, isocratic elution with MeOH). Fractions (15 mL, 
each) were collected and monitored by UHPLC-DAD and HPLC-DAD-ESIMS. Based on 
chromatographic monitoring, three pure metabolites were obtained: 3.01, 3.02 and 3.05. 
 Moreover, two fractions, F2.6 and F2.10, were selected for isolation of their components and were 
subjected to chromatographic separation using preparative reversed phase HPLC (Phenomenex 
Luna-C18, 21.2 mm ´ 25 cm, 10 µm, 20 mL/min, gradient elution 90% H2O/MeCN to 100% MeCN 
over 30 min) to yield eight metabolites (3.06–3.13). 
static solid medium grain rice
CMB-F563
(1.4 g)
DCM
(530 mg)
n-hexane
(573 mg)
MeOH
(120.1 mg)
F2
(417.1 mg)
F1
(71.4 mg)
a
b
c
F2.1-5
(274.8 mg)
F2.7-9
(33.1 mg)
F2.6
(38.9 mg)
F2.10
(16.2 mg)
F2.11-13
(11.6 mg)
3.02
(1.2 mg)
3.01
(6.4 mg)
3.05
(1.3 mg)
d
3.06
(0.3 mg)
3.07
(1.1 mg)
3.08
(1.6 mg)
3.09
(0.4 mg)
3.12
(0.8 mg)
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(5.7 mg)
3.11
(0.9 mg)
3.13
(0.7 mg)
(a) Trituration
(b) MeOH (6 mL)/centrifugation
(c) Sephadex LH-20 column chromatography
(d) Preparative HPLC
d
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3.6 Structure elucidation of prolinimines (3.07–3.09) 
3.6.1 Prolinimine B (3.07) 
 
HRESI(+)MS analysis of 3.07 revealed a sodium adduct ion ([M+Na]+) indicative of the molecular 
formula C18H24N4O5 (Dmmu –0.63) requiring nine double bond equivalents (DBE). Metabolite 3.07 
was assumed to possess an element of symmetry since the number of carbon signals recorded in the 
13C NMR (MeOH-d4) was half that demanded for the molecular formula determined by high 
resolution mass spectrometry. Further analysis of the NMR data identified a CO2CH3 moiety (dH 
3.73, CO2CH3; dC 52.7, CO2CH3; 175.8, CO2CH3), which 2D NMR correlations (Figure 3.9) linking 
it to equivalent N-substituted proline methyl ester residues, accounting for 4 DBE. Consideration of 
NMR resonances for the remaining elements of (C3H2N)2 - namely two deshielded sp2 methines (dH 
7.12, dC 125.4; dH 6.45, dC 110.6) and one sp2 quaternary carbon (dC 152.9) – together with the 
remaining 5 DBE, and additional 2D NMR correlations (Figure 3.9), supported the structure for 
prolinimine B (3.07) as indicated. The E imine configuration was assigned on the basis of diagnostic 
ROESY correlations between H-1 and H2-5' and H-2' (Figure 3.8). Structure elucidation of 3.07 was 
confirmed by total synthesis (see section 3.6.4). The absolute configuration of N-amino-proline was 
established to be L-configuration by C3 Marfey’s analysis (Figure 3.10). 
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Figure 3.6. 1H NMR (600 MHz, MeOH-d4) and UV-vis (HPLC-DAD, H2O/MeCN plus HCO2H) (inset) spectra for 
prolinimine B (3.07) 
 
 
 
Figure 3.7. 13C NMR (150 MHz, MeOH-d4) spectrum for prolinimine B (3.07) 
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Figure 3.8. Expanded 2D NMR ROESY (MeOH-d4) spectrum for prolinimine B (3.07) 
 
Figure 3.9. Key 2D NMR (MeOH-d4) correlations for prolinimine B (3.07) 
 
Table 3.2. NMR (600 MHz, MeOH-d4) data for prolinimine B (3.07) 
Pos. dH, mult (J in Hz) dC COSY 1H-13C HMBC ROESY 
Furanyl F1 
1 7.12, s 125.4 5′a, 5′b 2, 3 2′, 5′, 3 
2 --- 152.9 --- --- --- 
3 6.45, s 110.6 --- 1, 2, 3 1 
Prolinyl P1 
1' - 175.8   --- 
2' 4.30, dd (8.9, 3.2) 66.1 3′a, 3′b 1′, 3′, 4′, 5′ 5′ 
3' a. 2.02, m 29.5 2′, 3′b, 4′ 1′, 2′, 4′ --- 
 b. 2.27, m --- 2′, 3′a, 4′  --- 
4' 2.07, m 23.5 3′a, 3′b, 5′a, 5′b 2′, 3′, 5′ --- 
5' a. 3.26, m 49.9 2′, 4′, 5′b 2′, 3′, 4′ 1 
 b. 3.48, m --- 2′, 4′, 5′a  1 
1'-OMe 3.73, s 52.7  1′ --- 
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Figure 3.10. C3 Marfey’s HPLC-DAD-ESI(+)MS analysis of prolinimine B (3.07). (a) HPLC-DAD (340 nm) 
chromatogram (Agilent Zorbax, SB-C3 column 150 ´  4.6 mm, 5 µm, 50 °C, 1 mL/min, gradient over 55 min from 80:15:5 
H2O:MeOH:MeCN to 35:60:5 H2O:MeOH:MeCN with an isocratic 0.05% v/v formic acid modifier) for the hydrolysate 
of prolinimine B (3.07) derivatized with L-FDAA. (b) HPLC-ESIMS single ion extraction chromatograms at m/z = 368 
(L-Pro + L-FDAA (tR = 19.9 min) and D-Pro + L-FDAA (tR = 22.1 min) with * residual of Marfey’s reagent) for derivatized 
hydrolysate of 3.07 (red solid) compared to authentic amino acid standard(s) (dotted). 
 
3.6.2 Prolinimine C (3.08) 
 
HRESI(+)MS analysis of 3.08 revealed a sodium adduct ion ([M+Na]+) indicative of the molecular 
formula C23H28N4O6 (Dmmu –0.43) requiring 12 double bond equivalents (DBE). As with 3.07, the 
1D NMR (MeOH-d4) data of 3.08 (Figures 3.11 and 3.12) indicated symmetry, with selected 
resonances and correlations readily attributed to N-substituted Pro methyl ester residues inferring that 
3.08 was a C5H4O homologue of the co-metabolite 3.07. The major difference was the additional 
methylene carbon and methine carbon resonances at dC 28.3 and 109.8, respectively. In addition, the 
presence of two coupled proton resonances (dH 6.15, d, J= 3.3 Hz; dH 6.36, d, J= 3.3 Hz) instead of 
the singlet proton resonance (dH 6.45). Analysis of the available data showed that N-amino Pro 
residues were linked through an imine to a bis-furanyl moiety. Identical chemical shifts (dH 7.12) for 
H-1 in 3.08 and 3.07 supported a common E imine configuration, which is confirmed by diagnostic 
ROESY correlation between H-1 and H2-5'. Structure elucidation of 3.08 was confirmed with the L-
Pro absolute configuration assigned on the basis of biosynthetic considerations (co-metabolite with 
3.07) and total synthesis (see section 3.6.4) from L-Pro. 
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Figure 3.11. 1H NMR (600 MHz, MeOH-d4) and UV-vis (HPLC-DAD, H2O/MeCN plus HCO2H) (inset) spectra for 
prolinimine C (3.08) 
 
 
Figure 3.12. 13C NMR (150 MHz, MeOH-d4) spectrum for prolinimine C (3.08) 
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Figure 3.13. Key 2D NMR (MeOH-d4) correlations for prolinimine C (3.08) 
Table 3.3. NMR (600 MHz, MeOH-d4) data for prolinimine C (3.08) 
Pos. dH, mult (J in Hz) dC COSY 1H-13C HMBC ROESY 
Furanyl F1 
1 7.12, s 126.3 5′a, 5′b 2, 3 2′, 5′, 3 
2 --- 152.7 --- --- --- 
3 6.36, d (3.3) 109.9 4 1, 2, 3 1 
4 6.15, d (3.3) 109.8 3, 6 --- 6 
5 --- 152.4 --- --- --- 
6 4.02, s 28.3 4 --- 4 
Prolinyl P1 
1' --- 175.9 --- --- --- 
2' 4.26, dd (8.9, 3.2) 66.1 3′a, 3′b 1′, 3′, 4′, 5′ 1 
3' a. 2.01, m 29.4 2′, 3′b, 4′ 1′, 2′, 4′ --- 
 b. 2.26, m --- 2′, 3′a, 4′ --- --- 
4' 2.06, m 23.5 3′a, 3′b, 5′a, 5′b 2′, 3′, 5′ --- 
5' a. 3.23 50.0 2′, 4′, 5′b 2′, 3′, 4′ 1 
 b. 3.46, m --- 2′, 4′, 5′a  1 
1'-OMe 3.72, s 52.7 --- 1′ --- 
 
3.6.3 Prolinimine D (3.09) 
 
HRESI(+)-MS analysis of 3.09 afforded a sodium adduct ion of the molecular formula C35H42N6O9 
(Dmmu –2.2) requiring 18 double bond equivalents (DBE). The UV absorption maxima of 3.09 was 
quite similar to 3.08 proposing a similar chromophore. Although the quantity isolated was not enough 
for the acquisition of 1D and 2D NMR data sufficient for unambiguous structure assignment, analysis 
of the 1H NMR (MeOH-d4) data and comparing it with those of co-metabolites 3.07 and 3.08 (Figure 
3.14) revealed that 3.09 was an asymmetric molecule containing three each of furanyl and imine 
residues. Based on the available data, the structure of 3.09 was predicted as trimer analogue 
accounting for all DBE. Structure elucidation of 3.09 was confirmed by total synthesis (see section 
3.6.4). 
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Figure 3.14. Comparison of 1H NMR (600 MHz, MeOH-d4) spectra (downfield region) of 3.07–3.09 and UV-vis (HPLC-
DAD, H2O/MeCN plus HCO2H) spectrum of prolinimine D (3.09) (inset) 
 
With synthetic 3.09 in hand we acquired higher quality NMR (DMSO-d6) data (Figures 3.15 and 
3.16, and Table 3.4), revealing diagnostic ROESY correlations between H-11 and H2-12 (Figure 
3.17) which established the C-9 to C-12 substitution, and providing an unambiguous structure 
assignment for prolinimine D (3.09). 
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Figure 3.15. 1H NMR (600 MHz, DMSO-d6) and UV-vis (HPLC-DAD, H2O/MeCN plus HCO2H) (inset) spectra for 
synthetic prolinimine D (3.09) 
7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
9.9
6
3.1
1
3.7
3
9.9
5
1.8
1
2.0
3
3.1
1
1.8
2
0.9
7
0.9
2
0.9
9
2.0
0
1.0
0
2.02.12.2 ppm
3.23.33.4 ppm
ppm
6.16.26.3 ppm
7.10 ppm
3.7 ppm
1’-OMe,
1’’’-OMe
1’’-OMe
171
11
3 15 4 8
14
2’,2’’’
2’’
6
12
5’a, 
5’’a,
5’’’a
5’b, 
5’’b,
5’’’b
3’a, 
3’’a,
3’’’a
3’b, 
3’’b,
3’’’b
4’
4’’
4’’’
n m25 0 3 0 0 3 5 0 4 0 0 4 5 0 5 0 0 5 5 0
312
N ON NNO
F3
O N N
CO2Me MeO2C
P1 P2
MeO2CF1 F2
P3
1
3
6
4 8
12
11
5'''
3''
14
2'''
17
1 '
2'
5'
1 '''5''
 Chapter 3: Chemically diverse fungal metabolites from CMB-F563 
 
 
67 
 
Figure 3.16. 13C NMR (150 MHz, DMSO-d6) spectrum for synthetic prolinimine D (3.09) 
 
Figure 3.17. Expanded 2D NMR ROESY (DMSO-d6) spectrum for synthetic prolinimine D (3.09) 
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Figure 3.18. Key 2D NMR (DMSO-d6) correlations for prolinimine D (3.09) 
Table 3.4. NMR (600 MHz, DMSO-d6) data for synthetic prolinimine D (3.09) 
Pos. dH, mult (J in Hz) dC COSY 1H-13C HMBC ROESY 
Furanyl F1 
1 7.06, s 123.6 5′a, 5′b 2, 3 3, 5′ 
2 --- 150.9 --- --- --- 
3 6.34, d (3.3) 108.2A 4 2, 5 --- 
4 6.19, d (3.3) 108.7 3, 6 2, 5 --- 
5 --- 150.4 --- --- --- 
6 4.00, s 26.9 4, 5, 7, 8 --- 4, 8 
Furanyl F2    
7 --- 150.0 --- --- --- 
8 6.07, s 110.4 6 7, 9, 10 --- 
9 --- 118.8 --- --- --- 
10 --- 146.3 --- --- --- 
11 7.10, s 123.2 5′′a, 5′′b 9, 10 12, 5′′ 
Furanyl F3 
12 3.87, br s 23.4 14 8, 9, 10, 13, 14 11, 14 
13 --- 153.1 --- --- --- 
14 6.07, d (3.3) 107.8 12, 15 12, 13, 15, 16 --- 
15 6.31, d (3.3) 108.2A 14 13, 14, 16 --- 
16 --- 150.6 --- --- --- 
17 7.05, s 123.9 5′′′a, 5′′′b 15, 16 15, 5′′′ 
Prolinyl P1 
1' --- 173.3B ---  --- 
2' 4.22 A, dd (8.9, 2.3) 64.3C 3′a, 3′b 1′, 3′, 4′, 5′ --- 
3' a. 1.91B, m 27.8D 2′, 3′b, 4′a, 4′b  1′, 2′, 4′ --- 
 b. 2.18C, m --- 2′, 3′a, 4′a, 4′b  --- 
4' 1.97D, m 22.0E 3′a, 3′b, 5′a, 5′b 2′, 3′, 5′ --- 
5' a. 3.14E, m 48.6F 4′a, 4′b, 5′b 2′, 3′, 4′ 1 
 b. 3.36F, m --- 4′a, 4′b, 5′a  1 
1'-OMe 3.63G, s 51.7H --- 1′ --- 
Prolinyl P2    
1" --- 173.3B ---  --- 
2" 4.22A, dd (8.9, 2.3) 64.5 3′′a, 3′′b 1′′, 3′′, 4′′, 5′′ --- 
3" a. 1.91B, m 27.7 2′′, 3′′b, 4′′a, 4′′b  1′′, 2′′, 4′′ --- 
 b. 2.18C, m --- 2′′, 3′′a, 4′′a, 4′′b  --- 
4" 1.97D, m 22.0E 3′′a, 3′′b, 5′′a, 5′′b 2′′, 3′′, 5′′ --- 
5" a. 3.14E, m 48.5G 4′′a, 4′′b, 5′′b 2′′, 3′′, 4′′ 11 
 b. 3.36F, m --- 4′′a, 4′′b, 5′′a  11 
1''-OMe 3.62, s 51.7H --- 1′′ --- 
Prolinyl P3    
1"' --- 173.3B --- --- --- 
2"' 4.22A, dd (8.9, 2.3) 64.3C 3′′′a, 3′′′b 1′′′, 3′′′, 4′′′, 5′′′ --- 
3"' a 1.91B, m 27.8D 2′′′, 3′′′b, 4′′′a, 4′′′b  1′′′, 2′′′, 4′′′ --- 
 b 2.18C, m --- 2′′′, 3′′′a, 4′′′a, 4′′′b --- --- 
4"' 1.97D, m 22.0E 3′′′a, 3′′′b, 5′′′a, 5′′′b 2′′′, 3′′′, 5′′′ --- 
5"' a. 3.14E, m 48.6F 4′′′a, 4′′′b, 5′′′b 2′′′, 3′′′, 4′′′ 17 
 b. 3.36F, m --- 4′′′a, 4′′′b, 5′′′a  17 
1'''-OMe 3.63G, s 51.8 --- 1′′′ --- 
A-KAssignments for overlapping resonances (same superscript within a column) are interchangeable 
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3.6.4 Synthesis of prolinimines A–D 
To confirm structures assigned to 3.07 and 3.08 and assign a structure to 3.09, we designed a 
convergent biomimetic synthesis based on the putative biosynthetic precursors N-amino-L-Pro 
methyl ester (3.15), 2,5-furandicarboxaldehyde (3.16) and 5-hydroxymethylfurfural (3.17) (Scheme 
3.3). In a two-step process L-Pro (3.18) was converted to its N-nitroso methyl ester (3.19), which was 
in turn reduced to 3.15.95,96 Exposure of 3.15 to 3.16 readily yielded the bis-Schiff base prolinimine 
B (3.07), whereas exposure of 3.15 to 3.17 yielded the mono-Schiff base prolinimine A (3.14). 
Significantly, exposure of 3.14 to slightly acidic conditions yielded 3.08, with low accompanying 
yields of 3.09. 
 
Scheme 3.3. Synthesis of prolinimines A-D (3.14 and 3.07-3.09). (i) NaNO2, H2SO4 (3M), rt, 10 min; (ii) H2SO4, MeOH, rt, 12 h; (iii) 
Zn, H2O/HOAc, 0 oC, 15 min; (iv) anhydrous MeOH, rt, 4 h; (v) THF, TFA, rt, 7 days. 
 
Significantly, synthetic samples of 3.07–3.09 were chemically (UHPLC-DAD) and spectroscopically 
(1D and 2D NMR, HRESIMS, UV-vis, [a]D) identical to those isolated from CMB-F563 (Figures 
3.19–3.21). 
 
Figure 3.19. Comparison of 1H NMR (600 MHz, MeOH-d4) spectra of natural and synthetic prolinimine B (3.07) 
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Figure 3.20. Comparison of 1H NMR (600 MHz, MeOH-d4) spectra of natural and synthetic prolinimine C (3.08) 
 
 
 
Figure 3.21. Comparison of 1H NMR (600 MHz, DMSO-d6) spectra of natural and synthetic prolinimine D (3.09) 
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3.6.5 Prolinimine A (3.14) 
 
Careful and repeated HPLC-MS analysis of crude EtOAc extracts derived from CMB-F563 rice 
cultivations detected 3.14 and 3.07, but did not detect either 3.08 or 3.09 (Figure 3.22). From these 
observations, we conclude that prolinimine A (3.14) is indeed a natural product and co-metabolite of 
prolinimine B (3.07), albeit one that is acid labile and in need of care during extraction, fractionation 
and handling. The structure elucidation of natural 3.14 was confirmed by comparing its MS/MS 
fragmentation with that of its authentic synthetic homologue (Figure 3.23).  
 
Figure 3.22. (a) HPLC-DAD-MS chromatograms of crude EtOAc extract of CMB-F563. Single ion extraction 
chromatograms at m/z [M+H]+ (b) prolinimine A (m/z 253) (tR = 7.5 min), (c) prolinimine B (m/z 377) (tR = 10.5 min), (d) 
prolinimine C (m/z 457) showing the absence of the signal ,and (e) prolinimine D (m/z 691) showing the absence of the 
signal. 
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Figure 3.23. Comparison of MS/MS fragmentation of natural and synthetic prolinimine A (3.14) 
 
 
Figure 3.24. 1H NMR (600 MHz, MeOH-d4) and UV-vis (HPLC-DAD, H2O/MeCN plus HCO2H) (inset) spectra for 
synthetic prolinimine A (3.14) 
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Table 3.5. NMR (600 MHz, MeOH-d4) data for synthetic prolinimine A (3.14) 
Pos. dH, mult (J in Hz) dC COSY 1H-13C HMBC 
Furanyl F1 
1 7.14, s 125.9 --- 2, 3 
2 --- 153.1 --- --- 
3 6.37, d (3.3) 109.5 4 2, 4, 5 
4 6.32, d (3.3) 110.4 3 2, 3, 5 
5 --- 155.7 --- --- 
6 4.50, s 57.6 --- 4, 5 
Prolinyl P1 
1' --- 175.8 --- --- 
2' 4.28, dd (8.9, 3.1) 66.1 3′a, 3′b 1′, 3′, 4′, 5′ 
3' a 2.00, m 29.4 2′, 3′b, 4′ 1′, 2′, 4′ 
 b 2.26, m --- 2′, 3′a, 4′  
4' 2.05, m 23.5 3′a, 3′b, 5′ 2′, 3′, 5′ 
5' a 3.24, dd (16.9, 7.7) 49.9 4' 2′, 3′, 4′ 
 b 3.46, m ---  --- 
1'-OMe 3.72, s 52.7 --- 1' 
 
3.6.5.1 Acid-mediated interconversion of prolinimine A to prolinimines C and D 
A plausible mechanism for the acid-mediated transformation of 3.14 to 3.08 and 3.09 involves 
dehydration to form an activated furanyl oxonium species, primed for dimerization and the loss of 
formaldehyde to yield 3.08, and trimerisation to 3.09 (Scheme 3.4). By contrast, as 3.07 lacks an acid 
sensitive allylic 1°-OH moiety, it is incapable of generating a furanyl oxonium and is inert to acid-
mediated transformation. 
 
Scheme 3.4. Plausible mechanism for the acid-mediated interconversion of prolinimine A (3.14) to prolinimines C (3.08) 
and D (3.09) 
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3.7 Structure elucidation of alkyl nucleosides (3.10–3.12) 
3.7.1 Cordyrrole B (3.10)  
 
HRESI(+)MS analysis of 3.10 revealed a quasi-molecular ion ([M+H]+) indicative of the molecular 
formula C14H19N5O6 (Dmmu –0.09). Analysis of the NMR (DMSO-d6) data of 3.10 revealed 
resonances for a substituted adeninyl moiety (dH 8.37, s; dH 8.23, s; and dH 7.99, br s) and a furanosyl 
sugar. Online searching in Scifinder suggested that 3.10 was cordyrrole B, a metabolite isolated from 
the higher fungus Cordyceps militaris and reported to be an inhibitor for pancreatic lipase activity 
and adipocyte differentiation.97 The position of the acetyl moiety in 3.10 was established by 
diagnostic HMBC correlations between H2-2¢ (δH 4.20, t, J= 5.7 Hz) and the acetyl carbonyl (δC 
170.3). The structure elucidation was further supported by 2D NMR (DMSO-d6) data including 
HSQC, COSY and HMBC, as outlined in Table 3.6 and comparison of the experimental and 
published 1H NMR (MeOH-d4) data for 3.10 and cordyrrole B (MeOH-d4) in Table 3.7.97 The 
structure elucidation and absolute configuration of the furanosyl sugar moiety of 3.10 were assigned 
by comparing the 1H NMR (DMSO-d6) spectra (Figure 3.27) of 3.10 with that of authentic adenosine 
(3.20), especially J1′′,2′′ value for 3.10 (6.1 Hz) compared with J1′,2′ value for adenosine (6.2 Hz). In 
addition, the specific optical rotation for 3.10 ([a]22D= –50.2 (c 0.275, MeOH)) was compared to that 
of authentic adenosine ([a]22D= –42.7 (c 0.1, MeOH)). 
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Figure 3.25. 1H NMR (600 MHz, DMSO-d6) and UV-vis (HPLC-DAD, H2O/MeCN plus HCO2H) (inset) spectra for 
cordyrrole B (3.10) 
 
 
 
Figure 3.26. 13C NMR (150 MHz, DMSO-d6) spectrum for cordyrrole B (3.10) 
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Figure 3.27. Comparison of 1H NMR (600 MHz, DMSO-d6) spectra (upfield region) of cordyrrole B (3.10) with authentic 
adenosine (3.20) 
Table 3.6. NMR (600 MHz, DMSO-d6) data for cordyrrole B (3.10) 
Pos. dH, mult (J in Hz) dC COSY 1H-13C HMBC 
2 8.23, s 152.2 --- 4, 6 
4 --- 148.4 --- --- 
5 --- 119.8 --- --- 
6 --- 154.6 --- --- 
6-NH 7.99, br s --- 1′ --- 
8 8.37, s 139.9 --- 4, 5 
1′ 3.72, br s 38.7 6-NH, 2′ --- 
2′ 4.20, t (5.7) 62.4 1′ 1′, 2′ CO 
2′ COCH3 --- 170.3 --- --- 
2′ COCH3 1.97, s 20.7 --- 2′CO 
1′′ 5.89, d (6.1) 87.9 2′′ 4, 8, 2′′, 3′′, 4′′ 
2′′ 4.60, br s 73.4 1′′, 2′′OH, 3′′ 1′′, 4′′ 
2′′-OH 5.46, br s --- 2′′ --- 
3′′ 4.14, br s 70.6 2′′, 3′′OH, 4′′ 1′′, 5′′ 
3′′-OH 5.20, br s --- 3′′ --- 
4′′ 3.96, dd (6.8, 3.7)  85.8 3′′, 5′′a, 5′′b 2′′, 3′′ 
5′′ a 3.55, m 
b 3.67, dt (12.2, 3.7) 
61.6 4′′, 5′′b 
4′′, 5′′a 
3′′ 
3′′, 4′′ 
5′′-OH 5.38, br s  --- 5′′a, 5′′b --- 
Table 3.7. 1H NMR (MeOH-d4) data comparison of cordyrrole B (3.10) with published data 
Pos. * dH, mult (J in Hz)a experimental * δH, mult, (J in Hz)b lit. literature97 
2 8.24, s 8.26, s 
8 8.26, s 8.28, s 
1′ 3.89C, br s 3.91, m 
2′ 4.30D, t (5.4) 4.32, t (5.6) 
COCH3 2.03, s 2.03, s 
1′′ 5.96, d (6.4) 5.98, d (7.6) 
2′′ 4.74, dd (6.4, 5.1) 4.76, dd (6.4, 5.2) 
3′′ 4.32D, m 4.35, m 
4′′ 4.17, dd (5.1, 2.5) 4.19, dd (5.2, 2.5) 
5′ a 3.74, dd (12.6, 2.5) 
b 3.88C, dd (12.6, 2.5) 
3.76, dd (12.8, 2.4) 
3.90, dd (12.8, 2.4) 
*1H NMR measured in (a) 600 MHz, MeOH-d4 (b) 400 MHz, MeOH-d4, C,D Assignments for overlapping resonances (same 
superscript) are interchangeable 
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3.7.2 Evlachosine A (3.11) 
 
HRESI(+)MS analysis of 3.11 revealed an adduct ion [M+Na]+ indicative of the molecular formula 
C16H21N5O7 (Dmmu –0.21). The UV spectrum was very close to 3.10 indicating a similar purine 
nucleoside skeleton. The molecular formula and 1D NMR (DMSO-d6) data for 3.11 suggested it was 
an acetylated form of cordyrrole B (3.10). The position of the extra acetyl moiety was indicated from 
the HMBC correlation from H2-5¢¢ (δH 4.31, dd, J= 3.7 and 11.8 Hz) to the acetyl carbonyl (δc 170.2). 
The structure elucidation was further supported by 2D NMR (DMSO-d6) data including HSQC, 
COSY and HMBC, as outlined in Table 3.8. Consequently, 3.11 was elucidated as the new metabolite 
evlachosine A. 
 
Figure 3.28. 1H NMR (600 MHz, DMSO-d6) and UV-vis (HPLC-DAD, H2O/MeCN plus HCO2H) (inset) spectra for 
evlachosine A (3.11) 
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Figure 3.29. 13C NMR (150 MHz, DMSO-d6) spectrum for evlachosine A (3.11) 
 
Table 3.8. NMR (600 MHz, DMSO-d6) data for evlachosine A (3.11) 
Pos. dH, mult (J in Hz) dC COSY 1H-13C HMBC 
2 8.24, s 152.5 --- 4, 6 
4 --- 148.7 --- --- 
5 --- 119.6 --- --- 
6 --- 154.5 --- --- 
6-NH 7.95, s --- 1′ --- 
8 8.34, s 139.8 --- 4, 5 
1′ 3.72, br s 38.7 6-NH, 2′ --- 
2′ 4.20, dd (5.7, 5.7) 62.4 1′ 1′, 2′ CO 
2′ COCH3 --- 170.4 --- --- 
2′ COCH3 1.97, s 20.7 --- 2′CO 
1′′ 5.92, d (4.9) 87.8 2′′ 4, 8, 2′′, 3′′ 
2′′ 4.67, t (5.1) 73.4 1′′, 2′′OH, 3′′ --- 
2′′-OH 5.62, br s --- 2′′ --- 
3′′ 4.25, t (5.1) 70.3 2′′, 3′′OH, 4′′ 1′′, 5′′ 
3′′-OH 5.42, br s --- 3′′ --- 
4′′ 4.07,  81.5 3′′, 5′′a, 5′′b 3′′ 
5′′ a 4.17, m 
b 4.31, dd (11.9, 3.8) 
61.6 4′′, 5′′b 
4′′, 5′′a 
3′′, 4′′ 
3′′, 5′′CO 
5′′ COCH3 --- 170.2 --- --- 
5′′ COCH3 2.00, s 20.6  5′′CO 
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3.7.3 Evlachosine B (3.12) 
 
Metabolite 3.12 was obtained as a mixture, contaminated with a trace amount of cordyrrole B (3.10), 
sharing the same molecular weight and similar UV spectra and NMR. Further analytical HPLC 
analysis confirmed that 3.12 was a distinct and different isomer of 3.10 (Figure 3.30). 
 
Figure 3.30. HPLC (254 nm) chromatograms of a) evlachosine B (3.12), and b) cordyrrole B (3.10) and UV-vis (HPLC-
DAD, H2O/MeCN plus HCO2H) spectrum of evlachosine B (3.12) (inset) 
 
1H NMR (DMSO-d6) analysis of 3.12, comparing it with the 1H NMR (DMSO-d6) spectra for 3.10 
and 3.11 (Figure 3.31), revealed the sugar proton signals were quite similar, with the upfield shift 
(∆δH 0.65 ppm) of H2-2¢ consistent with 3.12 being the isomer of 3.10 with the acetyl moiety on C-
5¢¢ instead of C-2¢. Consequently, 3.12 was elucidated as the new metabolite evlachosine B. 
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Figure 3.31. Comparison of 1H NMR (600 MHz, DMSO-d6) spectra for cordyrrole B (3.10) and evlachosines A and B 
(3.11 and 3.12) 
 
3.7.4 N6-(hydroxyethyl)adenosine (3.21) 
 
An aliquot of cordyrrole B (3.10) (1 mg) was deacetylated by treatment with 7N methanolic ammonia 
(0.5 mL) for 4 h at room temperature to afford N6-(hydroxyethyl)adenosine (3.21) (0.8 mg, 92%). 
HRESI(+)MS analysis of 3.21 revealed an adduct ion ([M+Na]+) indicative of the molecular formula 
C12H17N6O5 which is consistent with N6-(hydroxyethyl)adenosine. The structure elucidation was 
confirmed by comparison of the 1H NMR (DMSO-d6) data for 3.21 with the published 1H NMR 
(DMSO-d6) data for N6-(hydroxyethyl)adenosine (Table 3.9).98 HPLC-DAD analysis of fraction 
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semisynthetic product (3.21) (Figure 3.32). N6-(hydroxyethyl)adenosine was isolated for the first 
time from Cordyceps sp. and Isaria sp. by Furuya et al 99 and was responsible for Ca2+ antagonistic 
and inotropic activities. Also, it has been reported as anti-inflammatory through suppression of 
lipopolysaccharide-induced pro-inflammatory responses.100 
 
Figure 3.32. HPLC (268 nm) chromatogram of F2.10. N6-(hydroxyethyl)adenosine (3.21) (red solid) compared to 
authentic semisynthetic standard (dotted) 
 
Figure 3.33. 1H NMR (600 MHz, DMSO-d6) and UV-vis (HPLC-DAD, H2O/MeCN plus HCO2H) (inset) spectra for N6-
(hydroxyethyl)adenosine (3.21) 
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Table 3.9. 1H NMR (DMSO-d6) data comparison of N6-(hydroxyethyl)adenosine (3.21) with published data 
Pos. * dH, mult (J in Hz) a experimental * δH, mult, (J in Hz)b lit. literature97 
2 8.21, s 8.21, s 
6-NH 7.71, br s 7.74, br s 
8 8.35, s 8.35, s 
1′ 3.55C 3.56, m 
2′ 3.56C 3.54, m 
2′-OH 4.76, br s 4.76, br s 
1′′ 5.88, d (6.2) 5.88, d (6.3) 
2′′ 4.60, dd (5.5, 5.5) 4.61, dd (11.3, 6.0) 
2′′-OH 5.48, br s 5.42, d (6.3) 
3′′ 4.14, dd (4.7, 3.2) 4.14, m 
3′′-OH 5.24, br s 5.17, d (4.7) 
4′′ 3.96, dd (6.6, 3.4) 3.96, dd (6.6, 3.5) 
5′′ a 3.54C 
b 3.67, dd (11.5, 2.5) 
3.55, dt (12.1, 3.9) 
3.67, dt (12.1, 3.9) 
5′′-OH 5.41, br s 5.40, dd (6.9, 4.7) 
*1H NMR measured in (a) 600 MHz, DMSO-d6 (b) 500 MHz, DMSO-d6, C assignment for overlapping resonance is interchangeable 
 
3.8 Structure elucidation of bianthraquinones (3.01, 3.02 and 3.05) 
3.8.1 Evlaquinone A (3.01)  
 
HRESI(–)MS data of 3.01 revealed a quasi-molecular ion ([M-H]–) corresponding to a molecular 
formula C30H18O13 (Dmmu 1.1) requiring 22 double bond equivalents (DBE). The 1H NMR (DMSO-
d6) data for 3.01 displayed two O-methyls, five chelated phenolic hydroxyls, two m-coupled aromatic 
protons, and three isolated aromatic protons (Figure 3.34). Online searching in Scifinder with the 
molecular formula and the 1H NMR (DMSO-d6) data determined that 3.01 was consistent with YM-
187781, a bianthraquinone isolated from the fungus Verticillium lecanii, reported in a 2000 in a 
Japanese patent,.91 Unfortunately, the patent didn’t provide tabulated spectral data and the absolute 
configuration was not determined. Comparison of 1H NMR (DMSO-d6) spectrum of 3.01 showed an 
upfield shift for H-3 and H-3¢ resonances in 3.01 compared to YM-187781 (∆dH ~0.3 ppm). In 
addition, the 13C NMR (DMSO-d6) spectrum for 3.01 failed to detect few quaternary resonances. To 
confirm the structure for 3.01, another sample was purified using a purification method with TFA as 
a modifier. The 1H NMR spectrum of the latter isolation showed clear resolution of the chelated 
phenolic hydroxyls (Figure 3.35) and the 13C NMR spectrum revealed all thirty carbon resonances. 
The substitution pattern was confirmed by 2D NMR data, including HSQC, COSY, ROESY and 
HMBC as outlined in Figure 3.40 and Table 3.10. 
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Figure 3.34. 1H NMR (600 MHz, DMSO-d6) spectra for evlaquinone A (3.01) purified (a) without, and (b) with, TFA 
modifier in the isolation protocol 
 
Figure 3.35. 1H NMR (600 MHz, DMSO-d6) and UV-vis (HPLC-DAD, H2O/MeCN plus HCO2H) (inset) spectra for 
evlaquinone A (3.01) 
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Figure 3.36. 13C NMR (150 MHz, DMSO-d6) spectrum for evlaquinone A (3.01) 
 
Atropisomerism is a form of isomerism arising from conformational restriction due to the presence 
of hindered rotation of a single bond. Atropisomerism typically requires an energy barrier about 23 
kcalmol-1.101 In silico conformational energy analysis of 3.01 showed a sufficient energy barrier to 
hinder the rotation about the biaryl axis, giving rise to (M) and (P) atropisomers (Figure 3.37). 
 
Figure 3.37. Possible atropisomers of evlaquinone A (3.01). (3.01a) M, and (3.01b) P atropisomers. 
 
O
O
O
O
OH
OH
OH
HO
OH
OH
OH
OMe
MeO
C'
C A
A'
MeO
OMe
OH
OH
HO
OH
OH
OH
O
O
O
O
C' A'
A
C
A
A'C'
C
(3.01a) (3.01b)
C'A'
A
C
OH
5060708090100110120130140150160170180190 ppm
107108109 ppm126128130132134 ppm163164 ppm
9
10
9’10’
8’a
1’
7’
4’4
5
2’
5’
2
7 8
9a9’a
1
8a
10’a
4a 4’a
3
63’ 8’ 6’
10a
7-
O
M
e
7’
-O
M
e
O
O
O
O
OH
OH
OH
HO
OH
OH
OH
OMe
MeO 1'
1
10'
3'
10
9
3
7
6
9'
6'
8'
Evlaquinone A (3.01)
 Chapter 3: Chemically diverse fungal metabolites from CMB-F563 
 
 
85 
The circular dichroism (CD) spectrum of 3.01 (Figure 3.38) confirmed this molecular chirality 
suggesting 3.01 to be (M) atropisomer. This suggestion was assigned based on the first negative 
COTTON EFFECT at 266.4 nm (De –45.4) and application of the exciton chirality method which 
was used for the determination the absolute configuration of (+) and (-) skyrins.102 However, this 
assumption was tentative as the phenolic group attached to C-8 might have an effect on CD data. 
To confirm the absolute configuration, a single crystal of 3.01•H2O (Figure 3.37) was obtained from 
MeOH by the vapor diffusion method using pentane/MeOH system at room temperature. Data were 
collected at 190 K using an Oxford Diffraction Gemini CCD diffractometer with Cu Kα radiation 
and the crystal was cooled with an Oxford Cryosystems Desktop Cooler. Data reduction was 
performed with the CrysAllisPro program (Oxford Diffraction vers. 171.34.40). The structure was 
solved by direct methods with SHELXS86 and refined with SHELX97.103  The thermal ellipsoid 
diagram was produced with ORTEP3104 and all calculations were performed within the WinGX 
package.From these observations, we propose 3.01 was isolated as unequal mixture of both 
atropisomers and the crystallization process favoured the assembly of a 1:1 (i.e. racemic) mixture of 
both M and P atropisomers. 
 
Figure 3.38. Experimental CD spectrum of evlaquinone A (3.01) 
 
 
Figure 3.39. (a) Microscopical photo of crystals of evlaquinone A (3.01) and (b) ORTEP104 structure generated from the 
single crystal X-ray diffraction of evlaquinone A (3.01) 
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Figure 3.40. Key 2D NMR (DMSO-d6) correlations for evlaquinone A (3.01) 
 
Table 3.10. NMR (600 MHz, DMSO-d6) data for evlaquinone A (3.01) 
Pos.  dH, mult (J in Hz)  dC  COSY  1H-13C HMBC ROESY 
1 --- 123.4 --- --- --- 
2 --- 163.52B --- --- --- 
2-OH 11.14A, br s --- --- ---  
3 6.75, s 107.9 --- 1, 4, 4a 4-OH 
4 --- 164.0C --- --- --- 
4-OH 13.05, s  --- --- 3, 4, 4a 3 
4a --- 109.2 --- --- --- 
5 --- 158.6 --- --- --- 
5-OH 12.75, s ---  5, 6, 10a 6 
6 6.93. s 107.6 --- 5, 7, 8, 10a 7-OMe 
7 --- 157.0 --- --- --- 
7-OMe 3.90, s 56.7 --- 7 6 
8 --- 149.6 --- --- --- 
8-OH 13.03, s --- --- 7, 8, 8a --- 
8a --- 112.0 --- --- --- 
9 --- 186.6 --- --- --- 
9a --- 130.6 --- --- --- 
10 --- 187.5 --- --- --- 
10a --- 104.4 --- --- --- 
1′ --- 123.6 --- --- --- 
2′ --- 163.76B --- --- --- 
2′-OH 11.14A, br s --- --- --- --- 
3′ 6.72, s 107.5 --- 1′, 4′, 4′a 4′-OH 
4′ --- 164.1C --- --- --- 
4′-OH 12.81, s --- --- 3′, 4′, 4′a 3′ 
4′a --- 108.7 --- --- --- 
5′ --- 163.69 --- --- --- 
5′-OH 12.27, s --- --- 5′, 6′, 10′a 6′ 
6′ 6.80, d (2.4) 106.7 8′ 5′, 7′, 8′, 10′a 7′-OMe 
7′ --- 165.6 --- --- --- 
7′-OMe 3.83, s 56.1 --- 7′ 6′, 8′ 
8′ 6.97, d (2.4) 106.9 6′ 6′, 7′, 9′, 10′a 7′-OMe 
8′a --- 135.0 --- --- --- 
9′ --- 181.6 --- --- --- 
9′a --- 130.9 --- --- --- 
10′ --- 188.6 --- --- --- 
10′a --- 109.4 --- --- --- 
A-C Assignments for overlapping resonances (same superscript) are interchangeable 
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3.8.2 1,1¢-bislunatin (3.02) 
 
Metabolite 3.02 was isolated as reddish orange powder. HRESI(–)MS data of 3.02 revealed a quasi-
molecular ion ([M-H]–) corresponding to a molecular formula C30H18O12 (Dmmu –1.5). The UV-vis 
spectrum was quite similar to 3.01. Comparison of the 1H NMR (DMSO-d6) data for 3.02 with 3.01 
revealed a symmetric molecule featuring a remarkably upfield shifted aromatic 3/3¢-H signal (δH 
5.58) compared to 1,1¢-bislunatin (δH 6.74). The finding associated with 3.01 structure elucidation, 
having variable chemical shift of proton resonances with variation in pH, led us to speculate 3.02 to 
be pH dependent as well. Significantly, treatment of 3.02 with 0.1% TFA in MeCN resulted in a 
change in powder colour from reddish orange to orange. The 1H NMR (DMSO-d6) data of 3.02 
treated with TFA revealed its conversion to a fully protonated form with clear resolution of the proton 
resonances especially the phenol moieties (Figure 3.41). The 1H NMR (DMSO-d6) data of 3.02 
treated with TFA was in agreement with 1,1¢-bislunatin except H-6/6¢ which we suggest being typos 
error in the published article (Table 3.12). The substitution pattern was confirmed by the 2D data 
including HMBC and ROESY (Figure 3.45 and Table 3.11). 
 
Figure 3.41. 1H NMR (600 MHz, DMSO-d6) spectra for 1,1¢-bislunatin (3.02) (a) before, and (b) after, treatment with 
0.1% TFA in MeCN 
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Figure 3.42. 1H NMR (600 MHz, DMSO-d6) and UV-vis (HPLC-DAD, H2O/MeCN plus HCO2H) (inset) spectra for 
1,1¢-bislunatin (3.02) 
 
 
Figure 3.43. 13C NMR (150 MHz, DMSO-d6) spectrum for 1,1¢-bislunatin (3.02) 
 
In silico conformational energy analysis of 3.02 showed a sufficient energy barrier to hinder the 
rotation about the biaryl axis. The experimental CD spectrum revealed the achirality of 3.02 (Figure 
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racemic mixtures, respectively, suggested the lack of regioselectivity of enzymes responsble for the 
coupling of the monomeric units. 
 
Figure 3.44. Experimental CD spectrum of 1,1¢-bislunatin (3.02) 
 
 
Figure 3.45. Key 2D NMR (DMSO-d6) correlations for 1,1¢-bislunatin (3.02) 
 
Table 3.11. NMR (600 MHz, DMSO-d6) data for 1,1¢-bislunatin (3.02) 
Pos.  dH, mult (J in 
Hz)  
dC  COSY  1H-13C HMBC ROESY 
1/1′ --- 123.7 --- --- --- 
2/2′ --- 163.6 --- --- --- 
2-OH/2′-OH 11.19, br s --- --- --- 3/3′ 
3/3′ 6.74, s 107.5 --- 1/1′,2/2′, 4/4′, 4a/4′a 2-OH/2′-OH, 4-OH/4′-OH 
4/4′ --- 164.13 --- --- --- 
4-OH/4′-OH 12.83, s --- --- 3/3′, 4/4′, 4′a 3/3′ 
4a/4′a --- 108.7 --- --- --- 
5/5′ --- 163.7 --- --- --- 
5-OH/5′-OH 12.29, s --- --- 5/5′, 6/6′, 10/10′a 6/6′ 
6/6′ 6.83, d (2.5) 106.8 8/8′ 5/5′, 7/7′, 8/8′, 
10a/10′a 
5-OH/5′-OH, 7-OMe/7′-OMe 
7/7′ --- 165.8 --- --- --- 
7-OMe/7′-OMe 3.85, s 56.2 --- 7/7′ 6/6′, 8/8′ 
8/8′ 6.97, d (2.5) 106.9 6/6′ 6/6′, 7/7′, 9/9′, 
10a/10′a 
--- 
8a/8′a --- 135.0 --- --- --- 
9/9′ --- 181.6 --- --- --- 
9a/9′a --- 130.9 --- --- --- 
10/10′ --- 188.6 --- --- --- 
10a/10′a --- 109.4 --- --- --- 
 
Table 3.12. 1H NMR (DMSO-d6) data comparison of 1,1¢-bislunatin (3.02) with published data 
Pos. (a) δH, mult, (J in Hz) experimentala  (b) dH, mult (J in Hz) experimentalb δH, mult, (J in Hz)c lit. literature92  
3/3¢ 5.58, br s  6.74, s  6.74, s  
6/6¢ 6.58, d (2.6) 6.83, d (2.5) 6.73, d (2.1) 
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8/8¢ 6.82, d (2.6) 6.97, d (2.5) 6.96, d (2.1) 
OH 13.23, s; 13.64 br s 11.19, br s; 12.29, s, 12.83, s 12.24, s; 12.82, s 
1H NMR measured in (a) 600 MHz, DMSO-d6, before, (b) 600 MHz, DMSO-d6, after, treatment with 0.1% TFA in MeCN, and (c) 
DMSO-d6 
3.8.3 Evlaquinone B (3.05)  
 
HRESI(–)MS of 3.05 showed a quasi-molecular ion ([M-H]–) corresponding to a molecular formula 
C30H18O14 (Dmmu 0.9) requiring 22 double bond equivalents (DBE). The UV-vis spectrum of 3.05 
was similar to co-metabolites 3.01 and 3.02. The 1H NMR (DMSO-d6) data for 3.05 revealed proton 
resonances that was half that required by molecular formula indicating a symmetric metabolite. As 
with 3.01 and 3.02, treatment of 3.05 with 0.1% TFA in MeCN resolved the proton resonances 
(Figure 3.46). Comparison of the 1H NMR (DMSO-d6) data for 3.05 with 3.02 suggested additional 
hydroxylation at either C-6/C-6' or C-8/C-8'. The position of the additional phenol moiety was 
confirmed to be at C-8/C-8' by the diagnostic HMBC correlation from the 8-OH/8'-OH (δH 13.02, s) 
to the quaternary C-8a/C-8'a (δC 112.1). The position of the substituents on the bianthracene scaffold 
was confirmed by the 2D NMR data (HMBS and ROESY) (Figure 3.50 and Table 3.13). 
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Figure 3.46. 1H NMR (600 MHz, DMSO-d6) spectra for evlaquinone B (3.05) (a) before, and (b) after, treatment with 
0.1% TFA in MeCN 
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Figure 3.47. 1H NMR (600 MHz, DMSO-d6) and UV-vis (HPLC-DAD, H2O/MeCN plus HCO2H) (inset) spectra for 
evlaquinone B (3.05) 
 
 
Figure 3.48. 13C NMR (150 MHz, DMSO-d6) for evlaquinone B (3.05) 
 
In silico conformational energy analysis of 3.02 showed a sufficient energy barrier to hinder the 
rotation about the biaryl axis. The experimental CD spectrum of 3.05 was similar to that of 3.01 
(Figure 3.49) indicating similar absolute configuration. The similar CD spectra precluded any 
possible effect of the phenolic moiety on the CD spectrum.  
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Figure 3.49. Experimental CD spectrum of evlaquinone B (3.05) 
 
 
Figure 3.50. Key 2D NMR (DMSO-d6) correlations for evlaquinone B (3.05) 
 
Table 3.13. NMR (600 MHz, DMSO-d6) data for evlaquinone B (3.05) 
Pos.  dH, mult (J in Hz)  dC  COSY  1H-13C HMBC ROESY 
1/1′ --- 123.4 --- --- --- 
2/2′ --- 163.3 --- --- --- 
2-OH/2′-OH 11.18, br s --- --- --- 3/3′* 
3/3′ 6.77, s 108.0 --- 1/1′, 2/2′*, 4/4′, 4a/4′a 2-OH/2′-OH*, 4-OH/4′-OH 
4/4′ --- 164.1 --- --- --- 
4-OH/4′-OH 13.05, s --- --- 3/3′, 4/4′, 4/4′a 3/3′ 
4a/4′a --- 109.3 --- --- --- 
5/5′ --- 158.7 --- --- --- 
5-OH/5′-OH 12.76, s --- --- 5/5′, 6/6′, 10/10′a 6/6′ 
6/6′ 6.95, s 107.6 8/8′ 5/5′, 7/7′, 8/8′, 10/10′a 5-OH/5′-OH, 7-OMe/7′-OMe 
7/7′ --- 157.1 --- --- --- 
7-OMe/7′-OMe 3.91, s 56.8 --- 7/7′ 6/6′ 
8/8′ --- 149.6 6/6′ --- --- 
8-OH/8′-OH 13.02, s ---  7/7′, 8/8′, 8a/8′a  
8a/8′a --- 112.1 --- --- --- 
9/9′ --- 186.6 --- --- --- 
9a/9′a --- 130.7 --- --- --- 
10/10′ --- 187.6 --- --- --- 
10a/10′a --- 104.5 --- --- --- 
* weak correlation 
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3.9 Structure elucidation of other miscellaneous metabolites (3.03, 3.04, 3.06, and 3.13) 
3.9.1 cyclo-(L-Leu-4-hydroxy-L-Pro) diketopiperazine (3.03) 
 
HRESI(+)MS analysis of 3.03 revealed an adduct ion ([M+Na]+) indicative of the molecular formula 
C11H18N2O3 (Dmmu –0.50). The UV-vis spectrum revealed the absence of conjugated system. The 
1H NMR and HSQC (DMSO-d6) data revealed the presence of two methyl signals attached to a 
methine carbon (δH 0.85 and 0.87), three diastereotopic methylenes (δH 1.34/1.75, 1.92/2.03 and 
3.22/3.47), four methine protons (δH 1.87, 4.05, 4.28, and 4.39), two exchangeable proton signals (δH 
5.10 and 8.00). Searching in-house database suggested a microbial metabolite previously isolated in 
the group cyclo(L-Leu-trans-4-hydroxy-L-pro). The structure elucidation of 3.03 was further 
confirmed by comparison of 1H NMR data (Table 3.15) and optical rotation [a]22D –85.8 (c 0.1, 
MeOH) for 3.03 with that reported in literature93 ([a]D –77.8 (c 0.38, MeOH). 
 
Figure 3.51. 1H NMR (600 MHz, DMSO-d6) and UV-vis (HPLC-DAD, H2O/MeCN plus HCO2H) (inset) spectra for 
cyclo-(L-Leu -4-hydroxy-L-Pro) (3.03) 
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Figure 3.52. 13C NMR (150 MHz, DMSO-d6) spectrum for cyclo-(L-Leu-4-hydroxy-L-Pro) (3.03) 
 
Figure 3.53. Key 2D NMR (DMSO-d6) correlations for cyclo-(L-Leu-4-hydroxy-L-Pro) (3.03) 
Table 3.14. NMR (600 MHz, DMSO-d6) data for cyclo-(L-Leu-4-hydroxy-L-Pro) (3.03) 
Pos.  dH, mult (J in Hz)  dC  COSY  1H-13C HMBC 
1 --- 170.7 --- --- 
3 a 3.22, d (12.2) 
b 3.47, dd (12.2, 4.3) 
53.7 3a, 4, 5a 
3b, 4 
4, 5, 6 
6 
4 4.28, br s 67.1 3a, 4-OH, 5a, 5b --- 
4-OH 5.10, d (2.8) --- 4 3, 4, 5 
5 a 1.92, m 
b 2.03, dd (13.1, 6.6) 
36.6 4, 5a, 6 
3b, 4, 5b, 6  
1, 6 
3, 4 
6 4.39, dd (10.6, 6.6) 57.0 5a, 5b, 8-NH, 9 1, 5 
7 --- 166.6 --- --- 
8-NH 8.00, s  --- 9 6, 7, 9, 10 
9 4.05, dd 52.5 8-NH, 10a, 10b 7, 10, 11 
10 a 1.34, m 
b 1.76, m  
37.7 9, 10a, 11 
9, 10b, 11 
7, 9, 11, 12, 13 
 
11 1.87, m 24.0 10a, 10b, 12, 13 9, 10, 12, 13 
12 0.87, d (4.2) 22.2 11 10, 11, 13 
13 0.85, t (4.2) 21.9 11 10, 11, 12 
 
Table 3.15. 1H NMR (MeOH-d4) data comparison of cyclo-(L-Leu-4-hydroxy-L-Pro) (3.03) with published data 
Pos. * dH, mult (J in Hz) a experimental * δH, mult, (J in Hz)b lit. literature93 
3 a 3.43, d (12.8) 
b 3.66, dd (12.8, 4.4) 
a 3.42, d (12.5) 
b 3.65, dd (12.5, 4.3) 
4 4.45, t (4.2) 4.45, t (4.3) 
5 a 2.09, ddd (13.3, 11.1, 4.3) 
b 2.28, dd (13.3, 6.5) 
a 2.08, ddd (13.3, 11.1, 4.3) 
b 2.27, dd (13.3, 6.5) 
6 4.52, dd (11.1, 6.5) 4.51, dd (11.1, 6.5) 
9 4.17, m 4.15, m 
10 a 1.50, m 
b 1.90, m 
a 1.50, dd (8.0) 
b 1.90, m 
11 1.88, m 1.88, m 
12 0.96, d (6.4) 0.95, d (6.4) 
13 0.97, d (6.4) 0.96, d (6.4) 
* 1H NMR measured in (a) 600 MHz, MeOH-d4 (b) 300 MHz, MeOH-d4 
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3.9.2  (–)-pestalotin (3.04) 
 
HRESI(+)-MS analysis of 3.04 afforded a sodium adduct ion of the molecular formula C11H18O4 
(Dmmu –0.3) requiring 3 double bond equivalents (DBE). The 1H NMR (DMSO-d6) data of 3.04 
showed one methyl signal (δH 0.87, t, J= 6.7 Hz), six methylne protons (δH 1.21-1.48, m), one olefinic 
proton (δH 5.13, d, J= 1.6 Hz) and one O-methyl signal (δH 3.72, s). Online searching in Scifinder 
determined that 3.04 was consistent with pestalotin, a gibberellin synergist isolated for the first time 
from the fungus Pestalotia cryptomeriaecola.105 The structure elucidation of 3.04 was further 
supported by 2D NMR data including HSQC, COSY and HMBC, as outlined in Table 3.16, and by 
comparison of 1H NMR data (Table 3.17) and optical rotation [a]22D –71.9 (c 0.07, MeOH) for 3.04 
with those reported for (–)-pestalotin ([a]D –64 (c 0.4, MeOH)).106  
 
Figure 3.54. 1H NMR (600 MHz, DMSO-d6) and UV-vis (HPLC-DAD, H2O/MeCN plus HCO2H) (inset) spectra for 
(–)-pestalotin (3.04) 
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Figure 3.55. 13C NMR (150 MHz, DMSO-d6) spectrum for (–)-pestalotin (3.04) 
 
Figure 3.56. Key 2D NMR (DMSO-d6) correlations for (–)-pestalotin (3.04) 
 
Table 3.16. NMR (600 MHz, DMSO-d6) data for (–)-pestalotin (3.04) 
Pos.  dH, mult (J in Hz)  dC  COSY  1H-13C HMBC 
2 --- 166.4 --- --- 
3 5.13, d (1.6) 89.7 5b 2, 4, 5 
4 --- 173.6 --- --- 
4-OMe 3.72, s 56.3 --- 4 
5 a 2.22, dd (17.2, 3.7) 28.6 5b, 6 3, 4 
 b 2.70, ddd (17.2, 12.7, 1.6)  3, 5a, 6 3, 4, 6, 1′ 
6 4.24, dt (12.7, 3.7) 78.0 5a, 5b, 1′ --- 
1′ 3.46, br s 70.2 6, 2′, 1′-OH 2′, 3′ 
1′-OH 4.89, d (6.6)  1′ 6, 1′, 2′ 
2¢ 1.45A, m 31.8 1′, 3′, 4′ 6, 1′, 3′, 4¢ 
3¢ a 1.26B, m 27.6 2′, 3′b, 4, 5′ 2′, 4¢, 5′ 
 b 1.42A, m  2′, 3′a, 4 1′, 2′, 4′, 5′ 
4¢ 1.29B, m 22.2 2′, 3′a, 3′b, 5′ 2¢, 3′, 5′ 
5¢ 0.87, t (7.0) 14.0 3′a, 4′ 3¢, 4¢ 
A,B Assignments for overlapping resonances (same superscript) are interchangeable  
 
Table 3.17. 1H NMR (CDCl3) data comparison of (–)-pestalotin (3.04) with published data  
Pos. * dH, mult (J in Hz) a experimental * δH, mult, (J in Hz)b lit. literature106 
3 5.12, d (1.8) 5.12, d (1.8) 
4-OMe 3.74, s 3.73, s 
5a 2.77, ddd (17.2, 12.9, 1.8) 2.72, ddd (18.0, 13.0, 1.8) 
5b 2.22, dd (17.2, 3.8) 2.22, dd (18.0, 4.0) 
6 4.27, dt (12.9, 3.8) 4.39, dt, (13.0, 4.0) 
1′ 3.60, dt (8.8, 3.8) 3.6, dt (8.4, 4.0) 
2′, 3′, 4′ 1.26-1.67, m 1.30-1.70, m 
5′ 0.90, t (7.2) 0.90, t (7.1) 
* 1H NMR measured in (a) 600 MHz, CDCl3 (b) 300 MHz, CDCl3 
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3.9.3 Evlachoside (3.06) 
 
HRESI(+)MS analysis of 3.06 revealed an adduct ion ([M+Na]+) indicative of the molecular formula 
C16H22O9 (Dmmu –0.11). The NMR (DMSO-d6) data for 3.06 (Table 3.18) suggested a glycoside 
composed of 1,3,4-trisubstituted benzene aglycone moiety attached to a pyranose sugar. The 
substituent positions on the aglycone moiety were supported by 2D NMR data, including HSQC, 
COSY and HMBC, as outlined in Figure 3.59 and Table 3.18. For the sugar moiety, five methine 
carbons, a methylene carbon and an O-methyl carbon were detected from 13C NMR and HSQC. The 
vicinal coupling constants (J1¢,2¢ = 7.9 Hz, J3¢,4¢ = 9.4 and J4¢,5¢ = 9.4) were supportive of 1¢, 2¢, 3¢, 4¢ 
and 5¢ axial methines on a pyranose ring. The connectivity position of the O-methyl at C-4¢ was 
assigned from HMBC correlation between O-methyl protons (δH 3.45) to C-4¢ (δC 78.7) of the sugar. 
Therefore, the sugar unit was identified as 4¢-O-methyl-b-glucopyranose.107 
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Figure 3.57. 1H NMR (600 MHz, DMSO-d6) and UV-vis (HPLC-DAD, H2O/MeCN plus HCO2H) (inset) spectra for 
evlachoside (3.06) 
 
 
Figure 3.58. 13C NMR (150 MHz, DMSO-d6) spectrum for evlachoside (3.06) 
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Figure 3.59. Key 2D NMR (DMSO-d6) correlations for evlachoside (3.06) 
 
Table 3.18. NMR (600 MHz, DMSO-d6) data for evlachoside (3.06) 
Pos.  dH, mult (J in Hz)  dC  COSY  1H-13C HMBC 
1 --- 121.7 --- --- 
2 7.63, d (1.7) 115.8 6 1, 3, 4, 6, 7 
3 --- 146 --- --- 
4 --- 153.2 --- --- 
4-OMe 3.84, s 55.7 --- 4 
5 7.10, d (9) 111.8 6 1, 3 
6 7.63, dd (9, 1.7) 124.2 2, 5 1,2, 3, 4, 7 
7 --- 165.8 --- --- 
7-OMe 3.80, s 51.9 --- 7 
1¢ 4.98, d (7.9) 100.0 2¢ 3 
2¢ 3.26, m 73.4 1¢, 2¢-OH, 3¢ --- 
2¢-OH 5.38, d (5.5) --- 2¢ --- 
3¢ 3.43, m 76.2 2¢, 3¢-OH, 4¢ --- 
3¢-OH 5.29, d (5.5) --- 3¢ --- 
4¢ 3.06, dd (9.4, 9.4) 78.7 3¢, 5¢ 3¢, 4¢-OMe, 5¢ 
4¢-OMe 3.45, s 59.6 --- 4¢ 
5¢ 3.34A 75.6 b --- 
6¢ a 3.51, m  60.0 5¢, 6¢b, 6¢-OH --- 
 b 3.58, dd (11.0, 3.9)  5¢, 6¢a, 6¢-OH --- 
6¢-OH 4.66, t (5.7) --- 6¢a, 6¢b --- 
A Obscured by H2O peak 
 
3.9.4 dimethyl-2,4-pyrrolo-dicarboxylate (3.13)  
 
HRESI(+)MS analysis of 3.13 revealed an adduct ion ([M+Na]+) indicative of the molecular formula 
C8H9NO4 (Dmmu –0.34). The 1D and 2D NMR (DMSO-d6) data for 3.13 revealed the presence of 
two methyl ester residues and a C4H2N residue consistent with disubstituted pyrrole ring. As 3.13 
was asymmetric, only two isomers were possible. Of the two possible isomers, dimethyl-2,3-pyrrolo-
dicarboxylate and dimethyl-2,4-pyrrolo-dicarboxylate, the later was chosen because of the magnitude 
of J2,4 (1.6 Hz). This assignment was further confirmed by comparison of 1H NMR (CDCl3) data with 
the published data (Table 3.20).108 
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Figure 3.60. 1H NMR (600 MHz, DMSO-d6) and UV-vis (HPLC-DAD, H2O/MeCN plus HCO2H) (inset) spectra for 
dimethyl-2,4-pyrrolo-dicarboxylate (3.13) 
 
Figure 3.61. 13C NMR (150 MHz, DMSO-d6) spectrum for dimethyl-2,4-pyrrolo-dicarboxylate (3.13) 
 
Table 3.19. NMR (600 MHz, DMSO-d6) data for dimethyl-2,4-pyrrolo-dicarboxylate (3.13) 
Pos.  dH, mult (J in Hz)  dC  COSY  1H-13C HMBC 
NH 12.60, br s --- --- --- 
2 --- 123.2 --- --- 
2-COO --- 160.3 --- --- 
2-COOMe 3.78, s 51.5 --- 2-COO 
3 7.07, d (1.6) 115.2 5 2, 4, 4-COO, 5 
4 --- 116.3 --- --- 
4-COO --- 163.6 --- --- 
4-COOMe 3.72, s 51.0 --- 4-COO 
5 7.57, d (5.57) 128.0 3 1, 2, 2-COO, 3 
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Table 3.20. 1H NMR (CDCl3) data comparison of dimethyl-2,4-pyrrolo-dicarboxylate (3.13) with published data 
Pos. * dH, mult (J in Hz) a experimental * δH, mult, (J in Hz)b lit. literature108 
NH 9.34, s 10.10, br d 
2-COOMe 3.86, s 3.90, s 
3 7.27, dd (2.6, 1.5) 7.30, m 
4-COOMe 3.81, s 3.85, s 
5 7.52, dd (3.2, 1.5) 7.50, m 
*1H NMR measured in (a) 600 MHz, CDCl3 (b) CDCl3 
 
3.10 Conclusion 
This chapter presents an example of the chemical diversity associated with fungi isolated from the 
GIT of mullet fish. A total of fifteen secondary metabolites were identified from Evlachovaea sp. 
CMB-F563 on the basis of detailed spectroscopic analysis, semi-synthesis, biomimetic total synthesis 
and analytical studies. The secondary metabolites were categorized into four classes (1) prolinimines, 
(2) alkyl nucleosides, (3) bisanthraquinones, and (4) miscellaneous metabolites. 
Although this fungus was prioritized for isolation of bianthraquinone class, other co-metabolites 
turned out to be more interesting revealing unprecedented class of N-aminoproline Schiff bases, 
prolinimines A–D. Structures of prolinimines A–D (3.14 and 3.07–3.09) inclusive of their absolute 
configurations were assigned based on detailed spectroscopic data, C3 Marfey’s analysis, biosynthetic 
considerations, biomimetic total synthesis, and chemical transformation. Despite prolinimine A 
(3.14) was not isolated, it is proved to be acid labile undergoing acid-mediated transformation to 
prolinimines C (3.08) and D (3.09) indicating 3.08 and 3.09 were handling artefacts. This acid-
mediated biomimetic transformation reveals a promising process for regio-controlled synthesis of 
2,2-methylenebisfuran scaffold. Naturally occurring hydrazines are also extremely rare, with only a 
handful of nonacylated examples reported to date.109 As the fungal prolinimines represent only the 
second reported occurrence of a naturally occurring metabolite incorporating an N-amino-Pro 
residue, further investigations into prolinimines were highlighted in Chapter 4.  
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3.11 Experimental 
3.11.1 General experimental details 
Refer to appendix 
3.11.2 Collection and taxonomy of Evlachovaea sp. CMB-F563 
The fungus Evlachovaea sp. CMB-F563) was isolated from the gastrointestinal tract of a specimen 
of Mugil mullet fish, on M1 agar plates incubated at 30 °C for 7 days. Genomic DNA was extracted 
from the mycelia using the DNeasy Plant Mini Kit (Qiagen) as per the manufacturer’s protocol. The 
18s rRNA genes were amplified by PCR using the universal primers ITS 1 (5"-
TCCGTAGGTGAACCTGCGG-3") and ITS 4 (5"TCCTCCGCTTATTGATATGC-3") purchased 
from Sigma-Aldrich. The PCR mixture (50 μL) contained genomic DNA (2 μL, 20–40 ng), 
EmeraldAmpn GT PCR Master Mix (2X Premix) (25 μL), primer (0.2 μM, each), and H2O (up to 50 
μL). PCR was performed using the following conditions: initial denaturation at 95 °C for 2 min, 40 
cycles in series of 95 °C for 20 s (denaturation), 56 °C for 20 s (annealing) and 72 °C for 30 s 
(extension), followed by one cycle at 72 °C for 5 min. The PCR products were purified with PCR 
purification kit (Qiagen) and sequenced. BLAST analysis (NCBI database) showed that the amplified 
ITS sequence has the closest identity with other members of the genus Evlachovaea.  
 
18S rRNA sequence 
CCCTATGTGACATACCAATCGTTGCTTCGGCGGACCCGCCCCGGCGTCCGGACGGCCCTGCGCCGC
CCGCGACCCGGACCCAGGCGGCCGCCGGGGACCCCAAACTCTGTATTCTTTACGTCTTCTGAATCC
GCCGCAAGGCAAAACAAATGAATCAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATGAA
GAACGCAGCGAAATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAATCTTTGAACG
CACATTGCGCCCGCCAGCATTCTGGCGGGCATGCCTGTTCGAGCGTCATTTCACCCCTCGACCCCG
CGCTTAGTGGGGTCGGCGTTGGGGGACGGCACTACCCCGCCGCCCCTGAAATGAAGTGGCGGCCCG
TCCGCGGCGACCTCTGCGTAGTAACTCAACGCGCACCGGAACCCCGACGTGGCCACGCCGTAAAAC
ACCCAACTTCTGAACGTTGACCTCGAATCAGGTAGGACTACCCGCTGAACTTAAGCATATCAATAA
AGCGGAGGA (537 bp) 
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BLAST search (closet match) 
An NCBI-BLAST database search of 18S rRNA sequence established a 99% similarity for CMB-
F563 with Evlachovaea sp. (Figure 3.62). 
 
Figure 3.62. BLAST search (closest match) for CMB-F563 
Phylogenetic Tree 
Phylogenetic tree obtained by PhyML Maximum Likelihood analysis was constructed using the top 
similar 18S rRNA sequences displayed after BLAST on NCBI database using CMB-F563 18S rRNA 
as query. The JC69 model was used to infer phylogeny sequences. Sequences alignments were 
produced with the MUSCLE program. Phylogenetic tree was constructed using the UGENE program 
using the aforementioned models and visualized using Ugene’s tree view.  
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3.11.3 Scale-up cultivation on M1 agar medium 
A seed culture was prepared by inoculating a single colony of Evlachovaea sp. (CMB-F563) in M1 
broth medium (80 mL in a 250 mL Schott flask) containing 1% starch, 0.4% yeast extract and 0.2% 
peptone and incubated at 26.5 °C for 7 days at 190 rpm at 26.5 °C. Aliquots of the seed culture (50 
µL) were transferred to M1 agar plates (´64) and incubated at 30 °C for 14 days. After the incubation 
period, the agar was chopped into pieces (approximately 1.5 cm ´ 1.5 cm) and transferred to 2 L 
flasks and extracted with EtOAc (2 ´ 400 mL), shaken at 150 rpm overnight, decanted, and the 
organic layer concentrated in vacuo at 40 °C to yield a crude extract (104 mg). The crude extract was 
subjected to successive trituration using solvents of increasing polarities viz., n-hexane, DCM and 
MeOH, which were concentrated under nitrogen at 40 °C. The DCM solubles were subjected to 
chromatographic separation using semi-preparative reversed phase HPLC (Zorbax Eclipse XDB-C8, 
9.4 mm ´ 25 cm, 5 µm, 3 mL/min, gradient elution 90% H2O/MeCN to 43% H2O/MeCN over 15.8 
min, then isocratic elution with 43% H2O/MeCN for 15.2 min, followed by gradient elution 43% 
H2O/MeCN to 100 % MeCN over 14 min, including 10 % isocratic 0.01 % TFA as modifier) to yield 
evlaquinone A (3.01) (0.7 mg, 0.67%), 1,1¢-bislunatin (3.02) (0.5 mg, 0.48%), cyclo-(L-Leu-4-
hydroxy-L-Pro) (3.03) (1.8 mg, 1.73%) and (–)-pestalotin (3.04) (1.5 mg, 1.44%). 
3.11.4 Scale-up cultivation on medium grain rice 
A seed culture was prepared by inoculating a single colony of Evlachovaea sp. CMB-F563 in M1 
broth medium (80 mL in a 250 mL Schott flask) containing 1% starch, 0.4% yeast extract and 0.2% 
peptone and incubated at 26.5 °C for 7 days at 190 rpm at 26.5 °C. Aliquots of the seed culture (5 
mL) were transferred to 2 L flasks (´2) containing medium grain rice (200 g), and the flasks were 
incubated at room temperature for 45 days. The resulting cultures were extracted with EtOAc (2 ´ 
400 mL), shaken at 150 rpm overnight, followed by filtration, and the organic layer concentrated in 
vacuo ~40 °C to yield a crude extract (1.4 g) which was sequentially triturated with solvents of 
increasing polarities viz., n-hexane (2 ´  50 mL), DCM (2 ´  50 mL), and MeOH (2 ´  50 mL) to afford, 
after concentration in vacuo, 573, 530 and 120 mg, respectively.  
The DCM fraction (530 mg) was triturated with MeOH (6 mL), centrifuged (2000 rpm, 5 min) and 
the supernatant was concentrated in vacuo to yield F2 (417.1 mg). F2 was subjected to Gel 
chromatography (Sephadex LH-20, 2.5 cm ´ 86 cm, 0.6 mL/min, isocratic elution with MeOH). 
Fractions (15 mL) were collected and monitored by UHPLC-DAD and HPLC-DAD-MS. Three pure 
metabolites were obtained: evlaquinone A (3.01) (6.4 mg, 0.45%), 1,1¢-bislunatin (3.02) (1.2 mg, 
0.08%) and evlaquinone B (3.05) (1.3 mg, 0.09%). 
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Moreover, two fractions, F2.6 and F2.10, were selected for isolation of their components and were 
subjected to chromatographic separation using preparative reversed phase HPLC (Phenomenex 
Luna-C18, 21.2 mm ´ 25 cm, 10 µm, 20 mL/min, gradient elution 90% H2O/MeCN to 100% MeCN 
over 30 min) to yield evlachoside (3.06) (0.3 mg, 0.02% ), prolinimine B (3.07) (1.1 mg, 0.08% ), 
prolinimine C (3.08) (1.6 mg, 0.11% ), prolinimine D (3.09) (0.4 mg, 0.03% ), cordyrrole B (3.10) 
(5.7 mg, 0.41% ), evlachosine A (3.11) (0.9 mg, 0.06% ), evlachosine B (3.12) (0.8 mg, 0.06% ), and 
dimethyl-2,4-pyrrolo-dicarboxylate (3.13) (0.7 mg, 0.05% ). 
Note: % yields for compounds 3.01-3.13 are calculated as weight-to-weight estimate against the 
crude extract (104 mg for M1 agar plates and 1400 mg for rice solid medium). 
 
Evlaquinone A (3.01): red powder; UV (EtOH) lmax (log e) 225 (4.53), 263 (4.50), 320 (4.35), 504 
(4.15) nm; CD (EtOH) lmax (De) 221.8 (+19.6), 234.8 (+5.1), 252.2 (+13.5), 266.4 (–45.4), 453.4 
(+14.2), 541.4 (–18.5); 1D and 2D NMR (600 MHz, DMSO-d6) see Table 3.10 and Figures 3.35 
and 3.36; HRESI(–)MS m/z 585.0664 [M–H]– (calcd for C30H17O13 585.0675). 
 
1,1¢-bislunatin (3.02): reddish orange powder; UV (EtOH) lmax (log e) 221.1 (4.37), 267 (4.25), 317.9 
(4.14), 480 (3.84) nm; 1D and 2D NMR (600 MHz, DMSO-d6) see Table 3.11 and Figures 3.42 and 
3.43; HRESI(–)MS m/z 569.0740 [M–H]– (calcd for C30H17O12 569.0725). 
 
cyclo-(L-Leu-4-hydroxy-L-Pro) (3.03): colourless oil; [a]22D –85.8 (c 0.1, MeOH); 1D and 2D NMR 
(600 MHz, DMSO-d6) see Table 3.14 and Figures 3.51 and 3.52; HRESI(+)MS m/z 249.1215 
[M+Na]+ (calcd for C11H18N2NaO3 249.1210). 
 
(–)-pestalotin (3.04): colourless oil; [a]22D –71.9 (c 0.07, MeOH); 1D and 2D NMR (600 MHz, 
DMSO-d6) see Table 3.16 and Figures 3.54 and 3.55; HRESI(+)MS m/z 237.1100 [M+Na]+ (calcd 
for C11H18NaO4 237.1097). 
 
Evlaquinone B (3.05): red powder; UV (EtOH) lmax (log e) 233 (4.29), 261.9 (4.24), 322 (4.04), 
507.1 (3.94) nm; CD (EtOH) lmax (De) 228.8 (+15.9), 242 (–51.9), 251.4 (+2.9), 265.6 (–24.9), 485.6 
(+12.4), 544.2 (-17.6); 1D and 2D NMR (600 MHz, DMSO-d6) see Table 3.13 and Figures 3.47 and 
3.48; HRESI(–)MS m/z 601.0615 [M–H]– (calcd for C30H17O14 601.0624). 
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Evlachoside (3.06): colourless oil; [a]22D –39.4 (c 0.02, MeOH); UV (MeOH) lmax (log e) 217 
(4.19), 257.1 (3.97), 284 (3.61) nm; 1D and 2D NMR (600 MHz, DMSO-d6) see Table 3.18 and 
Figures 3.57 and 3.58. HRESI(+)MS m/z 381.1157 [M+Na]+ (calcd for C16H22NaO9 381.1156). 
 
Prolinimine B (3.07): yellow oil; [a]22D –251.2 (c 0.025, MeOH); UV (MeOH) lmax (log e) 276 (4.09), 
362 (4.42) nm; 1D and 2D NMR (600 MHz, MeOH-d4) see Table 3.2 and Figures 3.6–3.8 and S8; 
HRESI(+)MS m/z 399.1645 [M+Na]+ (calcd for C18H24N4NaO5 399.1639).  
 
Prolinimine C (3.08): red oil; [a]22D –184.2 (c 0.027, MeOH); UV (MeOH) lmax (log e) 314 nm 
(4.56); 1D and 2D NMR (600 MHz, MeOH-d4) see Table 3.3 and Figures 3.11 and 3.12; 
HRESI(+)MS m/z 479.1905 [M+Na]+ (calcd for C23H28N4NaO6 479.1901).  
 
Prolinimine D (3.09): brown oil; [a]22D –152.8 (c 0.01, MeOH); 1D NMR (600 MHz, DMSO-d6) 
was identical to those of the synthetic prolinimine D; HRESI(+)MS m/z 713.2927 [M+Na]+ (calcd 
for C35H42N6NaO9 713.2905). 
 
Cordyrrole B (3.10): white needles; [a]22D –50.1 (c 0.275, MeOH); 1D and 2D NMR (600 MHz, 
DMSO-d6) see Table 3.6 and Figures 3.25 and 3.26; HRESI(+)MS m/z 479.1905 [M+Na]+ (calcd 
for C23H28N4NaO6 479.1901).; HRESI(+)MS m/z 354.1409 [M+H]+ (calcd for C14H20N5O6 
354.1408). 
 
Evlachosine A (3.11): white powder; [a]22D –35.6 (c 0.05, MeOH); 1D and 2D NMR (600 MHz, 
DMSO-d6) see Table 3.8 and Figures 3.28 and 3.29; HRESI(+)MS m/z 418.1335 [M+Na]+ (calcd 
for C16H21N5NaO7 418.1333). 
 
Evlachosine B (3.12): white powder; ESI(+)MS m/z 354.1 [M+H]+. 
 
dimethyl-2,4-pyrrolo-dicarboxylate (3.13): yellow oil; 1D and 2D NMR (600 MHz, DMSO-d6) see 
Table 3.19 and Figures 3.60 and 3.61; HRESI(+)MS m/z 206.0427 [M+Na]+ (calcd for C8H9NNaO4 
206.0424). 
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3.11.5 Biomimetic synthesis of prolinimines A–D (3.14 and 3.07–3.09) 
3.11.5.1 Synthesis of N-nitroso-L-proline methyl ester (3.19) 
 A sample of L-proline (3.18) (1 g, 8.69 mmol) and NaNO2 (6 g) in water 
(10 mL) was treated with H2SO4 (3 M, 16 mL) at room temperature over 
10 min, after which the reaction mixture was extracted with diethyl ether 
(4 ´ 25 mL). The combined organic layers were concentrated in vacuo to 
yield a 1.8:1 mixture of the syn and anti isomers of N-nitroso-L-proline (865 mg, 69%) as a white 
solid. 1H NMR (600 MHz, MeOH-d4),(mixture of isomers, syn: anti = 1.8:1) dH 5.28 (dd, J = 8.6, 3.1 
Hz, 1H) , 4.49 (dd, J = 8.6, 5.0 Hz, 1.8H), 4.46-4.42 (m, 1.8H), 4.35-4.30 (m, 1.8H), 3.70-3.60 (m, 
2H), 2.47-2.36 (m, 2.8H), 2.33-2.28 (m, 1H), 2.23-2.16 (m, 1.8H), 2.12-1.99 (m, 5.6H); 13C NMR 
(150 MHz, MeOH-d4) dc 174.0, 172.3, 63.7, 59.9, 51.5, 47.1, 30.0, 29.1, 24.3, 22.2; HRESI(+)MS 
m/z 167.0432 [M+Na]+ (calcd for C5H8N2NaO3 167.0427) 
A sample of N-nitroso-L-proline (1.2 g, 8.3 mmol) dissolved in anhydrous MeOH (40 mL) and conc. 
H2SO4 (700 µL) was stirred at room temperature overnight after which the reaction mixture was 
concentrated in vacuo and the residue dissolved in DCM (40 mL) and washed with saturated aqueous 
NaHCO3 (40 mL). After decanting the DCM layer, the aqueous layer was re-extracted with DCM (3 
´ 40 mL) and the combined DCM extracts were dried over Na2SO4, filtered and concentrated in 
vacuo to yield 1.6:1 mixture of the syn and anti isomers of N-nitroso-L-proline methyl ester (3.19) 
(1.03 g, 78%) as a yellow oil. 1H NMR (600 MHz, CDCl3),(mixture of isomers, syn: anti = 1.6:1), dH 
5.23 (dd, J = 8.5, 3.2 Hz, 1H) , 4.45 (dd, J = 8.0, 4.6 Hz, 1.6H), 4.42-4.38 (m, 1.6H), 4.35-4.30 (m, 
1.6H), 3.74 (s, 3H),  3.66 (s, 4.8H),  3.67-3.56 (m, 2H), 2.36-2.23 (m, 4.6H), 2.20-2.14 (m, 1.6H), 
2.06-1.97 (m, 5.2H); 13C NMR (150 MHz, CDCl3) dc 171, 169.2, 62.0, 58.0, 52.9, 52.6, 50.0, 45.7, 
29.0, 27.8, 23.3, 21.2; HRESI(+)MS m/z 181.0591 [M+Na]+ (calcd for C6H10N2NaO3 181.0584). 
3.11.5.2 Synthesis of N-amino-L-proline methyl ester (3.15) 
 Aliquots of N-nitroso-L-proline methyl ester (3.19) (250-363 mg, 1.58-2.29 mmol) 
was reduced with Zn dust (1.0-1.4 g) in 50% HOAc (12.5-18 mL) at 0 °C over 15 
min,95. with HPLC-MS analysis confirmed quantitative conversion to (3.15); 
HRESI(+)MS m/z 145.0973 [M+H]+ (calcd for C6H12N2O2 145.0972). 
3.11.5.3 Synthesis of prolinimine A (3.14) 
An aliquot of 3.19 (363 mg, 2.29 mmol) was transformed to 3.15. 3.15 was dissolved in anhydrous 
MeOH (20 mL) and treated with 5-hydroxymethylfurfural (3.17) (289 mg, 2.29 mmol) and stirred at 
room temperature for 4 h to yield prolinimine A (3.14) (392 mg, 68% yield). (3.14): [a]22D -111.9 (c 
0.155, MeOH); 1D and 2D NMR (600 MHz, MeOH-d4) see Table 3.5 and Figure 3.23; HRESI(+)MS 
m/z 275.1010 [M+Na]+ (calcd for C12H16N2NaO4 275.1002) 
O
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3.11.5.4 Synthesis of prolinimine B (3.07)  
An aliquot of 3.19 (250 mg, 1.58 mmol) was transformed to 3.15. 3.15 was dissolved in anhydrous 
MeOH (20 mL) and treated with 2,5-furandicarboxaldehyde (3.16) (90 mg, 0.72 mmol), stirred at 
room temperature for 4 h to yield prolinimine B (3.07) (251 mg, 93% yield). (3.05): [a]22D -260.4 (c 
0.14, MeOH); 1H NMR (600 MHz, MeOH-d4) d 7.11 (s, 1H) , 6.44 (s, 1H), 6.32 (d, J = 3.3, 1H), 
4.50 (s, 2H), 4.27 (dd, J = 8.9, 3.2 Hz, 1H), 3.72 (s, 3H), 3.46 (m, 1H), 3.23 (dd, J = 16.9, 7.7 Hz, 
1H), 2.26 (m, 1H), 2.06 (m, 2H), 2.01 (m, 1H); 13C NMR (150 MHz, MeOH-d4) dc 175.8, 152.8, 
125.4, 110.6, 66.1, 52.7, 49.9, 29.5, 23.5; HRESI(+)MS m/z 399.1650[M+Na]+ (calcd for 
C18H24N4NaO5 399.1639) 
3.11.5.5 Synthesis of prolinimines C (3.08) and D (3.09)  
A sample of prolinimine A (3.14) (30 mg, 0.12 mmol) dissolved in THF (1 mL) acidified with TFA 
(50 µL) and additional portions of 3.14 (100 mg) were added at room temperature over 7 days. The 
reaction mixture was purified using preparative reversed phase HPLC (Phenomenex Luna-C18, 21.2 
mm ✕ 25 cm, 10 µm, 20 mL/min, gradient elution 90% H2O/MeCN to 100% MeCN over 30 min) to 
yield prolinimine C (3.08) (10 mg, 8.5%). prolinimine D (3.09) (3 mg, 2.5%). (3.08): [a]22D -185.3 
(c 0.0082, MeOH); 1H NMR (600 MHz, MeOH-d4) d 7.13 (s, 1H) , 6.36 (d, J = 3.3 1H), 6.15 (d, J = 
3.3, 1H), 4.26 (dd, J = 8.9, 3.2 Hz, 1H), 4.02 (s, 2H), 3.48 (m, 1H), 3.26 (dd, J = 16.9, 7.7 Hz, 1H), 
2.26 (m, 1H), 2.06 (m, 2H), 2.01 (m, 1H); 13C NMR (150 MHz, MeOH-d4) dc 175.9, 152.7, 152.5, 
126.3, 109.9, 109.8, 66.1, 52.7, 50.0, 29.5, 28.4, 23.5; HRESI(+)MS m/z 479.1908 [M+Na]+ (calcd 
for C23H28N4NaO6 479.1901). (3.09): [a]22D -110.4 (c 0.01, MeOH); 1D and 2D NMR (600 MHz, 
DMSO-d6) see Table 3.4 and Figures 3.15-3.17. HRESI(+)MS m/z 713.2911 [M+Na]+ (calcd for 
C35H42N6NaO9 713.2905) 
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3.11.6 Marfey’s analysis of prolinimine B (3.07)  
An aliquot of the natural prolinimine B (3.07) (50 µg) dissolved in 6 M HCl (100 µL) was heated to 
100 °C in seal vial for 12 h, after which hydrolysates were evaporated to dryness at 40 °C under a 
stream of dry N2. The resulting hydrolysates were treated with 1 M NaHCO3 (20 µL) and L-FDAA 
(1-fluoro-2-4-dinitrophenyl-5-L-alanine amide, 1% solution in acetone, 40 µL) at 40 °C for 1 h, after 
which the reactions were neutralised with 1 M HCl (20 µL), diluted with MeCN (100 µL) and filtered 
(0.45 µm PTFE) prior to HPLC-ESIMS analysis [Agilent Zorbax SB-C3 column, 5 μm, 150 × 4.6 
mm, 50 °C, 1 mL/min, 55 min gradient elution from 80:15:5 H2O:MeOH:MeCN to 35:60:5 
H2O:MeOH:MeCN with an isocratic 0.05% v/v formic acid modifier]. Authentic samples of L amino 
acids were derivatized with either D-FDAA, or L-FDAA, and analysed by HPLC-DAD-ESIMS and 
UV (340 nm). 
3.11.7 Ammonolysis of cordyrrole B (3.10) 
An aliquot of the natural cordyrrole B (3.10) (1 mg, 0.003 mmol) was deacetylated using the 
previously described method110 by treatment with 7N methanolic ammonia (0.5 mL), incubated at 
room temperature in seal vial for 4 h, after which reaction mixture was evaporated to dryness at 40 
°C under a stream of dry N2 to to yield N6-(hydroxyethyl)adenosine (3.21) (0.8 mg, 92%).(3.21): 1H 
NMR (600 MHz, DMSO-d6) see Table 3.9 and Figure 3.33; HRESI(+)MS m/z 334.1128 [M+Na]+ 
(calcd for C12H17N5NaO5 334.1122). 
3.11.8 Detection of N6-(hydroxyethyl)adenosine (3.21) in F2.10 
Aliquots (5 µL) of F2.10 (2 mg/mL) and 3.21 (0.5 mg/mL) were analysed on Agilent 1100 series 
LC/MSD instrument with Zorbax C8 column (150 × 4.6 mm, 5 µm) under the standard gradient 
elution conditions (eluting with 1.0 mL/min from 90% H2O/MeCN to 100% MeCN over 15 min, then 
held at 100% MeCN for 5 min with UV-vis detection at 210, 254 and 268 nm). 
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3.11.9 Single crystal X-ray analysis of evlaquinone A (3.01) 
 
 
Table 3.21. Crystal data and structure refinement for evlaquinone A (3.01) 
Identification code 1701os1 
Empirical formula C30 H18 O13.H2O 
Formula weight 604.46 
 
Temperature 190(2) K 
Wavelength 1.54184 Å 
Crystal system Monoclinic 
Space group P21/n 
Unit cell dimensions a = 6.8401(5) Å      a= 90°. 
b = 15.1562(15) Å  b= 92.731(7)°. 
c = 24.0227(15) Å   g = 90°. 
Volume 2487.6(3) Å3 
Z 4 
Density (calculated) 1.614 Mg/m3 
Absorption coefficient 1.120 mm 
F(000) 1248 
Crystal size 0.15 x 0.05 x 0.05 mm3 
Theta range for data collection 3.45 to 62.48°. 
Index ranges -7<=h<=7, -17<=k<=16, -27<=l<=19 
Reflections collected 11645 
Independent reflections 3941 [R(int) = 0.0456] 
Completeness to theta = 
62.48° 
99.5 % 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1 and 0.98811 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3941 / 0 / 417 
Goodness-of-fit on F2 1.033 
Final R indices [I>2sigma(I)] R1 = 0.0492, wR2 = 0.1214 
R indices (all data) R1 = 0.0734, wR2 = 0.1362 
Largest diff. peak and hole 0.181 and -0.349 e.Å-3 
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Chapter 4 : Further investigations into prolinimines 
4.1 Introduction 
As noted in chapter 3, the Schiff bases of N-amino-L-proline, prolinimines A–D (4.01–4.04), were 
detected and/or isolated from rice grain solid medium culture of the fungus Evlachovaea sp. CMB-
F563. The rare amino acid, N-aminoproline, has a limited occurrence in the natural world, with its 
sole occurrence being conjugated into the potent flaxseed anti-pyridoxine dipeptide linatine (4.05). 
In chickens reared on flaxseed meal, linatine undergoes in vivo proteolysis to N-amino-D-Pro, which 
then forms a Schiff base with and sequesters the aldehyde pyridoxine, leading to vitamin B6  
deficiency  syndrome,7  rendering linseed meal unsuitable as animal feed.95,111,112 Naturally occurring 
hydrazones are also less common, with a recent review109 listing katorazone (4.06), yoropyrazone 
(4.07), NG-061 (4.08), gyromitrins (4.09–4.15), leucoagaricone (4.16), schaefferal A (4.17) and B 
(4.18), farylhydrazones A (4.19) and B (4.20), rubroflavins (4.21–4.23), veratrylidene-hydrazide 
(4.24), psammaplin G (4.25), and the toxic phosphorus-containing hydrazine 4.26. This chapter 
expands on our earlier prolinimine discovery, to understand the biosynthetic origin through detection 
of the presumed biosynthetic precursors. Prolinimines A (4.01) and B (4.02) are the condensation 
products of N-amino-L-proline methyl ester (4.27) with furan aldehydes, 5-hydroxymethylfurfural 
(4.28) and 2,5-furandicarboxaldehyde (4.29). To achieve our objective, we developed analytical 
methods for the detection of the putative precursors N-amino-L-proline methyl ester (4.27) and its 
carboxylic acid 4.30, and the furan aldehydes 4.28 and 4.29. This was achieved through chemical 
derivatization to yield more sensitive analytes that can be detected by UHPLC-DAD and HPLC-
DAD-ESIMS analyses. 
 
Figure 4.1. Structures of prolinimines A–D (4.01–4.04) 
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Figure 4.2. Structures of linatine (4.05) and known hydrazone natural products (4.06–4.26) 
 
4.2 Determination of the biosynthetic precursors of prolinimines 
In this section, we aimed to detect putative biosynthetic precursors of prolinimines A (4.01) and B 
(4.02), namely N-amino-L-proline methyl ester (4.27) and its carboxylic acid 4.30 and the furan 
aldehydes 4.28 and 4.29, in rice cultivations of CMB-F563. 
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Figure 4.3. Putative biosynthetic precursors 4.27–4.30 of prolinimines A and B 
 
4.2.1 What is the source of furan aldehydes? 
Reviewing the literature showed 5-hydroxymethylfurfural (4.28) as a thermal decomposition product 
of reducing sugars113 formed during the processing and preparation of carbohydrate containing foods 
such as dried fruits, jams, honeys and coffee.114-116 In addition to other reports highlighting the 
presence of this aldehyde in starch containing cereals including rice-wheat flakes.117 
The isolation of prolinimines from medium grain solid rice cultivation and their absence in various 
broth media, together with the aforementioned history of 4.28, led us to hypothesize the presence of 
5-hydroxymethylfurfural (4.26) and its oxidation product 4.29 in autoclaved un-inoculated rice grain 
media. To test this hypothesis, heterogeneous mixtures of 30 d matured, un-inoculated rice grain 
media (25 g) and EtOAc (50 mL), were prepared, with and without addition of N-amino-L-proline 
methyl ester (4.27) (20 mg) in MeOH (5 mL). Aliquots of solvent (1 mL) removed at regular intervals 
over 24 h, dried under N2 at 40 °C, suspended in MeOH (40 µL) and filtered, were subjected to 
HPLC-DAD-ESIMS analysis. Single ion extraction (SIE) successfully detected the presence of both 
4.01 (m/z 253) and 4.02 (m/z 377) in samples treated with 4.27 (Figure 4.4), confirming the presence 
of 4.28 and 4.29 in un-inoculated rice grain media. Likewise, the absence of 4.01 and 4.02 in rice 
grain media not treated with 4.27 confirmed CMB-F563 as the source of 4.27. Of note, the 
concentration of 4.01 and 4.02 was increasing with increasing time of extraction. This could be 
explained by the matrix nature of solid rice which results in sustained slow release of furan aldehydes. 
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Figure 4.4. Single ion extraction chromatograms at m/z [M+H]+ (a) prolinimine A (4.01) (m/z 253) (tR = 7.5 min) (b) 
prolinimine B (4.02) (m/z 377) (tR = 10.5 min), in 30 d rice medium treated with 4.27, (c) prolinimine A (4.01) (m/z 253) 
synthetic standard ,and (e) prolinimine B (4.02) (m/z 377) synthetic standard. 
 
4.2.2 How to detect N-amino-L-proline methyl ester and its carboxylic acid? 
Having synthetic standards of N-amino-L-proline methyl ester (4.27) and its carboxylic acid 4.30, the 
lack of a significant UV-vis chromophore, and water solubility characteristics encouraged us to 
develop a Schiff base HPLC method for their detection (inspired by the prolinimines). The furan 
aldehydes were deemed unsuitable given their presence in un-inoculated rice medium and their 
inability to form a Schiff base with N-amino-L-proline carboxylic acid (4.30). The latter was evident 
from the lack of Schiff base formation (Figure 4.5) upon addition of an aliquot (40 µL) of 5-
hydroxymethlfurfural (4.28) (5 mg/mL in H2O) to M1 broth (1.5 mL) supplemented with an aliquot 
(40 µL) of 4.30 (5 mg/mL in H2O). Consequently, a more reactive “unnatural” aldehyde, 2,4-
dinitrobenzaldehyde (4.31), was chosen. 
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Figure 4.5. UHPLC-DAD (300 nm) chromatograms of extracts of (a) M1 broth blank, (b) M1 broth supplemented with 
the acid 4.30 treated with 4.28 and (c) M1 broth supplemented with the ester 4.27 treated with 4.28 
 
4.2.2.1 Synthesis of 2,4-dinitrobenzaldehyde Schiff bases 
Synthetic Schiff bases 4.32 and 4.33 prepared by the reaction of 2,4-dintrobenzaldehyde with N-
amino-L-proline methyl ester (4.27) and its carboxylic acid 4.30, respectively (Scheme 4.1). N-
nitroso-L–Pro methyl ester (4.34) and its carboxylic acid 4.35 were individually reduced to N-amino 
analogues. Exposure of N-amino analogues to 4.31 yielded the corresponding Schiff bases (Scheme 
4.1). Synthetic 4.32 and 4.33 were elucidated by detailed spectroscopic analysis (1D and 2D NMR, 
HRESIMS). In addition, an aliquot of 4.32 and 4.33 were analysed by UHPLC-DAD, which revealed 
their obvious separation and common UV-vis chromophore (Figure 4.6). 
 
Scheme 4.1. Synthesis of 2,4-dinitrobenzaldehyde Schiff bases 4.32 and 4.33. (i) Zn, H2O/HOAc, 0 oC, 15 min; (ii) 
anhydrous MeOH, rt, 4 h 
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Figure 4.6. UHPLC-DAD (400 nm) chromatograms of synthetic 4.32 and 4.33 and their UV-vis (UHPLC-DAD, 
H2O/MeCN plus TFA) spectrum (inset) 
 
4.2.2.2 The presence of N-amino-L-proline methyl ester and/or its carboxylic acid in rice 
cultivation of CMB-F563 
 The ability of 4.31 to detect 4.27 and 4.30 in culture media was determined by supplementing un-
inoculated M1 broth (1.5 mL) in a 24-well microbioreactor format with an aliquot (40 µL) of stock 
solutions (5 mg/mL in H2O) of either aminoprolines 4.27 or 4.30. Both solutions were treated with 
an aliquot (40 µL) of stock solution of 4.31 (5 mg/mL in 20% aqueous DMSO) and extracted with 
EtOAc (2 mL) in situ at 150 rpm for 60 min. The organic layer was filtered through 0.45 µm Millipore 
sterile filter into 2 mL vials and dried under N2 at 40 oC. The crude extracts were dissolved in MeOH 
(200 µL) and subjected to UHPLC-DAD chromatographic analysis. Analysis of UHPLC-DAD data 
confirmed the rapid and quantitative formation of the Schiff bases 4.32 and 4.33 (Figure 4.7) 
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Figure 4.7. UHPLC-DAD (400 nm) chromatograms of extracts of (a) M1 broth blank, (b) M1 broth supplemented with 
4.30 treated with 4.31 and (c) M1 broth supplemented with 4.27 treated with 4.31 
 
Having established detection method, 30 d rice media (35 g) cultivations of CMB-F563 were 
extracted with EtOAc (200 mL) by shaking at 150 rpm with and without co-addition of 2,4-
dinitrobenzaldehyde (4.31) (60 mg) in 20% aqueous DMSO (12 mL). Aliquots (1 mL) were taken 
after 60 min and dried under N2 at 40 oC. The crude extracts were dissolved in MeOH (40 µL) and 
subjected to UHPLC-DAD and HPLC-DAD-MS analyses. UHPLC-DAD analysis (Figure 4.8) 
detected 4.32 in extracts exposed to 4.31 with no detection of 4.33. The identity of 4.32 was 
confirmed by comparing the retention time, UV-vis and ESI(±)MS data with the synthetic standard. 
This observation confirmed the production of the methyl ester 4.27 but not the carboxylic acid 4.30 
by CMB-F563.  
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Figure 4.8. UHPLC-DAD (400 nm) chromatograms of the crude extracts of 30 d CMB-F563 rice culture (a) without and 
(b) with, co-addition of 4.31 
 
4.2.2.3 Is N-amino-L-Pro methyl ester production exclusive to rice grain media? 
The discovery of N-amino-L-Pro methyl ester (4.27) as a real natural product in CMB-F563 rice 
cultivation led us to speculate the ability of CMB-F563 to produce 4.27 in various broth media. A 
panel of eleven broth media (MATRIX) were inoculated with an aliquot (20 µL) of CMB-F563 seed 
culture and incubated for 9 days at 26.5 oC. After incubation, cultures were extracted with EtOAc (2 
mL) in situ at 150 rpm for 60 min with and without co-addition of an aliquot (40 µL) of 4.31 (5 
mg/mL in 20% aqueous DMSO). The crude extracts were analysed by UHPLC-DAD. UHPLC-DAD 
analysis revealed optimal levels of production of 4.27 in peptone yeast glucose (PYG) broth and 
tryptone soy broth (TSB) media, significant levels in M1, M2 and yeast extract sucrose (YES) media, 
and no production in basal broth, sabouraud dextrose broth (SDB) and potato dextrose broth (PDB) 
media (Figure 4.9).  
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Figure 4.9. UHPLC-DAD (400 nm) chromatograms of crude extracts of CMB-F563 cultures treated with 4.31 cultivated 
in (a) M1 broth, (b) ISP2 broth, (c) PY broth, (d) M2 broth, (e) PDB, (f) TSB, (g) SDB, (h) PYG broth, (i) basal broth, 
(j) Czapek broth, and (k) YES broth. 
 
Correlating the production level of 4.27 with the media composition implicated the significance of 
either peptone and/or yeast extract in production of 4.27. To test this hypothesis, MATRIX trials were 
repeated using M1 broth deficient in peptone (M1-P), yeast extract (M1-Y), or both (M1-PY), and 
SDB broth augmented with peptone (SDB+P), yeast extract (SDB+Y), or both (SDB+PY). These 
analyses demonstrated that the production of 4.27 in CMB-F563 cultivations is dependent on the 
presence of peptone and/or yeast extract (Figures 4.10 and 4.11) which might act either as activating 
signals to genes responsible for the biosynhesis of 4.27 or precursor to 4.27. 
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Figure 4.10. UHPLC-DAD (400 nm) chromatograms of crude extracts of CMB-F563 cultures treated with 4.31 cultured 
in (a) M1 broth, (b) M1-P broth, (c) M1-Y broth and (d) M1-PY. 
 
Figure 4.11. UHPLC-DAD (400 nm) chromatograms of crude extracts of CMB-F563 cultures treated with 4.31 cultured 
in (a) SDB broth, (b) SDB+P broth, (c) SDB+Y broth and (d) SDB+PY. 
 
4.2.2.4 Is N-amino-L-Pro methyl ester production exclusive to CMB-F563? 
With knowledge of media requirements, and armed with a highly sensitive analytical method capable 
of detecting even trace levels of the cryptic secondary metabolite 4.27 in crude extracts, PYG 
(MATRIX)61 cultivations of ´9 additional fungi chosen from our collection (Fusarium sp. CMB-
NF041, Aspergillus terreus CMB-M0231F,118 Penicillium roseopurpureum CMB-MF038,69,118 
Eupenicillium javanicum CMB-MF036, Chaunopycnis sp. CMB-MF028,118,119 Beauvaria bassiana 
CMB-MF026,118 Penicillium herquei CMB-MF025, Paecilomyces sp. CMB-MF010,118,120 and 
Penicillium citrinum CMB-MF006 were examined. The chemical profiles of the crude extracts of the 
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cultures treated with 4.31 were compared with the crude extracts of untreated cultures. This study 
confirmed that the biosynthesis of 4.27 was unique to CMB-F563 (Figure 4.12). Two fungi, 
Paecilomyces sp. CMB-MF010 and Penicillium herquei CMB-MF025, were producing metabolites 
at the retention time of 4.32. However, these were confirmed not to be 4.32 by comparing their UV-
vis spectra and ESI(±)MS data with those of authentic 4.32. 
 
Figure 4.12. UHPLC-DAD (400 nm) chromatograms of crude extracts of different fungal cultures treated with 4.31 
 
4.3 Stability of N-amino-L-Pro methyl ester in M1 broth 
Mayengbam et al121 carried out a stability study of synthetic N-amino-D-Pro in solution, concluding 
that it was stable for 48 h if stored at 3 oC and only for 3 h at 37 oC. This finding led us to check the 
stability of N-amino-L-Pro methyl ester (4.27) in culture media. An aliquot of M1 broth (1.5 mL) in 
two wells was individually supplemented with an aliquot (40 µL) of 4.27 (5 mg/mL in H2O). The 
first well was treated with an aliquot (40 µL) of 4.31 (5 mg/mL in 20% aqueous DMSO) at day 0. 
Both wells were incubated for 9 days at 26.5 oC. After incubation, the second well was treated with 
an aliquot (40 µL) of 4.31 (5 mg/mL in 20% aqueous DMSO) and both wells were extracted with 
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EtOAC (2 mL) in situ at 150 rpm. UHPLC-DAD (Figure 4.13) analysis revealed hydrolysis of the 
methyl ester 4.27 (i.e. 4.32) to its carboxylic acid 4.30 (i.e. 4.33).  
 
Figure 4.13. UHPLC-DAD (400 nm) chromatograms of M1 broth supplemented with 4.27 treated with 4.31 (a) directly 
and (b) after 9 days of incubation at 26.5 oC. 
 
To confirm this observation, a timeline study was 
conducted. An aliquot of M1 broth (1.5 mL) in 15 mL 
falcon tube was supplemented with the methyl ester 4.27 
(40 µL, 5 mg/mL in H2O). An aliquot (40 µL, 5 mg/mL 
in 20% aqueous DMSO) of the derivatising agent 4.31 
was added to one of the aforementioned falcon tubes 
every 24 hours for 10 days, followed by extraction with 
EtOAc (2 mL) in situ at 150 rpm for 60 min. The organic 
layer was filtered through 0.45 µm Millipore sterile filter 
into 2 mL vials and dried under N2 at 40 oC. The crude 
extracts were dissolved in MeOH (40 µL) and subjected 
to UHPLC-DAD chromatographic analysis. The results 
(Figure 4.14) confirmed the gradual hydrolysis of 4.27 
(i.e. 4.32) to 4.30 (i.e. 4.33) in M1 broth. 
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4.4 The location of N-amino-L-Proline methyl ester in CMB-F563 
The observation that the methyl ester 4.27 was unstable in M1 broth, combined with the failure to 
detect the acid 4.30 in cultivation of CMB-F563, suggested that 4.27 was retained within the fungal 
mycelia. To test this hypothesis, M1 broth (5 mL) in a 50 mL falcon tube was inoculated with CMB-
F563 and incubated at 26.5 oC for 9 days under static conditions. After incubation, the mycelia were 
physically separated from the culture broth using an inoculation loop. The mycelia and culture broth 
were then individually extracted with EtOAc (5 mL) by shaking at 150 rpm for 60 min with co-
addition of an aliquot (150 µL) of a stock solution of the derivatising agent 4.31 (5 mg/mL in 20% 
aqueous DMSO). The organic layer was filtered through 0.45 µm Millipore sterile filter, dried under 
N2 at 40oC, and redissolved in MeOH (120 µL) and subjected to UHPLC-DAD chromatographic 
analysis. As predicted, the UHPLC-DAD analysis confirmed the presence of 4.27 in the mycelia of 
CMB-F563, but not in the culture broth (Figure 4.15). 
 
Figure 4.15. UHPLC-DAD (400 nm) chromatograms of crude extracts of CMB-F563 of (a) mycelia treated with 4.31 
and (b) culture broth treated with 4.31 
 
As a conclusion of the previous section, this is the first report of the natural metabolite 4.27. It is also 
evident that prolinimines A (4.01) and B (4.02) were the products of the chemical transformation 
between N-amino-L-Pro methyl ester (4.27) from the fungus, and furan aldehydes 4.28 and 4.29 from 
un-inoculated culture media. Although prolinimines A (4.01) and B (4.02) were detected in the crude 
extracts, and produced from natural sources, their status as natural products is intriguing, and depends 
heavily on which definition of natural products is applied. 
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4.5 N-amino-L-Pro methyl ester Schiff bases library  
4.5.1 Synthesis of N-amino-L-Pro methyl ester Schiff bases (4.36–4.58) 
A series of N-amino-L-Pro methyl ester Schiff bases (4.36–4.58) were prepared using the same 
method described in chapter 3 for the synthesis of prolinimines A (4.01) and B (4.02), where 4.34 
was reduced to 4.27. Schiff bases were synthesized by condensing the corresponding aromatic 
aldehydes with 4.27. 
 
Figure 4.16. Structures of synthetic N-amino-L-Pro methyl ester Schiff bases (4.36–4.58) 
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4.5.2 Stability study 
To evaluate the hydrolytic stability of the Schiff bases (4.01, 4.02, 4.36–4.45, and 4.49–4.58). An 
aliquot (0.25 mg) of the Schiff base was dissolved in 50% MeCN/H2O (500 µL) in 2 mL vials (´2), 
together with an aliquot (10 µL) of 4.31 (50 mg/mL in MeCN). An aliquot (5 µL) of 1% TFA in 
MeCN was added to one of the two vials to investigate stability under acidic conditions (i.e. 0.01% 
TFA). An aliquot (1 µL) from each vial was analysed by UHPLC-DAD every 24 h over a period of 
8 days. The extent of hydrolysis was quantified by comparing conversion to the 2,4-
dinitrobenzaldehyde Schiff base 4.32. 
In the absence of TFA, 4.32 was detected in the chemical profiles of two Schiff bases, namely 4.50 
and 4.56, while, in the presence of TFA, Schiff bases stability could be arranged to one of three 
categories (see Table 4.1 and Figure 4.17 for more details). 
 
Table 4.1. Classification of Schiff bases according to their stability in the presence of TFA 
Category Degree of stability Schiff base number 
A Strongly stable 4.01, 4.02, 4.36, 4.40–4.43, 4.53, 4.57 and 4.58  
B  Moderately stable 4.37, 4.39, 4.45, 4.52, and 4.54 
C Weakly stable 4.38, 4.44, 4.49–4.51, 4.55, and 4.56 
 
 
Figure 4.17. UHPLC-DAD (210 nm) peak area of 2,4-dinitrobenzaldehyde hydrazone 4.32 at day 8 in the presence of 
TFA (0.01% v/v). 
 
Figure 4.17 showed a hydrolytic stability relationship where Schiff bases derived from pyridine 
aldehydes, furan-2-carboxaldehydes and nitro substituted benzaldehydes have 
the highest stability while those derived from indole aldehydes and hydroxyl or 
carboxyl substituted benzaldehydes have the lowest stability. The high structure 
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similarity and hydrolytic stability of Schiff bases derived from pyridine-4-carboxaldehyde and 
pyridoxal (4.59) could explain the antipyridoxine (vitamin B6 inhibition) effect of N-amino-D-proline 
previously reported in literature.95,111,112 
4.5.3 Biological evaluation 
All synthetic Schiff bases (4.01–4.04, 4.32, 4.33, and 4.36–4.58) were evaluated for antimicrobial 
and cytotoxicity properties.  
4.5.3.1 Antibacterial assay 
Antibacterial properties of Schiff bases were tested against Gram-positive bacteria (S. aureus 
ATCC25923 and B. subtilis ATCC6633) and Gram-negative bacteria (E. coli ATCC11775 and P. 
aeruginosa ATCC10145). None of the tested compounds showed any activity (i.e. less than 50% 
inhibition) at concentration of 30 µM. 
 
Figure 4.18. Antibacterial properties of Schiff bases (30 µM) against (a) S. aureus ATCC25923, (b) B. subtilis 
ATCC6633, (c) E. coli ATCC11775, and (d) P. aeruginosa ATCC10145 
 
4.5.3.2 Antifungal assay 
Antifungal properties of Schiff bases were tested against C. albicans ATCC10231. None of the tested 
compounds showed any activity (i.e. less than 50% inhibition) at concentration of 30 µM. 
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Figure 4.19. Antifungal properties of Schiff bases (30 µM) against Candida albicans ATCC10231 
4.5.3.3 Cytotoxicity assay 
Cytotoxicity properties of Schiff bases were tested against human colon (SW620), lung (NCIH460), 
and hepatic (HepG2) cancer cells. None of the tested compounds showed any activity (i.e. less than 
50% inhibition) at concentration of 30 µM. 
 
Figure 4.20. Cytotoxicity properties of Schiff bases (30 µM) against (a) SW620, (b)NCIH460, and (c) HepG2 
 
4.6 Conclusion 
This chapter describes analytical studies designed to better understand the formation of prolinimines 
isolated from CMB-F563. Inspired by prolinimines Schiff bases, we developed analytical methods to 
4.
01
4.
02
4.
03
4.
04
4.
32
4.
33
4.
36
4.
37
4.
38
4.
39
4.
40
4.
41
4.
42
4.
43
4.
44
4.
45
4.
46
4.
47
4.
48
4.
49
4.
50
4.
51
4.
52
4.
53
4.
54
4.
55
4.
56
4.
57
4.
58
ke
to
co
na
zo
le
D
M
S
O
 (1
%
)0.0
0.5
1.0
1.5
2.0
O
D
60
0
4.
01
4.
02
4.
03
4.
04
4.
32
4.
33
4.
36
4.
37
4.
38
4.
39
4.
40
4.
41
4.
42
4.
43
4.
44
4.
45
4.
46
4.
47
4.
48
4.
49
4.
50
4.
51
4.
52
4.
53
4.
54
4.
55
4.
56
4.
57
4.
58
vi
nb
la
st
in
e
D
M
S
O
 (1
%
)0.0
0.2
0.4
0.6
0.8
1.0
1.2
O
D
60
0
(a)
4.
01
4.
02
4.
03
4.
04
4.
32
4.
33
4.
36
4.
37
4.
38
4.
39
4.
40
4.
41
4.
42
4.
43
4.
44
4.
45
4.
46
4.
47
4.
48
4.
49
4.
50
4.
51
4.
52
4.
53
4.
54
4.
55
4.
56
4.
57
4.
58
vi
nb
la
st
in
e
D
M
S
O
 (1
%
)0.0
0.2
0.4
0.6
0.8
1.0 (c)
4.
01
4.
02
4.
03
4.
04
4.
32
4.
33
4.
36
4.
37
4.
38
4.
39
4.
40
4.
41
4.
42
4.
43
4.
44
4.
45
4.
46
4.
47
4.
48
4.
49
4.
50
4.
51
4.
52
4.
53
4.
54
4.
55
4.
56
4.
57
4.
58
vi
nb
la
st
in
e
D
M
S
O
 (1
%
)0.0
0.5
1.0
O
D
60
0
(b)
O
D
60
0
Chapter 4: Further investigations into prolinimines 
 
 
129 
detect the putative precursors of prolinimines A and B, furan aldehydes and N-amino-L-Pro methyl 
ester and its carboxylic acid. The detection method for N-amino-L-Pro methyl ester and its carboxylic 
acid proved to be a valuable analytical tool to detect these UV-vis transparent water-soluble 
metabolites. Armed with sensitive analytical methods, the un-inoculated rice medium was determined 
to be the source of prolinimine precursor furan aldehydes, while, N-amino-L-Pro methyl ester was 
found to be a real natural product produced exclusively by CMB-F563 under a range of culture 
conditions, where it was retained in the mycelia. This finding suggested a new definition of natural 
products to be “the metabolites that are detected in the crude extract obtained from natural sources 
providing that they are not formed during the process of extraction”. According to our proposed 
definition, prolinimines A-D are considered artefacts. 
We evaluated and documented the chemical and biological properties of a range of Schiff bases 
between N-amino-L-Pro methyl ester and aromatic aldehydes whereas most Schiff bases were stable 
under neutral conditions, stability to acid conditions (TFA) was highly variable. The high stability of 
pyridine Schiff bases (i.e. irreversible) could explain the high selectivity of N-amino-Pro to pyridoxal 
(the main component of vitamin B6). 
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4.7  Experimental 
4.7.1 General experimental details 
Refer to Appendix 
4.7.2 Synthesis of Schiff bases library 
4.7.2.1 Synthesis of N-amino-L-Pro methyl ester (4.27) 
 Aliquots of N-nitroso-L-proline methyl ester (4.34) (258-456 mg, 1.79-2.89 mmol) 
were reduced with Zn dust (1.0-1.8 g) in 50% HOAc (13-22.5 mL) at 0 °C over 15 
min,95 with HPLC-MS analysis confirmed quantitative conversion to 4.27; 
HRESI(+)MS m/z 145.0973 [M+H]+ (calcd for C6H13N2O2 145.0972). 
4.7.2.2 Synthesis of 4.32 
 An aliquot of 4.34 (20 mg, 0.126 mmol) was transformed to 4.27, which 
was then dissolved in anhydrous MeOH (5 mL) and treated with 2,4-
dinitrobenzaldehyde (4.31) (20 mg, 0.102 mmol), at room temperature for 
4 h. The reaction mixture was then purified using preparative reversed 
phase HPLC (Phenomenex Luna-C18, 21.2 mm ✕ 25 cm, 10 µm, 20 
mL/min, gradient elution 50% H2O/MeCN to 100% MeCN over 15 min) to yield 4.32 (15 mg, 46.6% 
yield): [a]22D –170.6 (c 0.01, MeOH); 1H NMR (600 MHz, MeOH-d4) dH  8.75 (d, J = 2.2, 1H), 8.32 
(dd, J = 9.1, 2.2, 1H), 8.25 (d, J = 9.1, 1H), 7.61 (s, 1H), 4.51 (dd, J = 8.7, 3.0 Hz, 1H), 3.77 (s, 3H), 
3.60 (m, 1H), 3.49 (m, 1H), 2.36 (m, 1H), 2.16 (m, 2H), 2.13 (m,1H); 13C NMR (150 MHz, MeOH-
d4) dC 174.7, 146.7, 146.4, 138.8, 128.5, 127.7, 124.7, 122.0, 66.3, 53.0, 50.0, 29.6, 23.7; 
HRESI(+)MS m/z 345.0819 [M+Na]+ (calcd for C13H14N4NaO6 345.0806). 
4.7.2.3 Synthesis of 4.33 
 An aliquot of 4.35 (50 mg, 0.347 mmol) was transformed to 4.30, which 
was dissolved in anhydrous MeOH (5 mL) and treated with 2,4-
dinitrobenzaldehyde (4.31) (59 mg, 0.30 mmol), at room temperature for 
4 h to yield 4.33 (90 mg, 97% yield). An aliquot (12.7 mg) of 4.33 was 
purified using preparative reversed phase HPLC (Phenomenex Luna-C18, 
21.2 mm ✕ 25 cm, 10 µm, 20 mL/min, gradient elution 90% H2O/MeCN to 100% MeCN over 30 
min) to yield an analytically pure 4.33 (9.5 mg, 74.8 %): [a]22D –205.6 (c 0.01, MeOH); 1H NMR 
(600 MHz, MeOH-d4) dH 8.72 (dd, J = 2.2, 0.3, 1H) , 8.29 (ddd, J = 9.0, 2.2, 0.3 1H), 8.26 (d, J = 
9.0, 1H), 7.60 (s, 1H), 4.45 (dd, J = 8.7, 3.3 Hz, 1H), 3.60 (m, 1H), 3.47 (m, 1H), 2.38 (m, 1H), 2.16 
(m, 2H), 2.15 (m, 1H); 13C NMR (150 MHz, MeOH-d4) dC 176.1, 146.5, 146.2, 138.9, 128.4, 127.6, 
CO2Me
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124.2, 122.0, 66.4, 50.0, 29.8, 23.7; HRESI(+)MS m/z 331.0645 [M+Na]+ (calcd for C12H12N4NaO6 
331.0649). 
4.7.2.4 Synthesis of 4.36  
 An aliquot of 4.34 (365.5 mg, 2.25 mmol) was transformed to 4.27. 4.27 was 
dissolved in anhydrous MeOH (20 mL) and treated with 2-furancarboxaldehyde 
(185 µL, 2.23 mmol) at room temperature for 4 h to yield 4.36 (275 mg, 55.5% 
yield). (4.36): [a]22D –93.4 (c 0.16, MeOH); 1H NMR (600 MHz, MeOH-d4) 
dH 7.44 (t, J = 1.2, 1H), 7.17 (s, 1H) , 6.43 (2H), 4.28 (dd, J = 8.9, 3.2 Hz, 1H), 3.73 (s, 3H), 3.47 (m, 
1H), 3.25 (dd, J = 16.9, 7.8 Hz, 1H), 2.27 (m, 1H), 2.07 (m, 2H), 2.01 (m, 1H); 13C NMR (150 MHz, 
MeOH-d4) dc 175.8, 153.7, 143.4, 126.0, 112.6, 108.6, 66.1, 52.7, 49.9, 29.5, 23.5; HRESI(+)MS m/z 
245.0908 [M+Na]+ (calcd for C11H14N2NaO3 245.0897). 
4.7.2.5 Synthesis of 4.37 
 An aliquot of 4.27 (42 mg, 0.29 mmol) was dissolved in anhydrous MeOH (5 
mL) and treated with 3-furancarboxaldehyde (25 µL, 0.3 mmol) at room 
temperature for 4 h to yield 4.37 (35.8 mg, 55% yield). (4.37): [a]22D –105.2 (c 
0.01, MeOH); 1H NMR (600 MHz, MeOH-d4) d 7.62 (br s, 1H), 7.42 (t, J = 1.4, 1H), 7.27 (s, 1H) , 
6.65 (br s, 1H), 4.20 (dd, J = 8.8, 3.6 Hz, 1H), 3.72 (s, 3H), 3.47 (m, 1H), 3.19 (dd, J = 16.5, 7.9 Hz, 
1H), 2.25 (m, 1H), 2.05 (m, 2H), 1.99 (m, 1H); 13C NMR (150 MHz, MeOH-d4) dc 176.1, 144.9, 
144.8, 142.8, 129.1, 125.8, 108.3, 66.4, 52.6, 50.3, 29.3, 23.5; HRESI(+)MS m/z 245.0903 [M+Na]+ 
(calcd for C11H14N2NaO3 245.0897). 
4.7.2.6 Synthesis of 4.38 
An aliquot of 4.27 (42 mg, 0.29 mmol) was dissolved in anhydrous MeOH (5 mL) 
and treated with N-methyl-pyrrole-2-carboxaldehyde (25 µL, 0.25 mmol) at room 
temperature for 4 h to yield 4.38 (34.3 mg, 60% yield). (4.38): [a]22D –138 (c 
0.005, MeOH); 1H NMR (600 MHz, MeOH-d4) dH 7.34 (s, 1H), 6.61 (dd, J = 2.7, 
1.7, 1H), 6.20 (dd, J = 3.7, 1.7, 1H) , 5.99 (dd, J = 3.7, 2.7, 1H), 4.14 (dd, J = 8.6, 4.4 Hz, 1H), 3.72 
(s, 3H), 3.71 (s, 3H), 3.44 (m, 1H), 3.16 (dd, J = 16.5, 7.9 Hz, 1H), 2.23 (m, 1H), 2.05 (m, 2H), 1.99 
(m, 1H); 13C NMR (150 MHz, MeOH-d4) dc 176.3, 131.7, 130.8, 126.3, 111.8, 108.7, 67.0, 52.6, 
50.3, 36.4, 28.9, 23.5; HRESI(+)MS m/z 258.1214 [M+Na]+ (calcd for C12H17N3NaO2 258.1213). 
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4.7.2.7 Synthesis of 4.39 
An aliquot of 4.27 (42 mg, 0.29 mmol) was dissolved in anhydrous MeOH (5 mL) 
and treated with pyrrole-2-carboxaldehyde (24.8 mg, 0.25 mmol) at room 
temperature for 4 h to yield 4.39 (34.3 mg, 60% yield). (4.39): [a]22D –200.5 (c 
0.005, MeOH); 1H NMR (600 MHz, MeOH-d4) dH 7.29 (s, 1H), 6.72 (dd, J = 2.4, 
1.4, 1H), 6.19 (dd, J = 3.4, 1.4, 1H) , 6.06 (dd, J = 3.4, 2.4, 1H), 4.13 (dd, J = 8.8, 4.1  Hz, 1H), 3.72 
(s, 3H), 3.47 (m, 1H), 3.13 (dd, J = 16.5, 7.9 Hz, 1H), 2.23 (m, 1H), 2.05 (m, 2H), 1.98 (m, 1H); 13C 
NMR (150 MHz, MeOH-d4) dc 176.3, 131.5, 130.7, 120.5, 110.6, 109.7, 66.8, 52.6, 50.8, 29.1, 23.5; 
HRESI(+)MS m/z 244.1061 [M+Na]+ (calcd for C11H15N3NaO2 244.1056). 
4.7.2.8 Synthesis of 4.40 
An aliquot of 4.27 (15 mg, 0.108 mmol) was dissolved in anhydrous MeOH (3 
mL) and treated with pyridine-2-carboxaldehyde (10 µL, 0.12 mmol) at room 
temperature for 4 h to yield 4.40 (14.9 mg, 59% yield). (4.40): [a]22D –173.6 (c 
0.01, MeOH); 1H NMR (600 MHz, MeOH-d4) dH 8.37 (m, 1H), 7.75 (d, J = 8.4 
Hz, 1H), 7.71 (dd, J = 8.4, 7.5, 1.3 Hz, 1H), 7.18 (dd, J = 7.5, 5.5, 1.3 Hz, 1H), 7.18 (s, 1H) , 4.39 
(dd, J = 8.7, 3.3 Hz, 1H), 3.74 (s, 3H), 3.54 (m, 1H), 3.38 (dd, J = 17.4, 7.7 Hz, 1H), 2.30 (m, 1H), 
2.11 (m, 2H), 2.07 (m, 1H); 13C NMR (150 MHz, MeOH-d4) dc 175.5, 157.0, 149.4, 138.3, 131.9, 
123.1, 120.2, 66.1, 52.8, 49.8, 29.6, 23.7; HRESI(+)MS m/z 234.1241 [M+H]+ (calcd for C12H16N3O2 
234.1237). 
4.7.2.9 Synthesis of 4.41 
An aliquot of 4.27 (42 mg, 0.29 mmol) was dissolved in anhydrous MeOH (5 
mL) and treated with pyridine-3-carboxaldehyde (24 µL, 0.25 mmol) at room 
temperature for 4 h to yield 4.41 (41.7 mg, 72% yield). (4.41): [a]22D –204 (c 
0.01, MeOH); 1H NMR (600 MHz, MeOH-d4) dH 8.61 (d, J = 1.6, 1H), 8.31 (dd, 
J = 4.9, 1.5, 1H), 7.94 (dd, J = 8.0, 1.6, 1H), 7.34 (dd, J = 8.0, 4.9, 1H), 7.21 (s, 1H) , 4.36 (dd, J = 
8.7, 3.4 Hz, 1H), 3.74 (s, 3H), 3.52 (m, 1H), 3.34 (dd, J = 17.0, 7.6 Hz, 1H), 2.28 (m, 1H), 2.10 (m, 
2H), 2.04 (m, 1H); 13C NMR (150 MHz, MeOH-d4) dc 175.8, 148.1, 147.6, 135.2, 133.9, 129.8, 
125.3, 66.3, 52.7, 49.6, 29.4, 23.7; HRESI(+)MS m/z 234.1238 [M+H]+ (calcd for C12H16N3O2 
234.1237). 
CO2Me
N N
N
H
CO2Me
N N
N
CO2Me
N N
N
Chapter 4: Further investigations into prolinimines 
 
 
133 
4.7.2.10 Synthesis of 4.42 
An aliquot of 4.27 (42 mg, 0.29 mmol) was dissolved in anhydrous MeOH (5 mL) 
and treated with pyridine-4-carboxaldehyde (24 µL, 0.25 mmol) at room 
temperature for 4 h to yield 4.42 (48.3 mg, 84% yield). (4.42): [a]22D –200.8 (c 
0.01, MeOH); 1H NMR (600 MHz, MeOH-d4) dH 8.36 (dd, J = 4.9, 1.3, 1H), 7.47 
(dd, J = 4.9, 1.3, 2H), 7.10 (s, 1H) , 4.42 (dd, J = 8.7, 3.3 Hz, 1H), 3.74 (s, 3H), 3.53 (m, 1H), 3.37 
(dd, J = 17.6, 7.6 Hz, 1H), 2.29 (m, 1H), 2.12 (m, 2H), 2.07 (m, 1H); 13C NMR (150 MHz, MeOH-
d4) dc 175.4, 150.0, 147.3, 129.3, 121.1, 66.3, 52.8, 49.5, 29.5, 23.7; HRESI(+)MS m/z 234.1240 
[M+H]+ (calcd for C12H16N3O2 234.1237). 
4.7.2.11 Synthesis of 4.43 
An aliquot of 4.27 (15 mg, 0.108 mmol) was dissolved in anhydrous MeOH (3 
mL) and treated with 4(5)-imidazolecarboxaldehyde (9.7 mg, 0.10 mmol) at 
room temperature for 4 h. The reaction mixture was purified using preparative 
reversed phase HPLC (Zorbax SB-C8, 21.2 mm ✕ 15 cm, 5 µm, 20 mL/min, 
gradient elution 90% H2O/MeCN to 50% H2O/MeCN over 20 min including 
isocratic 0.01% TFA) to yield 4.43 (18.2 mg, 82% yield). (4.43): [a]22D –124.8 (c 0.01, MeOH); 1H 
NMR (600 MHz, MeOH-d4) dH 8.73 (br s, 1H), 7.42 (s, 1H), 7.14 (br s, 1H) , 4.40 (br d, J = 7.2 Hz, 
1H), 3.73 (s, 3H), 3.50 (m, 1H), 3.33 (dd, J = 17.3, 7.6 Hz, 1H), 2.30 (m, 1H), 2.12 (m, 2H), 2.07 (m, 
1H); 13C NMR (150 MHz, MeOH-d4) dc 175.4, 135.0, 133.6, 119.0, 116.0, 66.1, 52.8, 49.6, 29.5, 
23.6; HRESI(+)MS m/z 223.1195 [M+H]+ (calcd for C10H15N4O2 223.1190). 
4.7.2.12 Synthesis of 4.44 
An aliquot of 4.27 (15 mg, 0.108 mmol) was dissolved in anhydrous MeOH (3 
mL) and treated with indole-3-carboxaldehyde (15.3 mg, 0.105 mmol) at room 
temperature for 4 h to yield 4.44 (28 mg, 98% yield). (4.44): [a]22D –181.6 (c 
0.01, MeOH); 1H NMR (600 MHz, MeOH-d4) dH 8.06 (d, J = 8.0 Hz , 1H), 
7.72 (s, 1H), 7.37 (br s, 1H) , 7.34 (d, J = 8.0 Hz , 1H), 7.13 (dd, J = 8.0, 7.1 
Hz , 1H), 7.04 (dd, J = 8.0, 7.1 Hz , 1H),  4.16 (dd, J = 8.4, 4.6 Hz, 1H), 3.75 (s, 3H), 3.51 (m, 1H), 
3.17 (dd, J = 16.2, 8.0 Hz, 1H), 2.24 (m, 1H), 2.07 (m, 2H), 1.99 (m, 1H); 13C NMR (150 MHz, 
MeOH-d4) dc 176.6, 138.7, 136.7, 127.0, 126.2, 123.4, 122.8, 120.9, 115.1, 112.3, 67.5, 52.8, 50.9, 
28.8, 23.6; HRESI(+)MS m/z 272.1398 [M+H]+ (calcd for C15H18N3O2 272.1394). 
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4.7.2.13 Synthesis of 4.45 
An aliquot of 4.27 (15 mg, 0.108 mmol) was dissolved in anhydrous MeOH (3 
mL) and treated with benzaldehyde (10 µL, 0.10 mmol) at room temperature for 
4 h to yield 4.45 (21.8 mg, 94% yield). (4.45): [a]22D –204.4 (c 0.01, MeOH); 1H 
NMR (600 MHz, MeOH-d4) dH 7.49 (dd, J = 8.0, 1.2 Hz , 2H), 7.28 (dd, J = 8.0, 
7.5 Hz, 2H), 7.25 (s, 1H) , 7.19 (dd, J = 7.5, 1.2 Hz , 1H), 4.28 (dd, J = 8.6, 3.6 Hz, 1H), 3.73 (s, 3H), 
3.51 (m, 1H), 3.27 (dd, J = 16.9, 7.9 Hz, 1H), 2.26 (m, 1H), 2.07 (m, 2H), 2.00 (m, 1H); 13C NMR 
(150 MHz, MeOH-d4) dc 176.1, 138.3, 135.4, 129.5, 128.6, 126.7, 66.4, 52.7, 50.0, 29.3, 23.6; 
HRESI(+)MS m/z 255.1105 [M+Na]+ (calcd for C13H16N2NaO2 255.1104). 
4.7.2.14 Synthesis of 4.46 
An aliquot of 4.27 (15 mg, 0.108 mmol) was dissolved in anhydrous MeOH 
(3 mL) and treated with 2,4-dihydroxybenzaldehyde (14 mg, 0.10 mmol) at 
room temperature for 4 h to yield 4.46 (26.4 mg (91% purity), 91% yield). 
(4.46): [a]22D –237.8 (c 0.01, MeOH); 1H NMR (600 MHz, MeOH-d4) dH 
7.47 (s, 1H), 7.01 (d, J = 8.4, 1H), 6.30 (dd, J = 8.4, 2.4 Hz , 1H) , 6.25 (d, J 
= 2.4 Hz , 1H), 4.11 (dd, J = 8.4, 4.1 Hz, 1H), 3.74 (s, 3H), 3.46 (m, 1H), 3.17 (dd, J = 16.0, 7.5 Hz, 
1H), 2.24 (m, 1H), 2.07 (m, 2H), 2.04 (m, 1H); 13C NMR (150 MHz, MeOH-d4) dc 175.4, 160.0, 
159.8, 141.5, 131.7, 113.8, 108.2, 103.7, 66.9, 52.7, 50.3, 28.7, 23.4; HRESI(+)MS m/z 287.1010 
[M+Na]+ (calcd for C13H16N2NaO4 287.1002). 
4.7.2.15 Synthesis of 4.47 
An aliquot of 4.27 (15 mg, 0.108 mmol) was dissolved in anhydrous MeOH (3 
mL) and treated with 2,5-dihydroxybenzaldehyde (14.5 mg, 0.105 mmol) at room 
temperature for 4 h to yield 4.47 (25.6 mg, 92% yield). (4.47): [a]22D –223.6 (c 
0.01, MeOH);1H NMR (600 MHz, MeOH-d4) dH 7.37 (s, 1H), 6.65 (d, J = 2.8, 
1H), 6.64 (d, J = 8.7 Hz , 1H) , 6.58 (dd, J = 8.7, 2.8 Hz , 1H), 4.21 (dd, J = 8.5, 
3.8 Hz, 1H), 3.74 (s, 3H), 3.47 (m, 1H), 3.25 (dd, J = 16.1, 7.4 Hz, 1H), 2.25 (m, 1H), 2.09 (m, 2H), 
2.07 (m, 1H); 13C NMR (150 MHz, MeOH-d4) dc 175.2, 151.0, 151.0, 138.9, 121.5, 117.5, 117.0, 
115.9, 66.5, 52.7, 49.8, 28.9, 23.5; HRESI(+)MS m/z 287.1003 [M+Na]+ (calcd for C13H16N2NaO4 
287.1002). 
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4.7.2.16 Synthesis of 4.48 
An aliquot of 4.27 (15 mg, 0.108 mmol) was dissolved in anhydrous MeOH 
(3 mL) and treated with 3,4-dihydroxybenzaldehyde (14.7 mg, 0.106 mmol) 
at room temperature for 4 h to yield 4.48 (29 mg (91% purity), 94% yield). 
(4.48): [a]22D –248.2 (c 0.01, MeOH); 1H NMR (600 MHz, MeOH-d4) dH 
7.20 (s, 1H), 7.03 (d, J = 1.8, 1H), 6.80 (dd, J = 8.1, 1.8 Hz , 1H) , 6.70 (d, J 
= 8.1 Hz , 1H), 4.19 (dd, J = 8.8, 4.0 Hz, 1H), 3.73 (s, 3H), 3.47 (m, 1H), 3.19 (dd, J = 16.6, 8.0 Hz, 
1H), 2.23 (m, 1H), 2.05 (m, 2H), 1.98 (m, 1H); 13C NMR (150 MHz, MeOH-d4) dc 176.4, 146.9, 
146.6, 137.6, 130.3, 119.9, 116.2, 113.1, 66.6, 52.6, 50.4, 29.1, 23.6; HRESI(+)MS m/z 287.1007 
[M+Na]+ (calcd for C13H16N2NaO4 287.1002). 
4.7.2.17 Synthesis of 4.49 
An aliquot of 4.27 (15 mg, 0.108 mmol) was dissolved in anhydrous MeOH 
(3 mL) and treated with 2,3-dihydroxybenzaldehyde (14.1 mg, 0.102 mmol) 
at room temperature for 4 h to yield 4.49 (23.4 mg, 87% yield). (4.49): [a]22D 
–291.2 (c 0.01, MeOH); 1H NMR (600 MHz, MeOH-d4) dH 7.45 (s, 1H), 
6.66-6.72 (m, 3H), 4.22 (dd, J = 8.9, 4.1 Hz, 1H), 3.74 (s, 3H), 3.48 (m, 1H), 3.25 (dd, J = 16.2, 7.8 
Hz, 1H), 2.26 (m, 1H), 2.10 (m, 2H), 2.07 (m, 1H); 13C NMR (150 MHz, MeOH-d4) dc 175.2, 146.3, 
145.8, 139.6, 121.5, 121.3, 120.3, 116.2, 66.6, 52.8, 49.8, 28.9, 23.5; HRESI(+)MS m/z 287.1007 
[M+Na]+ (calcd for C13H16N2NaO4 287.1002). 
4.7.2.18 Synthesis of 4.50 
An aliquot of 4.27 (15 mg, 0.108 mmol) was dissolved in anhydrous MeOH 
(3 mL) and treated with 2,3,4-trihydroxybenzaldehyde (16.1 mg, 0.104 
mmol) at room temperature for 4 h to yield 4.50 (24.3 mg (77% purity), 64% 
yield). An analytically pure sample was purified for the stability study using 
preparative reversed phase HPLC (Phenomenex Luna-C8, 21.2 mm ✕ 25 cm, 
10 µm, 20 mL/min, gradient elution 90% H2O/MeCN to 100% over 30 min). (4.50): [a]22D –281 (c 
0.01, MeOH); 1H NMR (600 MHz, MeOH-d4) dH 7.44 (s, 1H), 6.58 (d, J = 8.4, 1H), 6.34 (d, J = 8.4 
Hz , 1H), 4.12 (dd, J = 8.4, 4.1 Hz, 1H), 3.74 (s, 3H), 3.47 (m, 1H), 3.18 (dd, J = 16.2, 7.5 Hz, 1H), 
2.24 (m, 1H), 2.09 (m, 2H), 2.04 (m, 1H); 13C NMR (150 MHz, MeOH-d4) dc 175.4, 147.7 (x2), 
147.2, 141.9, 133.8, 121.5, 108.1, 66.9, 52.7, 50.3, 28.7, 23.4; HRESI(+)MS m/z 303.0955 [M+Na]+ 
(calcd for C13H16N2NaO5 303.0951). 
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4.7.2.19 Synthesis of 4.51 
An aliquot of 4.27 (15 mg, 0.108 mmol) was dissolved in anhydrous MeOH 
(3 mL) and treated with 2-hydroxy-4-methoxybenzaldehyde (15.8 mg, 
0.104 mmol) at room temperature for 4 h to yield 4.51 (27.5 mg, 95% yield). 
(4.51): [a]22D –179.8 (c 0.01, MeOH); 1H NMR (600 MHz, MeOH-d4) dH 
7.48 (s, 1H), 7.09 (d, J = 8.5 Hz, 1H), 6.42 (dd, J = 8.5, 2.5 Hz , 1H), 6.37 
(d, J = 2.5, 1H), 4.12 (dd, J = 8.5, 4.1 Hz, 1H), 3.76 (s, 3H), 3.74 (s, 3H), 3.47 (m, 1H), 3.20 (dd, J = 
16.1, 7.5 Hz, 1H), 2.24 (m, 1H), 2.09 (m, 2H), 2.06 (m, 1H); 13C NMR (150 MHz, MeOH-d4) dc 
175.4, 162.2, 159.7, 140.7, 131.5, 114.8, 106.9, 102.3, 66.8, 55.8, 52.7, 50.2, 28.7, 23.4; 
HRESI(+)MS m/z 301.1160 [M+Na]+ (calcd for C14 H18N2NaO4 301.1159). 
4.7.2.20 Synthesis of 4.52 
An aliquot of 4.27 (15 mg, 0.108 mmol) was dissolved in anhydrous MeOH 
(3 mL) and treated with 4-isopropylbenzaldehyde (14 µL, 0.093 mmol) at 
room temperature for 4 h to yield 4.52 (22.7 mg, 89% yield). (4.52): [a]22D –
167.5 (c 0.01, MeOH); 1H NMR (600 MHz, MeOH-d4) dH 7.42 (d, J = 8.2 
Hz, 2H), 7.26 (s, 1H), 7.16 (d, J = 8.2, Hz , 2H), 4.26 (dd, J = 8.7, 3.7 Hz, 1H), 3.73 (s, 3H), 3.50 (m, 
1H), 3.25 (dd, J = 16.6, 7.7 Hz, 1H), 2.87 (m, 1H), 2.25 (m, 1H), 2.07 (m, 2H), 2.01 (m, 1H), 1.23 
(d, J = 6.9 Hz, 6H); 13C NMR (150 MHz, MeOH-d4) dc 176.2, 149.8, 136.0, 135.9, 127.6 (✕2), 126.9 
(✕2), 66.5, 52.6, 50.1, 35.3, 29.3, 24.5 (x2), 23.6; HRESI(+)MS m/z 297.1577 [M+Na]+ (calcd for 
C16H22N2NaO2 297.1573). 
4.7.2.21 Synthesis of 4.53 
An aliquot of 4.27 (15 mg, 0.108 mmol) was dissolved in anhydrous MeOH 
(3 mL) and treated with 3,5-Di-tert-butyl-2-hydroxybenzaldehyde (24 mg, 
0.102 mmol) at room temperature for 4 h to yield 4.52 (24.6 mg, 67% yield). 
(4.52): [a]22D –205.2 (c 0.01, MeOH); 1H NMR (600 MHz, MeOH-d4) dH 
7.53 (s, 1H), 7.20 (d, J = 2.1 Hz, 1H), 7.06 (d, J = 2.1 Hz , 1H), 4.21 (dd, J 
= 8.2, 3.6 Hz, 1H), 3.76 (s, 3H), 3.51 (m, 1H), 3.26 (dd, J = 15.7, 7.5 Hz, 1H), 2.26 (m, 1H), 2.10 (m, 
2H), 2.07 (m, 1H), 1.41 (s, 9H), 1.29 (s, 9H); 13C NMR (150 MHz, MeOH-d4) dc 175.4, 154.9, 141.8 
(✕2), 136.8, 125.6, 124.6, 120.3, 66.7, 52.8, 50.1, 36.0, 35.1, 32.1 (✕3), 30.1 (✕3), 28.9, 23.5; 
HRESI(+)MS m/z 383.2305 [M+Na]+ (calcd for C21H32N2NaO3 383.2305). 
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4.7.2.22 Synthesis of 4.54 
An aliquot of 4.27 (15 mg, 0.108 mmol) was dissolved in anhydrous MeOH 
(3 mL) and treated with 4-diethylaminebenzaldehyde (18 mg, 0.10 mmol) 
at room temperature for 4 h to yield 4.54 (27.4 mg (92% purity), 83% yield). 
An analytically pure sample was purified for the stability study using 
preparative reversed phase HPLC (Phenomenex Luna-C8, 21.2 mm ✕ 25 
cm, 10 µm, 20 mL/min, gradient elution 90% H2O/MeCN to 100% MeCN over 30 min). (4.54): 
[a]22D –175.4 (c 0.01, MeOH); 1H NMR (600 MHz, MeOH-d4) dH 7.34 (d, J = 8.9 Hz, 2H), 7.30 (s, 
1H), 6.64 (d, J = 8.9 Hz , 2H), 4.16 (dd, J = 8.8, 4.1 Hz, 1H), 3.73 (s, 3H), 3.49 (m, 1H), 3.37 (q, J = 
7, 2H), 3.17 (dd, J = 16.9, 7.9 Hz, 1H), 2.23 (m, 1H), 2.04 (m, 2H), 1.97 (m, 1H), 1.41 (t, J = 7, 6H); 
13C NMR (150 MHz, MeOH-d4) dc 176.4, 149.3, 139.5, 128.5 (x2), 125.2, 112.9 (x2), 66.8, 52.6, 
50.9, 45.5 (✕2), 29.1, 23.5, 13.0 (✕2); HRESI(+)MS m/z 304.2029 [M+H]+ (calcd for C17H26N3O2 
304.2020). 
4.7.2.23 Synthesis of 4.55 
An aliquot of 4.27 (15 mg, 0.108 mmol) was dissolved in anhydrous MeOH (3 
mL) and treated with 2-hydroxybenzaldehyde (10 µL, 0.094 mmol) at room 
temperature for 4 h to yield 4.55 (23 mg, 98% yield). (4.55): [a]22D –283 (c 0.01, 
MeOH); 1H NMR (600 MHz, MeOH-d4) dH 7.48 (s, 1H), 7.19 (dd, J= 7.6, 1.4 Hz, 
1H), 7.10 (ddd, J = 8.5, 8.0, 1.4 Hz , 1H), 6.82 (ddd, J = 8.5, 7.6, 0.7 Hz, 1H), 6.80 (dd, J = 8.0, 0.7, 
1H), 4.22 (dd, J = 8.8, 4.1 Hz, 1H), 3.74 (s, 3H), 3.48 (m, 1H), 3.26 (dd, J = 16.2, 7.7 Hz, 1H), 2.26 
(m, 1H), 2.08 (m, 2H), 2.05 (m, 1H); 13C NMR (150 MHz, MeOH-d4) dc 175.2, 157.9, 139.4, 130.3, 
129.9, 121.4, 120.4, 117.1, 66.5, 52.8, 49.8, 28.9, 23.5; HRESI(+)MS m/z 271.1057 [M+Na]+ (calcd 
for C13H16N2NaO3 271.1053). 
4.7.2.24 Synthesis of 4.56 
An aliquot of 4.27 (15 mg, 0.108 mmol) was dissolved in anhydrous MeOH (3 
mL) and treated with 2-carboxybenzaldehyde (15.5 mg, 0.103 mmol) at room 
temperature for 4 h to yield 4.56 (26.6 mg, 93% yield). (4.56): [a]22D –144 (c 
0.01, MeOH); 1H NMR (600 MHz, MeOH-d4) dH 8.07 (s, 1H), 7.90 (dd, J= 8.0, 
0.6, 1H), 7.87 (dd, J = 7.8, 0.6 Hz , 1H), 7.43 (dd, J = 8.0, 7.4, 0.6 Hz, 1H), 7.26 (dd, J = 7.8, 7.4, 
0.6, 1H), 4.31 (dd, J = 8.5, 3.6 Hz, 1H), 3.74 (s, 3H), 3.54 (m, 1H), 3.34 (dd, J = 16.8, 7.7 Hz, 1H), 
2.28 (m, 1H), 2.08 (m, 2H), 2.03 (m, 1H); 13C NMR (150 MHz, MeOH-d4) dc 175.9, 171.1, 138.8, 
133.8, 132.8, 131.8, 129.6, 127.9, 126.8, 66.1, 52.7, 50.3, 29.5, 23.6; HRESI(+)MS m/z 299.1006 
[M+Na]+ (calcd for C14 h16N2NaO4 299.1002). 
CO2Me
N N
NEt2
CO2Me
N N OH
CO2Me
N N COOH
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4.7.2.25 Synthesis of 4.57 
An aliquot of 4.27 (15 mg, 0.108 mmol) was dissolved in anhydrous MeOH (3 
mL) and treated with 2-nitrobenzaldehyde (15.5 mg, 0.102 mmol) at room 
temperature for 4 h to yield 4.57 (24.9 mg, 88% yield). (4.57): [a]22D –153.2 (c 
0.01, MeOH); 1H NMR (600 MHz, MeOH-d4) dH 7.99 ( br d, J = 7.8 Hz, 1H), 
7.88 (br d, J= 8.2, 1H), 7.58 (s, 1H), 7.54 (dd, J = 8.0, 7.8 Hz, 1H), 7.34 (dd, J = 8.2, 8.0, 1H), 4.38 
(dd, J = 8.6, 3.5 Hz, 1H), 3.75 (s, 3H), 3.53 (m, 1H), 3.38 (dd, J = 16.9, 7.6 Hz, 1H), 2.30 (m, 1H), 
2.12 (m, 2H), 2.05 (m, 1H); 13C NMR (150 MHz, MeOH-d4) dc 175.5, 148.4, 133.9, 132.8, 128.3, 
127.9, 127.7, 125.6, 66.1, 52.8, 49.9, 29.5, 23.7; HRESI(+)MS m/z 300.0959 [M+Na]+ (calcd for 
C13H15N3NaO4 300.0955). 
4.7.2.26 Synthesis of 4.58 
An aliquot of 4.27 (15 mg, 0.108 mmol) was dissolved in anhydrous MeOH 
(3 mL) and treated with 4-nitrobenzaldehyde (16.2 mg, 0.107 mmol) at room 
temperature for 4 h to yield 4.58 (25.4 mg, 85% yield). (4.58): [a]22D –232.4 
(c 0.01, MeOH); 1H NMR (600 MHz, MeOH-d4) dH 8.13 (d, J = 8.8 Hz, 2H), 
7.65 (d, J= 8.8, 2H), 7.21 (s, 1H), 4.41 (dd, J = 8.7, 3.3 Hz, 1H), 3.74 (s, 3H), 3.54 (m, 1H), 3.37 (dd, 
J = 17.4, 7.6 Hz, 1H), 2.30 (m, 1H), 2.12 (m, 2H), 2.05 (m, 1H); 13C NMR (150 MHz, MeOH-d4) dc 
175.5, 147.5, 145.3, 130.5, 126.6 (✕2), 125.0 (✕2), 66.3, 52.8, 49.6, 29.4, 23.7; HRESI(+)MS m/z 
300.0962 [M+Na]+ (calcd for C13H15N3NaO4 300.0955). 
4.7.3 Stability study 
An aliquot (0.25 mg) of each Schiff base was dissolved in 50% MeCN/H2O (500 µL) in 2 mL vials 
(´2). An aliquot (10 µL) of 2,4-dinitrobenzaldehyde (4.31) (50 mg/mL in MeCN) was added, and an 
aliquot (5 µL) of 1% TFA in MeCN was added to one of the two vials. An aliquot (1 µL) was injected 
to UHPLC-DAD every 24 h over a period of 8 days. (refer to Appendix A for details of 
chromatographic conditions) 
4.7.4 Biological assays 
4.7.4.1 Antibacterial assay 
The bacterium to be tested was streaked onto a tryptic soy agar plate and was incubated at 37 °C for 
24 h. One colony was then transferred to fresh tryptic soy broth (15 mL), and the cell density was 
adjusted to 104−105 cfu/mL. The tested metabolites were dissolved in DMSO and diluted with H2O 
to give 600 μM stock solutions (20% DMSO). An aliquot (10μL) of each dilution was transferred to 
a 96-well microtiter plate, and freshly prepared microbial broth (190μL) was added to each well. The 
plates were incubated at 37 °C for 24 h, and the optical density of each well was measured 
CO2Me
N N NO2
CO2Me
N N
NO2
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spectrophotometrically at 600 nm using a POLARstar Omega plate (BMG LABTECH, Offenburg, 
Germany). Each test compound was screened in dublicate against the Gram-positive bacteria (S. 
aureus ATCC25923 and B. subtilis ATCC6633) and Gram-negative bacteria (E. coli ATCC11775 
and P. aeruginosa ATCC10145). Rifampicin was used as a positive control (30μM in 20% DMSO). 
4.7.4.2 Antifungal assay 
The fungus to be tested was streaked onto a Sabouraud agar plate and was incubated at 26.5 °C for 
48 h. One colony was then transferred to fresh Sabouraud broth (15 mL) and the cell density was 
adjusted to 104–105 cfu/mL. Test compounds were dissolved in DMSO and diluted with H2O to give 
a 300 µM stock solution (10% DMSO). The stock solution was then serially diluted with 10% DMSO 
to give final concentrations of 30 µM to 0.01 µM in 1% DMSO. An aliquot (20 µL) of each dilution 
was transferred to a 96-well microtiter plate and freshly prepared microbial broth (180 µL) was added 
to each well. The plates were incubated at 26.5 °C for 48 h and the optical density of each well was 
measured spectrophotometrically at 600 nm. Each test compound was screened against the fungi 
Candida albicans (ATCC90028). 
4.7.4.3 Cytotoxicity assay 
The MTT assay was modified from that previously described 89using adherent cell lines SW620 and 
NCIH460. SW620 and NCIH460 were cultured in RPMI medium 164090 and HepG2122 (adherent 
human hepatocellular carcinoma) was cultured in DMEM medium as adherent mono-layer in flasks 
supplemented with 10% foetal bovine serum, 2 mM L-glutamine, 100 unit/mL penicillin and 100 
µg/mL streptomycin in a humidified 37°C incubator supplied with 5% CO2. Briefly, cells were 
harvested with trypsin and dispensed into 96-well microtiter assay plates at 3,000 cells/well for 
SW620, and 5,000 cells/well for NCIH460, then incubated for 18 h at 37 °C with 5% CO2 (to allow 
cells to attach). Testing compounds were dissolved in 5% DMSO in PBS (v/v) and aliquots (20 µL) 
tested over a series of final concentrations ranging from 10 nM to 30 μM. Control wells were treated 
with 5% aqueous DMSO. After 68 h incubation at 37 °C with 5% CO2 an aliquot (20 µL) of MTT in 
PBS (5 mg/mL) was added to each well (final concentration of 0.4 mg/mL), and the microtiter plates 
incubated for a further 4 h at 37 °C with 5% CO2. After this final incubation, the medium was 
aspirated, and precipitated formazan crystals dissolved in DMSO (100 µL/well). The absorbance of 
each well was measured at 580 nm with a PowerWave XS Microplate Reader from Bio-Tek 
Instruments Inc. (Vinooski, VT). IC50 values were calculated using Prism 7.0 (GraphPad Software 
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Inc., La Jolla, CA), as the concentration of analyte required for 50% inhibition of cancer cell growth 
(compared to negative controls). All experiments were performed in duplicate.
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Chapter 5 : Integrative strategy to explore the chemical diversity of a fish GIT associated 
fungus Metarhizium sp. CMB-F624 
5.1 Introduction 
Preliminary studies by our research group have demonstrated that fungi isolated from the 
gastrointestinal tract (GIT) of fish are a promising source of new classes of chemistry (as shown in 
chapter 3). This chapter describes a case study that investigated the effect of culture conditions on 
the secondary metabolism of Metarhizium sp. CMB-F624 isolated from the GIT of a mullet fish. 
Chemical profiling of culture extracts was performed using UHPLC-DAD. Analysis of UHPLC-
DAD data was done by visual inspection of UHPLC chromatograms and UV-vis spectra extracted 
from DAD data (described in chapter 2). These analyses identified rice-solid medium as optimum for 
scale-up cultivation, yielding five new (5.01a/b, 5.02a/b, 5.03a/b, 5.04 and 5.06) and two known 
(5.05 and 5.07) metabolites. Structures were assigned on the basis of detailed spectroscopic analysis 
as detailed below. 
 
5.2 Isolation and morphology of Metarhizium sp. CMB-F624 
The fungus Metarhizium sp. CMB-F624 was isolated from the gastrointestinal tract content sourced 
from a Mugil mullet fish on M1 agar and subjected to cryopreservation from both solid and liquid 
media in 15% aqueous glycerol and archived at –80 °C. CMB-F624 grows as circular dark green 
colonies with white centre and edges (Figure 5.1).  
 
Figure 5.1. Morphology of CMB-F624 cultured on M1 agar plate. 
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5.3 DNA taxonomy and phylogenetic analysis of Metarhizium sp. CMB-F624 
BLAST analysis (NCBI database) showed that the amplified ITS sequence of CMB-F624 has the 
closest identity with the genus Metarhizium sp. (98% identity). A phylogenetic tree obtained by 
PhyML Maximum Likelihood analysis was constructed using the top similar 18S rRNA sequences 
(>95% identity) displayed after BLAST on NCBI database using CMB-F624 18S rRNA as the query 
(Figure 5.2). 
 
Figure 5.2. Phylogenetic analysis of CMB-F624 using PhyML Maximum likelihood analysis of ITS DNA sequences 
using the optimal nucleotide substitution model determined by jModeltest271 using UGENE72 software. Phylogenetic 
relationship of CMB-F624 with selected strains (nucleotide collection Genbank) shown with their accession numbers 
indicated in brackets, highlighted in blue. 
  
Metarhizium lepidiotae ARSEF 7488 [NR_132018.1]
Metarhizium anisopliae var. lepidiotum strain FI-1042 [AF137066.1]
Metarhizium lepidiotae isolate 100512-4-2 [JF495769.1]
Metarhizium sp. KTU-9 [FJ177480.1]
Metarhizium anisopliae xsd08103 [FJ481014.1]
CMB-F624
Metarhizium sp. CENIEN034 [HQ722914.1]
Metarhizium anisopliae CNGD7 [FJ545282.1]
Metarhizium sp. EMP4 [KY408033.1]
Metarhizium anisopliae [LT604481.1]
Metarhizium anisopliae LSNM2 [FJ545312.1]
Metarhizium anisopliae CNHB1 [FJ545291.1]
Metarhizium guizhouense TMSL75A [LT220706.1]
Metarhizium guizhouense ARSEF 977 [HM055445.1]
Metarhizium guizhouense ARSEF 703 [HM055444.1]
Metarhizium anisopliae LSPK [FJ545314.1]
Metarhizium anisopliae CNGD2 [FJ545277.1]
Metarhizium anisopliae NHJ6195 [AY646393.1]
Metarhizium anisopliae CNGD4 [FJ545279.1]
Metarhizium pinghaense ARSEF 2162 [HM055447.1]
Metarhizium anisopliae LSNM1 [FJ545311.1]
Metarhizium anisopliae MA25 [JX624255.1]
Metarhizium anisopliae D1 [KX809521.1]
Metarhizium anisopliae C1 [KX809520.1]
Metarhizium anisopliae TF19 [JX122737.1]
Metarhizium anisopliae TSBP1 [JQ766113.1]
Metarhizium anisopliae A1 [KX806656.1]
Metarhizium anisopliae A1 [KX809518.1]
Metarhizium anisopliae HEP5 [KJ767256.1]
Metarhizium guizhouense M335-11 [KJ542166.1]
Metarhizium anisopliae [AY237118.1]
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5.4 Analytical cultivation and chemical analysis 
A seed culture of CMB-F624 was prepared by inoculating a 250 mL flask containing M1 broth 
medium (80 mL) with a single colony of the fungus, followed by shaking at 190 rpm at 26.5 °C for 
4 days. Aliquots of the seed culture (20 µL) were cultured in a panel of eleven different liquid media 
in a micro-bioreactor (MATRIX) 61 (1.5 mL, each well) format, incubated under both static and 
shaking conditions, as well as on twelve solid media (2.5 g, each well) (Table 5.1). All cultures were 
incubated at 26.5 °C for 10 d, after which the MATRIX cultures were extracted in situ with EtOAc 
(2 mL) by shaking at 150 rpm for 30 min. All organic extracts were individually concentrated in 
vacuo, redissolved in MeOH (40 µL) and analysed by UHPLC-DAD (Zorbax C8 RRHD column 1.8 
µm 50 ´ 2.1 mm column, 2.50 min, 0.417 mL/min gradient elution from 90% H2O: MeCN to 100% 
MeCN with an isocratic 0.01% TFA modifier) and HPLC-DAD-ESIMS (Zorbax SB-C8 5 µm 150 ´ 
4.6 mm column, 15 min, 1 mL/min gradient elution from 90% H2O/MeCN to 100% MeCN with a 
constant 0.05% HCO2H in MeCN modifier). UHPLC-DAD chromatograms were analysed for the 
presence of distinct homologous metabolites having similar UV-vis spectra. 
 
Table 5.1. List of different culture conditions of CMB-F624 
Number Medium Number Medium Number Medium 
1 M1 agar 13 M1 broth-static 24 M1 broth-shake 
2 ISP2 agar 14 ISP2 broth-static 25 ISP2 broth-shake 
3 ISP4 agar 15 ISP4-broth-static 26 ISP4-broth-shake 
4 M2-agar 16 M2-broth-static 27 M2-broth-shake 
5 PDA 17 PDB-static 28 PDB-shake 
6 TSA 18 TSB-static 29 TSB-shake 
7 SDA 19 SDB-static 30 SDB-shake 
8 PYG-agar 20 PYG-broth-static 31 PYG-broth-shake 
9 Basal agar 21 Basal broth-static 32 Basal broth-shake 
10 Czapek agar 22 Czapek broth-static 33 Czapek broth-shake 
11 YES agar 23 YES broth-static 34 YES broth-shake 
12 Medium grain rice 
 
The UHPLC-DAD and HPLC-DAD-ESIMS chromatographic analyses showed the production of 
distinct homologous metabolites (i, ii, and v) and (vii-xi) having similar UV-vis spectra with 
absorbance (lmax) peak maxima in rice-solid cultivation (Figure 5.3). As a consequence, the medium 
grain rice solid medium was chosen for scale-up cultivation. 
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Figure 5.3. HPLC-DAD (210 nm) chromatogram of the crude extract of CMB-F624 from rice cultivation 
 
5.5 Scale-up cultivation on medium grain rice 
A seed culture of CMB-F624 was prepared by inoculating a 250 mL flask containing M1 broth 
medium (80 mL) with a single colony of the fungus followed by shaking at 190 rpm at 26.5 °C for 4 
days. An aliquot of the seed culture (5 mL) was transferred to a 2 L flask containing medium grain 
rice (200 g) and incubated at room temperature for 45 days. The resulting culture was extracted with 
EtOAc (2 ´ 400 mL), shaken at 150 rpm overnight, followed by filtration, and the organic layer 
concentrated in vacuo at 40 °C to yield a crude extract (461.9 mg). The crude extract was sequentially 
triturated with solvents of increasing polarities viz., n-hexane (2 ´ 50 mL), DCM (2 ´ 50 mL), and 
MeOH (2 ´ 50 mL) to afford, after concentration in vacuo, 257.3, 51.7 and 144.1 mg, respectively. 
HPLC-DAD analysis of the three fractions showed the enrichment in n-hexane and MeOH fractions 
with metabolites of interest. The n-hexane fraction was partitioned between n-hexane (3 ´ 10 mL) 
and MeOH (10 mL) to yield F1 (220 mg) and F2 (22 mg), respectively. F2 was subjected to 
chromatographic purification using semi-preparative reversed phase HPLC (Zorbax RX-C8, 9.4 mm 
´ 25 cm, 5 µm, 3 mL/min, isocratic elution with 40% H2O/MeCN for 35 min) to yield four 
macrocyclic metabolites, 5.01a, 5.01b, 5.02a/b and 5.03a/b. 
The MeOH fraction was loaded on a C18 SPE column and fractionated with stepwise elution from 
25% MeOH/H2O to 100% MeOH, to afford four fractions (F3–F6). F4 was subjected to 
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chromatographic separation using preparative HPLC (Zorbax SB-C8, 21.2 mm ´ 15 cm, 5 µm, 20 
mL/min, isocratic elution with 85% H2O/MeCN over 20 min including 0.01% TFA as modifier) to 
yield 5.04 and 5.05. F3 was subjected to chromatographic separation using preparative HPLC 
(Phenomenex Luna-C18, 21.2 mm ´ 25 cm, 10 µm, 20 mL/min, gradient elution 90% H2O/MeCN to 
30% H2O/MeCN over 22 min including isocratic 0.01% TFA) to yield 5.04. 
Further fractionation using semi-preparative reversed phase HPLC (Zorbax SB-CN, 9.4 mm ´ 25 cm, 
5 µm, 3 mL/min, gradient elution 90% H2O/MeCN to 75% H2O/MeCN over 15 min including 
isocratic 0.01% TFA) yielded 5.06, while semi-preparative reversed phase HPLC (Zorbax SB-
phenyl, 9.4 mm ´ 25 cm, 5 µm, 3 mL/min, isocratic elution with 85% H2O/MeCN for 40 min 
including 10% isocratic 0.01% TFA as modifier) yielded 5.07 (Scheme 5.1).  
 
 
Scheme 5.1. Fractionation scheme for CMB-F624 medium grain rice extract 
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5.6 Metarhizolides A–C 
5.6.1 Metarhizolide A (5.01a/b) 
 
HRESI(+)MS analysis of 5.01a revealed a sodium adduct ion ([M+Na]+) indicative of the molecular 
formula C33H45NO8 (Dmmu –1.05) requiring twelve double bond equivalents (DBE). Analysis of the 
1H NMR and 13C NMR (DMSO-d6) spectra for 5.01a revealed two sets of signals, suggestive of a 
mixture, while HPLC analysis directly after purification revealed two components corresponding to 
5.01a and 5.01b. Similarly, the HPLC trace of 5.01b showed a mixture of the two peaks with 5.01a 
as the major peak. These results suggest that 5.01a and 5.01b undergo rapid and facile interconversion 
soon after separation (Figure 5.4). Analysis of the 2D NMR (DMSO-d6) data for the mixture 5.01a/b 
revealed the partial structures I and II (Figure 5.5). Partial structure I consisted of a phenylalanine 
moiety and partial structure II consisted of a polyketide moiety (Figure 5.5). The position of acetyl 
groups in partial structure II of 5.01a/b was established based on HMBC correlations from (i) H-7 
(dH 5.15, br s) to the acetyl carbonyl 7-COCH3 (δC 169.6) and (ii) H-11 (dH 4.60, dd, J= 10.7, 2.8 Hz) 
to the acetyl carbonyl 11-COCH3 (δC 170.5). These two partial structures accounted for 11 DBE, 
required that 5.01a/b incorporate an addition ring system. The connectivity of Phe moiety to the 
polyketide moiety was established from the diagnostic HMBC correlations from H-13 (dH 4.72) to 
the carbonyl C-1' (δC 170.5), and from NH (dH 8.16) and 2-Me (dH 1.00) to a common amide carbonyl 
C-1 (δC 169.3). As 5.02b showed the same COSY and HMBC correlations as 5.01a, it was assigned 
same connectivity. 
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Figure 5.4. HPLC-DAD (230 nm) chromatograms of (a) 5.01a and (b) 5.01b, kept for 1 hr in 85% H2O/MeCN at rt after 
HPLC purification. 
 
Figure 5.5. Key 2D NMR (DMSO-d6) correlations for partial structures of metarhizolide A (5.01a/b) 
 
Analysis of the NMR (DMSO-d6) data of both 5.01a/b revealed the major difference as deshielding 
of H-2 (DdH +0.26). Online searching in Scifinder for natural metabolites containing partial structure 
III showed two examples where C-2 was prone to facile epimerization, scalusamides A-C (5.08–
5.10)45 and perinadine A (5.11)44 (Figure 5.6). 
 
Figure 5.6. Structures of selected examples of epimeric metabolites 
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To establish whether 5.01a and 5.01b were interconverting through epimerization, 5.01a/b was 
dissolved in MeOH-d4 and 1H NMR spectra were acquired at different time intervals ranging from 0 
h, 12 h, 36 h, 60 h, 84 h, 132 h, 156 h and 228 h post dissolution. Analysis of 1H NMR data disclosed 
100% deuterium exchange of H-2 (dH 3.86) in 5.01b after 5 h and 85% exchange of H-2 (dH 4.17) in 
5.01a after 228 h, with associated decoupling of doublet coupling of 2-Me (Figure 5.10). Moreover, 
HRESI(+)MS analysis 5 days post incubation of 5.01a/b with D2O revealed a sodium adduct ion 
([M+Na]+) indicative of the molecular formula C33H44DNO8 (Dmmu 0.3). These two experiments 
confirmed that 5.01a and 5.01b were indeed equilibrating epimers at C-2. 
 
Figure 5.7. Epimerization of metarhizolide A (5.01a/b) (absolute configurations are arbitrary) 
 
The L-absolute configuration of the Phe residue in 5.01a/b was established by C3 Marfey’s analysis 
(Figure 5.11). The double bonds geometries of the olefins at C-4 and C-8 were determined as trans 
by diagnostic ROESY correlations between (i) 4-Me and H-6 and (ii) 8-Me and H-10 (Figure 5.12).  
The macrocycle ring flexibility precluded the use of ROESY correlations to assign relative 
configurations at C-6, C-7, C-11, C-12 and C-13. Attempts to obtain a single crystal of 5.01a/b for 
X-ray crystallography were unsuccessful, no doubt compromised by rapid epimerisation. The 
structure for metarhizolide A (5.01a/b), as a mixture of C-2 epimers, is therefore as shown. 
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Figure 5.8. 1H NMR (600 MHz, DMSO-d6) and UV-vis (HPLC-DAD, H2O/MeCN plus HCO2H) (inset) spectra  for 
metarhizolide A (5.01a/b). blue annotations represent major epimer and red annotations represent minor epimer. 
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Figure 5.9. 13C NMR (150 MHz, DMSO-d6) spectrum for metarhizolide A (5.01a/b). Blue annotations represent major 
epimer and red annotations represent minor epimer. 
 
Figure 5.10. Comparison of expanded regions of 1H NMR (600 MHz, MeOH-d4) spectra of metarhizolide A (5.01a/b) 
at (a) 0 h, (b) 12 h and (c) 228 h after dissolution in MeOH-d4 
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Figure 5.11. C3 Marfey’s HPLC-DAD-ESI(+)MS analysis of metarhizolide A (5.01a/b). (a) HPLC-DAD (340 nm) 
chromatograms (Agilent Zorbax, SB-C3 column 150 ´ 4.6 mm, 5 µm, 50 °C, 1 mL/min, gradient over 55 min from 
80:15:5 H2O:MeOH:MeCN to 35:60:5 H2O:MeOH:MeCN with an isocratic 0.05% v/v formic acid modifier) for the 
hydrolysate of (5.01a/b) derivatized with L-FDAA. (b) HPLC-ESIMS single ion extraction chromatograms at m/z = 418 
(L-Phe + L-FDAA (tR = 35.2 min) and D-Phe + L-FDAA (tR = 42.4 min) with * residual of Marfey’s reagent) for 
derivatized hydrolysate of 5.01a/b (blue solid) compared to authentic amino acid standard(s) (dashed). 
 
 
Figure 5.12. Expanded 2D NMR ROESY (DMSO-d6) spectrum for metarhizolide A (5.01a/b). Blue annotations 
represent major epimer and red annotations represent minor epimer. 
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Figure 5.13. Key 2D NMR (DMSO-d6) correlations for metarhizolide A (5.01a/b) 
 
Table 5.2. NMR (600 MHz, DMSO-d6) data for L-Phe residue of metarhizolide A (5.01a/b) 
Pos. dH, mult (J in Hz) dC COSY 1H-13C HMBC ROESY 
L-Phe (major epimer 5.01a) 
1' --- 170.5    
2' 4.12, ddd (10.2, 7.3, 5.7)  53.8 3', NH 1, 1', 3' NH, 5'/9' 
3' a 2.98B, dd, (14.1, 10.2) 
b 3.09, dd, (14.1, 5.7) 
35.1 2', 3'b 
2', 3'a 
1', 2', 4', 5'/9',  5'/9' 
4'  138.0    
5', 9' 7.18B, m 129.3 6'/8' 3', 7' 2', 3' 
6', 8' 7.26C, m 128.0 7', 5'/9' 4', 6'/8'  
7' 7.19D, m 126.2 6'/8' 5'/9'  
NH 8.16, d, (7.3)  2' 1', 1 2', 2 
L-Phe (minor epimer 5.01b) 
1' --- 170.1    
2' 4.27, ddd (10.7, 7.9, 4.6) 53.2 3', NH 1, 1', 3' NH, 5'/9' 
3' a 2.98A, m 
b 3.06, dd (13.9, 4.6) 
34.6 2', 3'b 
2', 3'a 
1', 2', 4', 5'/9',  5'/9' 
4'  138.2    
5', 9' 7.18B, m 129.3 6'/8' 3', 7' 2', 3' 
6', 8' 7.26C, m 128.0 7', 5'/9' 4, 6/8  
7' 7.19D, m 126.2 6'/8' 5'/9'  
NH 8.22, d, (7.9)  2' 1', 1 2', 2  
A-D Assignments for overlapping resonances (same superscript) are interchangeable 
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Table 5.3. NMR (600 MHz, DMSO-d6) data for polyketide residue of metarhizolide A (5.01a/b) 
Pos. dH, mult (J in Hz) dC COSY 1H-13C HMBC ROESY 
Polyketide (major epimer 5.01a) 
1 --- 169.3    
2 4.04, q, (7.1) 47.1 2-Me 1, 2-Me, 3 5, NH 
2-Me 1.00, d, (7.1) 17.0 2 1, 2, 3 NH 
3 --- 199.5    
4 --- 137.0    
4-Me 1.69, d, (1.0) 12.1 5 3, 4, 5 6 
5 6.52, dd, (10.1, 1.0) 142.5 4-Me, 6 3, 4-Me, 6-Me 2, 6-Me, 7 
6 3.20, dqd (10.1, 6.7, 2.4) 35.1 5, 6-Me 4, 5, 6-Me 4-Me, 7, 8-Me 
6-Me 1.07, d, (6.7) 17.1B 6 5, 6, 7 5, 7 
7 5.15A 77.6 6 5, 6, 6-Me, 7-
COCH3, 8, 8-Me, 9 
5, 6, 6-Me, 8-Me 
7-COCH3 --- 169.6    
7-COCH3 2.18, s 20.8  7-COCH3 9 
8 --- 132.7    
8-Me 1.57, s 14.3 9 7, 8, 9 6, 7, 10 
9 5.15A 122.0 8-Me, 10 7, 8-Me 10, 10-Me, 12 
10 2.58, dqd, (9.8, 6.9, 2.8) 32.8 9, 10-Me 8, 9, 10-Me 8-Me, 11, 12-Me,  
10-Me 0.73, d, (6.9) 17.1B 10 9, 10, 11 11 
11 4.60, dd, (10.5, 2.8) 76.2 10, 12 9, 10, 10-Me, 11-
COCH3, 12, 12-Me, 
13 
10-Me, 12-Me, 13-
Me 
11-COCH3 --- 170.5C    
11-COCH3 2.08, s 20.6  11-COCH3 10-Me, 13 
12 1.55, dqd, (10.5, 6.9, 3.2) 39.0 11, 12-Me  9, 13 
12-Me 0.49, d, (6.9) 8.8 12 11, 12, 13 10, 11 
13 4.72, qd (6.5, 3.2) 69.6 13-Me Phe-1, 11, 12, 12-
Me 
12, 13-Me 
13-Me 0.92, d, (6.5) 13.1 13 12, 13 11 
Polyketide (minor epimer 5.01b) 
1 --- 168.8    
2 3.78, q (7.1) 49.5 2-Me 1, 2-Me, 3 4-Me, NH 
2-Me 1.08, d (7.1) 15.9 2 1, 2, 3 NH 
3 --- 197.4    
4 --- 133.6    
4-Me 1.84, d (1.2) 12.9 5 3, 4, 5 2, 6 
5 6.56, dd (10.5, 1.2) 140.8 4-Me, 6 3, 4-Me 2, 6-Me, 7 
6 2.93, m 34.1 5, 6-Me 5, 6-Me 4-Me, 7, 8-Me 
6-Me 1.02, d (6.8) 18.6 6 5, 6, 7 5, 7 
7 4.98, brs 78.9 6 5, 6, 6-Me, 7-
COCH3, 8, 8-Me, 9 
5, 6, 6-Me, 8-Me 
7-COCH3 --- 169.5    
7-COCH3 2.13, s 20.8  7-COCH3 9 
8 --- 133.2    
8-Me 1.66, s 14.8 9 7, 8, 9 6, 7, 10 
9 5.07, d (10.1) 121.5 8-Me, 10 7, 8-Me 10, 10-Me, 12 
10 2.64, dqd (10.1, 6.9, 2.4) 32.8 9, 10-Me 8, 9, 10-Me 8-Me, 11, 12-Me,  
10-Me 0.70, d (6.9) 17.6 10 9, 10, 11 11 
11 4.66, dd (11.1, 2.4) 76.1 10, 12 9, 10-Me, 11-
COCH3, 12, 13 
10-Me, 12-Me, 13-
Me 
11-COCH3 --- 170.5 C    
11-COCH3 2.08, s 20.6  11-COCH3 10-Me, 13 
12 1.49, dqd (11.1, 6.9, 3.3) 38.8 11, 12-Me  9, 13 
12-Me 0.63, d (6.9) 9.1 12 11, 12, 13 10, 11 
13 4.47, qd (6.5, 3.3) 70.4 13-Me Phe-1, 11, 12-Me 12, 13-Me 
13-Me 0.99, d, (6.5) 12.6 13 12, 13 11 
A-C Assignments for overlapping resonances (same superscript) are interchangeable 
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Table 5.4. Differences of NMR (600 MHz, DMSO-d6) data for the two epimers of metarhizolide A (5.01a/b) 
Pos. dH (5.01a)- dH (5.01b) dC(5.01a)- dC (5.01b) 
1' --- +0.4 
2' -0.15 +0.6 
3' 0 +0.5 
 +0.03  
4'  -0.2 
5', 9' 0 0 
6', 8' 0 0 
7' 0 0 
NH -0.06 --- 
1  +0.5 
2 +0.26 -2.4 
2-Me -0.08 +1.1 
3 --- +2.1 
4 --- +3.4 
4-Me -0.15 -0.8 
5 -0.04 +1.7 
6 +0.27 +1 
6-Me +0.05 -1.5 
7 +0.17 -1.3 
7-COCH3 --- +0.1 
7-COCH3 +0.05 +0 
8  -0.5 
8-Me -0.09 -0.5 
9 +0.08 +0.5 
10 -0.06 +0 
10-Me +0.03 -0.5 
11 -0.06 +0.1 
11-COCH3 --- 0 
11-COCH3 0 0 
12 +0.06 +0.2 
12-Me -0.14 -0.3 
13 +0.25 -0.8 
13-Me -0.07 0.5 
 
 
 
Figure 5.14. Key (a) ∆dH (dH (5.01a)- dH (5.01b)), and (b) ∆dC (dC (5.01a)- dC (5.01b)) for metarhizolide A (5.01a/b) 
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5.6.2 Metarhizolide B (5.02a/b) 
 
HRESI(+)MS analysis of 5.02a/b revealed a sodium adduct ion ([M+Na]+) indicative of the 
molecular formula C31H43NO7 (Dmmu 1.2), consistent with a mono deacetyl homologue of 5.01a/b. 
The 1H NMR (DMSO-d6) data for 5.02a/b revealed a doubling of resonances consistent with C-2 
epimers as determined for 5.01a/b. This was confirmed when addition of D2O resulted in exchange 
of H-2, further confirmed by HRESI(+)MS analysis (C31H42DNO7, Dmmu –0.1). The key difference 
in the 1H NMR (DMSO-d6) data for 5.02a/b compared to 5.01a/b, was the absence of resonances 
attributed to the 7-OAc, and the upfield shift of H-7 (∆dH=1.26) (Figure 5.16). These data indicated 
replacement of 7-OAc with a 7-OH moiety. The 2D NMR data for 5.02a/b confirmed the structure 
elucidation as outlined in Table 5.5 and Figure 5.17. While the L-Phe configuration was assigned 
based on biosynthetic considerations with co-metabolite 5.01a/b. The E ∆4,5 and E ∆8,9 configurations 
were evident from diagnostic ROESY correlations between (i) 4-Me and H-6, and (ii) 8-Me and H-
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Figure 5.15. 1H NMR (600 MHz, DMSO-d6) and UV-vis (HPLC-DAD, H2O/MeCN plus HCO2H) (inset) spectra for 
metarhizolide B (5.02a/b). Blue annotations represent major epimer and red annotation represents minor epimer. 
 
Figure 5.16. Comparison of 1H NMR (600 MHz, DMSO-d6) spectra for (a) metarhizolide A (5.01a/b), and (b) 
metarhizolide B (5.02a/b) 
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Figure 5.17. Key 2D NMR (DMSO-d6) correlations for metarhizolide B (5.02a/b) 
 
Table 5.5. NMR (600 MHz, DMSO-d6) data for metarhizolide B (5.02a/b) 
Pos. dH, mult (J in Hz) dC COSY 1H-13C HMBC ROESY 
L-Phe (major epimer 5.02a) 
1' --- 170.4    
2' 4.18, ddd (10.3, 7.7, 5.4) 53.5 3', NH 1, 1', 3' NH, 5'/9' 
3' a 2.95, dd, (13.8, 10.3) 
b 3.10, dd, (13.8, 5.4) 
35.0 2', 3'b 
2', 3'a 
2', 4', 5'/9',  5'/9' 
4'  138.2    
5', 9' 7.18A, m 129.3 6'/8' 3', 7' 2', 3' 
6', 8' 7.25, dd (7.8, 7.0) 128.0 7', 5'/9' 4', 6'/8'  
7' 7.18A, m 126.1 6'/8' 5'/9'  
NH 8.08, d, (7.7)  2' 1 2', 2 
Polyketide (major epimer 5.02a) 
1 --- 168.9    
2 4.05, q (7.1) 45.9 2-Me 1, 2-Me, 3 5, NH 
2-Me 0.96, d (7.1) 17.5 2 1, 2, 3  
3 --- 199.7    
4 --- 135.5    
4-Me 1.65, s 12.0 5 3, 4, 5 6 
5 6.71, d (10.4) 144.9 4-Me, 6 3, 4-Me 2 
6 2.99, m 36.4 5, 6-Me  4-Me, 7, 8-Me 
6-Me 1.13, d, (6.7) 18.6 6 5, 6, 7 5, 7 
7 3.89, s 76.2c 7-OH 5, 6, 6-Me, 7-
COCH3, 8, 8-Me, 9 
6, 6-Me, 8-Me, 9 
7-OH 5.13, br s --- 7   
8 --- 137.3    
8-Me 1.51B, s 13.8 9 7, 8, 9 6, 7, 10 
9 5.53, d, (9.6) 120.9 7, 8-Me, 10 7, 8-Me 12 
10 2.54C 32.7 9, 10-Me  8-Me, 11, 12-Me,  
10-Me 0.78, d, (6.9) 17.2 10 9, 10, 11 11 
11 4.62, dd, (10.9, 2.2) 76.2 c 10, 12 9, 11-COCH3 10-Me, 12-Me, 13-
Me 
11-COCH3 --- 170.5    
11-COCH3 2.09, s 20.6  11-COCH3 10-Me, 13 
12 1.53 B, m 39.3 11, 12-Me  9, 13 
12-Me 0.41, d, (6.9) 8.1 12 11, 12, 13 10, 11 
13 4.68, qd (6.6, 2.8) 69.6 13-Me 12-Me 12, 13-Me 
13-Me 0.94, d, (6.6) 13.0 13 12, 13 11 
A,B Assignments for overlapping resonances (same superscript) are interchangeable, C Obscured with solvent peak, 
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5.6.3 Metarhizolide C (5.03a/b) 
 
HRESI(+)MS analysis of 5.03a/b revealed a sodium adduct ion ([M+Na]+) indicative of the 
molecular formula C39H55NO9 (Dmmu 0.9), consistent with a C6H10O homologue of 5.01a/b. The 1H 
NMR (DMSO-d6) data for 5.03a/b revealed a doubling of resonances consistent with C-2 epimers as 
determined for 5.01a/b. This was confirmed when addition of D2O resulted in exchange of H-2, 
further confirmed by HRESI(+)MS analysis (C39H54DNO9, Dmmu –0.5). The key difference in the 
1H NMR (DMSO-d6) data for 5.03a/b compared to 5.01a/b, was the additional resonances, including 
a 3o methyl, a 2o methyl and 3 methine signals, attributed to the partial structure III (Figure 5.18). 
The 2D NMR data for 5.03a/b confirmed the structure elucidation as outlined in Table 5.6 and 
Figure 5.21. While the L-Phe configuration was assigned based on biosynthetic considerations with 
co-metabolite 5.01a/b. The E ∆4,5, E ∆8,9 and E ∆12,13 configurations were evident from diagnostic 
ROESY correlations between (i) 4-Me and H-6, and (ii) 8-Me and H-10, and (iii) 12-Me and H-14. 
 
 
Figure 5.18. Partial structure III of metarhizolide C (5.03a/b) 
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Figure 5.19. 1H NMR (600 MHz, DMSO-d6) and UV-vis (HPLC-DAD, H2O/MeCN plus HCO2H) (inset) spectra for 
metarhizolide C (5.03a/b) 
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Figure 5.20. 13C NMR (150 MHz, DMSO-d6) spectrum for metarhizolide C (5.03a/b) 
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Figure 5.21. Key 2D NMR (DMSO-d6) correlations for metarhizolide C (5.03a/b) 
 
Table 5.6. NMR (600 MHz, DMSO-d6) data for metarhizolide C (5.03a/b) 
Pos. dH, mult (J in Hz) dC COSY 1H-13C HMBC ROESY 
L-Phe (major epimer 5.03a) 
1' --- 170.0    
2' 4.56, dd (11.0, 6.1) 53.7 3', NH 1, 1', 3', 4' NH, 5'/9' 
3' 2.98, m 37.8 2' 1', 2', 4', 5'/9',   
4'  136.5C    
5', 9' 7.02, d, (7.4) 129.3 6'/8' 3', 5'/9', 7' 2', 3', 2-Me, 17-Me 
6', 8' 7.27, m 128.1 7', 5'/9' 4', 6'/8'  
7' 7.20, m 126.6 6'/8' 5'/9'  
NH 8.36, d, (6.1)  2' 1, 1', 2' 2', 2, 5 
Polyketide (major epimer 5.03a) 
1 --- 171.6    
2 4.33, q, (6.7) 47.4 2-Me 1, 2-Me, 3 5, NH 
2-Me 1.11, d, (6.7) 13.5 2 1, 2, 3  
3 --- 197.2    
4 --- 134.7    
4-Me 1.63, s 11.5 5 3, 4, 5 6 
5 6.81, d, (9.1) 147.8 4-Me, 6 3, 4-Me, 7 2, 6-Me, 7, NH 
6 2.49A 37.7 D 5, 6-Me 4, 5, 6-Me, 7 4-Me, 6-Me, 8-Me 
6-Me 0.63, d, (6.8) 16.6 6 5, 6, 7 5, 7, 9 
7 3.35B 82.6 7-OH  5, 9 
7-OH 3.69, d, (8.7) --- 7 7  
8 --- 136.5C    
8-Me 1.48, s 9.8 9 7, 8, 9 7-OH, 10 
9 5.12, d, (9.5) 120.9 8-Me, 10 7, 8-Me 6-Me, 7, 10, 10-Me 
10 2.84, dqd (9.5, 6.7, 1.9) 32.5 9, 10-Me 8, 9, 10-Me 8-Me, 11, 12-Me,  
10-Me 0.91, d, (6.7) 18.3 10 9, 10, 11 11 
11 4.97, br s 78.6 10, 12-Me 9, 10, 10-Me, 11-
COCH3, 12, 13 
8-Me, 10, 10-Me, 
12-Me 
11-COCH3 --- 169.6    
11-COCH3 2.10, s 20.7  11-COCH3  
12 --- 132.9    
12-Me 1.55, s 14.0 13 11, 12, 13 10, 11, 14 
13 5.20, d, (9.8) 120.6 12-Me, 14 11, 12-Me 14-Me, 16 
14 2.65, dqd (9.8, 6.8, 1.3) 32.8 13, 14-Me 12, 13, 14-Me 12-Me, 15, 16-Me 
14-Me 0.71, d, (6.8) 18.4 14 13, 14, 15 15 
15 4.67, dd, (11.0, 1.3) 77.3 14, 16 9, 13, 14-Me, 15-
COCH3, 16, 17 
14, 14-Me, 16-Me, 
17-Me 
15-COCH3 --- 170.5    
15-COCH3 2.09, s 20.5  15-COCH3  
16 2.03, dqd (11.0, 6.9, 3.6) 37.7 D 15, 16-Me  16-Me, 17 
16-Me 0.61, d, (6.9) 8.1 16 15, 16, 17 14, 15, 16,  
17 4.70, qd (6.5, 3.6) 71.2 17-Me  16, 17-Me 
17-Me 0.92, d, (6.5) 13.0 17 16, 17 15, 17 
A obscured by DMSO signal, B obscured by H2O signal, C,D Assignments for overlapping resonances (same superscript) are 
interchangeable 
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Searching the literature for structurally similar macrocyclic metabolites revealed only a handful of 
reports where Phe residue was combined with a polyketide macrocycle, including torrubiellutins A–
C (5.12–5.14)123 and metacridamides A and B (5.15 and 5.16)124. Torrubiellutins were isolated from 
entomopathogenic fungus Torrubiella luteorostrata. The L-configuration of the N-MePhe was 
determined by hydrolysis and derivatization with Marfey’s reagent, the stereochemistry of secondary 
alcohols was determined by chemical means using Mosher reaction, while configuration of other 
stereogenic centres were assigned based on NOESY spectral data and coupling constant values.123 
Metacridamides were isolated from an entomopathogenic fungus Metarhizzium acridum, the absolute 
configuration of metacridamide A was assigned based on X-ray crystallographic analysis combined 
with chiral amino acid analysis.124 Torrubiellutin C (5.14) was reported to have cytotoxic activity 
against MCF-7 (breast cancer), KB (skin cancer), NCI-H187 (lung cancer) and Vero (monkey 
kidney) cell lines with IC50 0.78, 1.3, 1.32 and 4.36 µg/mL, respectively. Metacridamide A (5.15) 
showed moderate cytotoxicity against Caco-2 (epithelial colorectal adenocarcinoma), MCF-7 (breast 
cancer), HepG2/C3A (hepatoma) with IC50 values of 6.2, 11 and 10.8 µM, respectively, while 
metacridamide B (5.16) had an activity only against HepG2/C3A with IC50 of 18.2 µM. 
 
Figure 5.22. Structures of known examples of macrocycles incorporating a Phe residue with a polyketide 
  
O O
NH
OR1
OR1
torrubiellutin A (5.12): R1 = R2 = H
torrubiellutin B (5.13): R1 = R2 = COCH3
torrubiellutin C (5.14): R1 =H, R2 = COCH3
O O HO
O
N
H
OR
metacridamide A (5.15): R = COCH3
metacridamide B (5.16): R = H
O
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5.7 Aromatic aglycones and glucosides 
5.7.1 4-hydroxy-3,6-dimethyl-2H-pyrone-2-one (5.07) 
 
HRESI(+)MS analysis of 5.07 revealed a sodium adduct ion ([M+Na]+) indicative of the molecular 
formula C7H8O3 (Dmmu 0.3) requiring four double bond equivalents (DBE). Analysis of the 1H NMR 
(DMSO-d6) data for 5.07 revealed resonances for two 3o methyls (dH 1.73 and dH 2.13) and one 
deshielded methine (dH 5.98). Online searching in Scifinder suggested 5.07 to be 4-hydroxy-3,6-
dimethyl-2H-pyrone-2-one, a well-known fungal metabolite isolated from different fungal genera 
including Aspergillus ochraceopetaliformis125, Penicillium sp.126, and Ampleomyces sp.127 Of note, 
5.07 was also isolated as a co-metabolite of  3-methylorcinaldehyde and tropolones from 
Talaromyces stipitatus128. The structure elucidation was confirmed by comparison of the 1H NMR 
(MeOH-d4) data for 5.07 with literature data (Table 5.8).129  
 
Figure 5.23. 1H NMR (600 MHz, DMSO-d6) and UV-vis (HPLC-DAD, H2O/MeCN plus HCO2H) (inset) spectra for 4-
hydroxy-3,6-dimethyl-2H-pyrone-2-one (5.07) 
 
Table 5.7. NMR (600 MHz, DMSO-d6) data for 4-hydroxy-3,6-dimethyl-2H-pyrone-2-one (5.07) 
Pos.  dH, mult (J in Hz)  dC  COSY  1H-13C HMBC ROESY 
2 --- 165.2A --- --- --- 
3 --- 96.1B ---  --- 
3-Me 1.73, s 8.3 --- 2, 3, 4 --- 
4 --- 165.2A --- --- --- 
5 5.98, s 99.8 6-Me 3, 6, 6-Me 6-Me 
6 --- 159.3B --- --- --- 
6-Me 2.13, s 19.2 5 5, 6 5 
A Assignment for overlapping resonances is interchangeable; B resonances determined by HMBC 
 
Table 5.8. 1H NMR (MeOH-d4) data comparison of 4-hydroxy-3,6-dimethyl-2H-pyrone-2-one (5.07) with published data 
Pos. * δH, mult (J in Hz) a experimental * δH, mult, (J in Hz)b lit. literature129 
O O
OH
5.07
2
4
6
1.52.02.53.03.54.04.55.05.56.0 ppm
3.
14
3.
15
1.
00
5
6-Me
3-Me
n m2 5 0 3 0 0 3 5 0 4 0 0 4 5 0 5 0 0 5 5 0
290
O O
OH
(5.09)
2
4
6
 Chapter 5: Integrative strategy to explore the chemical diversity of CMB-F624 
 
164 
3-Me 1.84, s 1.85, s 
5 5.96, s 5.99, s 
6-Me 2.18, s 2.19, s 
*1H NMR measured in (a) 600 MHz, MeOH-d4 (b) 400 MHz, MeOH-d4 
 
5.7.2 cordytropolone (5.05) 
 
HRESI(+)MS analysis of 5.05 revealed a quasi-molecular ion ion ([M+H]+) indicative of the 
molecular formula C9H8O4 (Dmmu –1.3) requiring six double bond equivalents (DBE). Analysis of 
the 1H NMR (DMSO-d6) data for 5.05 revealed resonances for two oxy methylene resonances (dH 
4.97, m; and dH 5.02, m) and two aromatic protons (dH 6.79, s; and dH 6.81, s). Online searching in 
Scifinder with the available data suggested that 5.05 was consistent with the known metabolite 
cordytropolone isolated from Cordyceps sp. 130 which was reported to exhibit moderate antimalarial 
activity against Plasmodium falciparum with IC50 of 2.2 µg/mL and cytotoxicity against cancer cell 
lines (KB and BC-1) with IC50 of 17 and 2.2 µg/mL, respectively. Detailed spectroscopic analysis of 
1H and 2D NMR (DMSO-d6) with comparison to literature data confirmed 5.05 to be cordytroplone130 
as shown in Table 5.10.  
 
Figure 5.24. 1H NMR (600 MHz, DMSO-d6) and UV-vis (HPLC-DAD, H2O/MeCN plus HCO2H) (inset) spectra for 
cordytropolone (5.05) 
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Table 5.9. NMR (600 MHz, DMSO-d6) data of cordytropolone (5.05) 
Pos.  dH, mult (J in Hz)  dC  COSY  1H-13C HMBC 
1 4.97, m 74.9 3 3a, 8a 
3 5.02, m 77.7 1 3a, 8a 
3a --- 145.4 ---  
4 6.81, s 106.3 --- 3, 5, 6, 8a 
5 --- 164.2 ---  
6 --- 172.9A ---  
7 6.79, s 112.9 --- 5, 6, 8, 8a 
8 --- 161.8 ---  
8a --- 127.3 ---  
A resonance determined by HMBC 
 
Table 5.10. 1H NMR (DMSO-d6) data comparison of cordytropolone (5.05) with published data 
Pos. * δH, mult (J in Hz) a experimental * δH, mult, (J in Hz)b lit. literature130 
1 4.97, m 4.97, d (2.8) 
3 5.02, m 5.02, d (2.8) 
4 6.81, s 6.81, s 
7 6.79, s 6.79, s 
*1H NMR measured in (a) 600 MHz, DMSO-d6 (b) DMSO-d6 
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5.7.3 Metarhizide A (5.04)  
 
HRESI(+)MS data of 5.04 revealed a quasi-molecular ion ([M+H]+) indicative of the molecular 
formula C16H22O8 (Dmmu –0.44). The NMR (DMSO-d6) data for 5.04 suggested a glycoside 
composed of an aromatic aglycone moiety attached to a hexose sugar. The 1D and 2DNMR (DMSO-
d6) data for 5.04, revealed resonances attributed to an aldehyde (dH 10.11; dC 195.2), two para 
disposed methyls (dH 2.99; dC 7.4) and (dH 2.53; dC 18.1), and a chelated phenolic hydroxy (dH 12.49), 
in a pentasubstituted benzene ring, with regiochemistry about the aromatic ring supported by 2D 
NMR correlations as outlined in Table 5.11 and Figure 5.27. Comparison of 1D NMR data with 
those of the previously characterized evlachoside (3.06) in chapter 3 identified the hexose moiety as 
a 1¢-b linked 4¢-O-methyl glucose permitting identification of 5.04 as the new natural product 
metarhizide A. Of note, the aglycone for 5.04, 3-methylorcinaldehyde, was previously reported from 
the phytopathogenic fungus Leptosphaeria maculans131, and is considered to be the polyketide-
derived intermediate of tropolones.132 
 
Figure 5.25. 1H NMR (600 MHz DMSO-d6) and UV-vis (HPLC-DAD, H2O/MeCN plus HCO2H) (inset) spectra for 
metarhizide A (5.04) 
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Figure 5.26. 13C NMR (150 MHz DMSO-d6) spectrum for metarhizide A (5.04) 
 
 
Figure 5.27. key 2D NMR (DMSO-d6) correlations for metarhizide A (5.04) 
 
Table 5.11. NMR (600 MHz, DMSO-d6) data for metarhizide A (5.04) 
Pos.  dH, mult (J in Hz)  dC  COSY  1H-13C HMBC ROESY 
1 --- 113.6  --- --- 
1-CHO 10.11, s 195.2  1, 2, 3 2-OH, 6-Me 
2 --- 162.1  --- --- 
2-OH 12.49, s ---  1, 2, 3 1-CHO, 3-Me 
3 --- 110.9  --- --- 
3-Me 1.99, s 7.4  2, 3, 4 --- 
4 --- 161.7  --- --- 
5 6.58, s 108.6 6-Me 1, 3, 4, 6-Me 1', 6-Me 
6 --- 141.9    
6-Me 2.53, s 18.1 5 1, 5, 6 1-CHO, 5 
1' 5.01, d (7.7) 99.4 2' 4, 3', 5' 5, 3', 5' 
2' 3.29, dd (8.3, 7.7) 73.4 1', 3' 1', 3' --- 
3' 3.42A 76.2 2', 4' 4' 1' 
4' 3.06, dd (9.3, 9.3) 78.9 3', 5' 4'-OMe, 5' --- 
4'-OMe 3.46, s 59.7  4' --- 
5' 3.43A 75.7 6'a, 6'b 3', 4' 1' 
6' a, 3.50, dd (11.7, 4.5) 60.2 5', 6'b 4', 5' --- 
 b, 3.63, d, (11.7)  5', 6'a  --- 
A Assignment for overlapping resonance is interchangeable 
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5.7.4 Metarhizide B (5.06) 
 
HRESI(+)MS analysis of 5.06 revealed an adduct ion ([M+Na]+) indicative of the molecular formula 
C16H22O8 (∆mmu 0.58). The UV absorption maxima of 5.06 were quite similar to co-metabolite 5.05, 
supportive of a common tropolone chromophore. Analysis of the 1H NMR (DMSO-d6) spectrum 
suggested a 1¢-b linked 4'-O-methyl glucoside of a tropolone aglycone. The C-6 position of the 
hexose connectivity to the tropolone nucleus was confirmed by a diagnostic HMBC correlation from 
the anomeric proton H-1' to C-6 and a ROESY correlation between H-1' and H-7. The two methyls 
were suggested to be adjacent to each other and attached to C-4 and C-5 by the diagnostic HMBC 
correlations from 4-Me to C-3, C-4 and C-5 and from 5-Me to C-4, C-5 and C-6. As a result, 5.06 
was identified as the new natural product metarhizide B.  
 
Figure 5.28. 1H NMR (600 MHz, DMSO-d6) and UV-vis (HPLC-DAD, H2O/MeCN plus HCO2H) (inset) spectra for 
metarhizide B (5.06) 
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Figure 5.29. 13C NMR (150 MHz, DMSO-d6) spectrum for metarhizide B (5.06) 
 
 
Figure 5.30. Key 2D NMR (DMSO-d6) correlations for metarhizide B (5.06) 
 
Table 5.12. NMR (600 MHz, DMSO-d6) data for metarhizide B (5.06) 
Pos.  dH, mult (J in Hz)  dC  COSY  1H-13C HMBC ROESY 
1 --- 172.3 --- --- --- 
2 --- 163.3B --- --- --- 
3 7.06, s 120.3 --- 1, 2, 4-Me, 5 4-Me 
4 --- 144.7 --- --- --- 
4-Me 2.36, s 27.07 5-Me 3, 4, 5 3 
5 --- 130.2 --- --- --- 
5-Me 2.19, s 16.62 4-Me 4, 5, 6 --- 
6 --- 163.3B --- --- --- 
7 7.00, s 113.4 --- 1, 2, 5, 6 1′ 
1′ 4.94, d (7.7) 100.9 2′ 6 7 
2′ 3.30, dd (8.5, 7.7) 73.5 1′, 3′ 1′, 3′ --- 
3′ 3.43A 76.0 2′, 4′ 2′, 4′ --- 
4′ 3.05, dd (9.3, 9.3) 78.7 3′ 3′, 4′-OMe, 6′ --- 
4′-OMe 3.45, s 59.7 --- 4′ --- 
5′ 3.41A 75.76 --- --- --- 
6′ a 3.52, dd (11.9, 4.6) 
b 3.62, dd (11.9, 1.2) 
60.2 6′b 
6′a 
4′ 
5′ 
--- 
A,B Assignments for overlapping resonances (same superscript) are interchangeable 
 
 
5.8 Cytotoxicity (MTT) assay 
The cytotoxic properties of the known macrocyclic metabolites, torrubiellutin C (5.14) and 
metacridamide A (5.15), and cordytropolone (5.05) suggested a possible cytotoxic activity of the 
extract and isolated metabolites. 
The crude extract and its subsequent fractions (n-hexane, DCM and MeOH) were tested against 
human lung cancer (NCIH460) and colon cancer (SW620) cells. The crude extract and the MeOH 
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fraction showed cytotoxic activity (>95% inhibition at 50 µg/mL). Consequently, the cytotoxic 
properties of isolated metabolites 5.01-5.07 were examined, however none showed cytotoxic activity 
(up to 30 µM). 
 
Figure 5.31. Cytotoxicity properties of 5.01-5.07 against (a) NCIH460, and (b) SW620 
 
5.9 Conclusion 
This chapter highlights the chemical investigation of Metarhizium sp CMB-F624 sourced from GIT 
of mullet fish. A total of seven metabolites, including five new ones, were isolated and characterized. 
Structure elucidation was assigned on the basis of detailed spectroscopic analysis and C3 Marfey’s 
analysis. The characterized metabolites were divided into two groups: (1) C-2 epimeric macrocycles 
named metarhizolides A–C (5.01a/b–5.03a/b), and (2) aromatic aglycones and glucosides (5.04–
5.07). The MeOH fraction showed cytotoxic activity (>95% inhibition at 50 µg/mL), however the 
isolated metabolites were nontoxic (up to 30 µM). The cytotoxic activity of MeOH fraction was most 
likely due to the high concentration of cordytropolone (5.05), reported to be cytotoxic to KB cancer 
cell line with IC50 94 µM, or synergism of different metabolites. The discovery of these metabolites 
supports our earlier hypothesis regarding bottom feeding fish as a promising source of fungal strains 
that can yield new chemical diversity. 
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5.10 Experimental 
5.10.1 General experimental details 
Refer to Appendix 
5.10.2 Collection and Taxonomy of Metarhizium sp. CMB-F624 
The fungus Metarhizium sp. CMB-F624 was isolated from the gastrointestinal tract of a specimen of 
Mugil mullet fish on M1 agar plates and incubated at 30 °C for 7 days. Genomic DNA was extracted 
from the mycelia using the DNeasy Plant Mini Kit (Qiagen) as per the manufacturer’s protocol. The 
18s rRNA genes were amplified by PCR using the universal primers ITS 1 (5"-
TCCGTAGGTGAACCTGCGG-3") and ITS 4 (5"TCCTCCGCTTATTGATATGC-3") purchased 
from Sigma-Aldrich. The PCR mixture (50 μL) contained genomic DNA (2 μL, 20–40 ng), 
EmeraldAmpn GT PCR Master Mix (2X Premix) (25 μL), primer (0.2 μM, each), and H2O (up to 50 
μL). PCR was performed using the following conditions: initial denaturation at 95 °C for 2 min, 40 
cycles in series of 95 °C for 20 s (denaturation), 56 °C for 20 s (annealing) and 72 °C for 30 s 
(extension), followed by one cycle at 72 °C for 5 min. The PCR products were purified with PCR 
purification kit (Qiagen) and sequenced. BLAST analysis (NCBI database) showed that the amplified 
ITS sequence has the closest identity with other members of the genus Metarhizium. 
 
18S rRNA sequence 
CCTGTGACTATACCTGTAATTGTTGCTTCGGCGGGACTTCGCGCCCGCCGGGGGACCCAAACCTTC
TGAATTTTTTTTATTTTAAGTATCTTCTGAGTGGTAAAAAAAAACGAATCAAAACTTTCAACAACG
GATCTCTTGGTTCTGGCATCGATGAAGAACGCAGCGAAATGCGATAAGTAATGTGAATTGCAGAAT
TCAGTGAATCATCGAATCTTTGAACGCACATTGCGCCCGTCAGTATTCTGGCGGGCATGCCTGTTC
GAGCGTCATTACGCCCCTCAAGTCCCCCCGTGGACTTGGTGTTGGGGATCGGCGAGCGCTGTCTTT
TCAGCACGCCGTCCCCTAAATTTATTGGCGGTCTCGCCGTGGCCCTCCTCTGCGCAGTAGTAAAAC
ACTCGCAACGGGAGCCCGGTGAGGTCCACTGCCGTAAAACCCCCCCAACTTTTTTTTATAGTTGAC
CTCGAATCAGGTAGGACTACCCGCTGAACTTAAGCATATCAATAAGCGGAGGA (515 bp) 
BLAST search (closet match) 
An NCBI-BLAST database search of 18s rRNA sequence established a 98% similarity for CMB-
F624 with Metarhizium sp. (Figure 5.32) 
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Figure 5.32. BLAST search (closest match) for CMB-F624 
Phylogenetic Tree 
Phylogenetic tree obtained by PhyML Maximum Likelihood analysis was constructed using the top 
similar 18S rRNA sequences displayed after BLAST on NCBI database using CMB-F624 18S rRNA 
as query. The JC69 model was used to infer phylogeny sequences. Sequences alignments were 
produced with the MUSCLE program. Phylogenetic tree was constructed using the UGENE program 
using the aforementioned models and visualized using Ugene’s tree view.  
5.10.3 Micro-bioreactor analytical cultivation (MATRIX) and chemical analysis 
A seed culture of CMB-F624 was prepared by inoculating a 250 mL flask containing M1 broth 
medium (80 mL) with a single colony of the fungus, followed by shaking at 190 rpm at 26.5 °C for 
4 days. Aliquots of the seed culture (20 µL) were cultured in a panel of eleven different liquid media 
in a micro-bioreactor (MBR) (1.5 mL, each well) format, incubated under both static and shaking 
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conditions, as well as cultured twelve solid media (2.5 g, each well) (Tables 5.13 and 5.14). All 
cultures were incubated at 26.5 °C for 10 d, after which the MBR cultures were extracted with EtOAc 
(2 mL). All organic extracts were concentrated in vacuo, redissolved in MeOH (40 µL). Aliquots (1 
µL) of samples were analysed on Agilent 1290 infinity UHPLC system (Zorbax C8 RRHD column 
1.8 µm 50 ´ 2.1 mm column, 2.50 min, 0.417 mL/min gradient elution from 90% H2O: MeCN to 
100% MeCN with an isocratic 0.01% TFA modifier) with UV-vis detection was done at 210, 230, 
254, 300 and 400 nm. All data was analysed using Agilent ChemStation Open Lab CDS Rev. C.0103 
(37) software. The resulting chromatograms were overlaid and compared in the same scale. 
 
Table 5.13. Types and compositions of liquid-based media of media matrix 
Medium Composition (per Litre) 
M1  Peptone (2.0 g), yeast extract (4.0 g), and starch (10.0 g). pH 7.0 
ISP2 Yeast extract (4.0 g), malt extract (10.0 g), and dextrose (4.0 g). pH 7.2 
ISP4 Soluble starch (10.0 g), CaCO3 (2.0 g), (NH4)2SO4 (2.0 g), K2HPO4 (1.0 g), MgSO4.7H2O (1.0 g), NaCl (1.0 g), FeSO4.7H2O (1.0 mg), MnCl2.7H2O (1.0 mg), ZnSO4.7H2O (1.0 mg), and agar (20.0 g). pH 7.2 
M2  Mannitol (40.0 g), maltose (40.0 g), yeast extract (10.0 g), K2HPO4 (2.0 g), MgSO4.7H2O (0.5 g), and FeSO4.7H2O (0.01 g)  
PDB Potato extract (4.0 g), and dextrose (20.0 g). pH 5.6 
TSB Pancreatic digest of casein (15.0 g), papaic digest of soybean (5.0 g), and NaCl (5.0 g). pH 7.3 
SDB Peptic digest of animal tissue (5.0 g), pancreatic digest of casein (5.0 g), and dextrose (40.0 g). pH 5.6 
PYG Peptone (10 g), yeast Extract (5 g) and dextrose (20 g)  
Basel K2HPO4 (1.5 g), MgSO4.7H2O (0.025 g), CaCl2 (0.025 g), FeSO4.7H2O (0.015 g), and ZnSO4.7H2O (0.005). pH 7.8 
Czapek K2HPO4 (1.0 g), NaNO3 (0.3 g), KCl (0.005 g), MgSO4.7H2O (0.005 g), FeSO4 (0.0001 g), and sucrose (30 g). pH 7.0 
YES Sucrose (150 g), yeast extract (20 g), MgSO4.7H2O (0.5 g), ZnSO4.7H2O (0.01 g), and CuSO4.5H2O (0.005 g) 
 
Table 5.14. Types and compositions of solid-based media of media matrix 
Medium Composition (per Litre) 
M1  Peptone (2.0 g), yeast extract (4.0 g), starch (10.0 g), and agar (18.0 g). pH 7.0 
ISP2 Yeast extract (4.0 g), malt extract (10.0 g), dextrose (4.0 g), and agar (20.0 g). pH 7.2 
ISP4 Soluble starch (10.0 g), CaCO3 (2.0 g), (NH4)2SO4 (2.0 g), K2HPO4 (1.0 g), MgSO4.7H2O (1.0 g), NaCl (1.0 
g), FeSO4.7H2O (1.0 mg), MnCl2.7H2O (1.0 mg), ZnSO4.7H2O (1.0 mg), and agar (20.0 g). pH 7.2 
M2  Mannitol (40.0 g), maltose (40.0 g), yeast extract (10.0 g), K2HPO4 (2.0 g), MgSO4.7H2O (0.5 g), 
FeSO4.7H2O (0.01 g), and agar (18.0 g) 
PDA Potato extract (4.0 g), dextrose (20.0 g), and agar (15.0 g). pH 5.6 
 
TSA Pancreatic digest of casein (15.0 g), papaic digest of soybean (5.0 g), NaCl (5.0 g), and agar (15.0 g).      pH 
7.3 
SDA Peptic digest of animal tissue (5.0 g), pancreatic digest of casein (5.0 g), dextrose (40.0 g), and agar (15.0 
g). pH 5.6 
PYG Peptone (10.0 g), yeast Extract (5.0 g) dextrose (20.0 g), and agar (20.0 g) 
Basel K2HPO4 (1.5 g), MgSO4.7H2O (0.025 g), CaCl2 (0.025 g), FeSO4.7H2O (0.015 g), and ZnSO4.7H2O (0.005), 
and agar (18.0 g). pH 7.8 
Czapek K2HPO4 (1.0 g), NaNO3 (0.3 g), KCl (0.005 g), MgSO4.7H2O (0.005 g), FeSO4 (0.0001 g), sucrose (30 g), 
and agar (18.0 g). pH 7.0 
YES Sucrose (150 g), yeast extract (20 g), MgSO4.7H2O (0.5 g), ZnSO4.7H2O (0.01 g), CuSO4.5H2O (0.005 g), 
and agar (18.0 g) 
Rice-solid Medium grain rice (700g), peptone (3.0 g), yeast extract (3.0 g), and monosodium glutamate (1.0 g) 
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5.10.4 Scale-up cultivation on solid-rice medium 
A seed culture was prepared by inoculating a single colony of Metarhizium sp. CMB-F624 in M1 
broth medium (80 mL in a 250 mL Schott flask) containing 1% starch, 0.4% yeast extract and 0.2% 
peptone and incubated at 26.5 °C for 7 days at 190 rpm at 26.5 °C. Aliquots of the seed culture (5 
mL) were transferred to 2 L flask containing medium grain rice medium (200 g), and the flask was 
incubated at room temperature for 45 days. The resulting culture was extracted with EtOAc (2 ´ 400 
mL), shaken at 150 rpm overnight, decanted, and the organic layer concentrated in vacuo at 40 °C to 
yield a crude extract (461.9 mg) which was sequentially triturated with solvents of increasing 
polarities viz., n-hexane (2 ´ 50 mL), DCM (2 ´ 50 mL), and MeOH (2 ´ 50 mL) to afford, after 
concentration in vacuo, 257.3, 51.7 and 144.1 mg respectively. 
The hexane fraction was partitioned between n-hexane (3 ´ 10 mL) and MeOH (10 mL) to yield F1 
(220 mg) and F2 (22 mg), respectively. F2 was subjected to chromatographic purification using semi-
preparative reversed phase HPLC (Zorbax RX-C8, 9.4 mm ´  25 cm, 5 µm, 3 mL/min, isocratic elution 
with 40% H2O/MeCN for 35 min) to yield 5.01a (3.6 mg, 0.99%), 5.01b (0.4 mg, 0.11%), 5.02a/b 
(0.4 mg, 0.11%), and 5.03a/b (1.5 mg, 0.41%).  
The MeOH fraction was loaded on a Grace C18-Max SPE column (5 g) and subjected to stepwise 
elution with 25% MeOH/H2O to 100% MeOH to afford four fractions (F3-F6). F4 was subjected to 
chromatographic separation using preparative HPLC (Zorbax SB-C8, 21.2 mm ´ 15 cm, 5 µm, 20 
mL/min, isocratic elution with 85% H2O/MeCN over 20 min including 0.01% TFA as modifier) to 
yield 5.04 (2.5 mg, 0.69%) and 5.05 (1 mg, 0.27%). F3 was subjected to chromatographic separation 
using preparative HPLC (Phenomenex Luna-C18, 21.2 mm ´ 25 cm, 10 µm, 20 mL/min, gradient 
elution 90% H2O/MeCN to 30% H2O/MeCN over 22 min including isocratic 0.01% TFA) to yield 
5.04 (23 mg, 6.36%). 
Further fractionation using semi-preparative reversed phase HPLC (Zorbax SB-CN, 9.4 mm ´ 25 cm, 
5 µm, 3 mL/min, gradient elution 90% H2O/MeCN to 75% H2O/MeCN over 15 min including 
isocratic 0.01% TFA) yielded 5.06 (3 mg, 0.83%), while semi-preparative reversed phase HPLC 
(Zorbax SB-phenyl, 9.4 mm ´ 25 cm, 5 µm, 3 mL/min, isocratic elution with 85% H2O/MeCN for 
40 min including 10% isocratic 0.01% TFA as modifier) yielded 5.07 (0.4 mg, 0.11%).  
 
Metarhizolide A (5.01a/b): white solid; [a]22D +16.2 (c 0.2, MeOH); UV (MeOH) lmax (log e) 235 
(4.09), 1D and 2D NMR (600 MHz, DMSO-d6) see Tables 5.2 and 5.3, and Figures 5.8 and 5.9; 
HRESI(+)MS m/z 606.3048 [M+Na]+ (calcd for C33H45NNaO8 606.3037). 
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Metarhizolide B (5.02a/b): white solid; [a]22D -9.9 (c 0.025, MeOH); UV (MeOH) lmax (log e) 233.1 
(3.67), 1D and 2D NMR (600 MHz, DMSO-d6) see Table 5.5 and Figure 5.15; HRESI(+)MS m/z 
564.2944 [M+Na]+ (calcd for C31H43NNaO7 564.2932). 
 
Metarhizolide C (5.03a/b): white solid; [a]22D +14.6 (c 0.1, MeOH); UV (MeOH) lmax (log e) 233.1 
(3.73), 1D and 2D NMR (600 MHz, DMSO-d6) see Table 5.6 and Figures 5.19 and 5.20; 
HRESI(+)MS m/z 704.3778 [M+Na]+ (calcd for C39H55NNaO9 704.3769). 
 
Metarhizide A (5.04): white solid; [a]22D -93.1 (c 0.06, MeOH); UV (MeOH) lmax (log e) 221 
(4.41), 289 (4.48); 1D and 2D NMR (600 MHz, DMSO-d6) see Table 5.11 and Figures 5.25 and 
5.26; HRESI(+)MS m/z 365.1211 [M+Na]+ (calcd for C12H22NaO8 365.1207). 
 
Cordytropolone (5.05): yellow solid; 1D and 2D NMR (600 MHz, DMSO-d6) see Table 5.9 and 
Figure 5.24; ESI(+)MS m/z 181.0 [M+H]+; ESI(–)MS m/z 179.1 [M–H]–; HRESI(+)MS m/z 
181.0508 [M+H]+ (calcd for C9H9O4 181.495). 
 
Metarhizide B (5.06): colourless solid; [a]22D -16.7 (c 0.1, MeOH); UV (MeOH) lmax (log e) 256 
(4.26), 334 (3.70); 1D and 2D NMR (600 MHz, DMSO-d6) see Table 5.12 and Figures 5.28 and 
5.29; HRESI(+)MS m/z 365.1201 [M+Na]+ (calcd for C16H22NaO8 365.1207). 
 
4-hydroxy-3,6-dimethyl-2H-pyran-2-one (5.07): colourless oil; 1D and 2D NMR (600 MHz, DMSO-
d6) see Table 5.7 and Figure 5.23; ESI(+)MS m/z 141.1 [M+H]+, ESI(–)MS m/z 139.1 [M–H]–; 
HRESI(+)MS m/z 163.0363 [M+Na]+ (calcd for C7H8NaO3 163.366). 
5.10.5 Marfey’s analysis of metarhizolide A (5.01a/b) 
An aliquot of the natural metarhizolide A (5.01a/b) (50 µg) dissolved in 6 M HCl (100 µL) was 
heated to 100 °C in a sealed vial for 12 h, after which hydrolysates were evaporated to dryness at 40 
°C under a stream of dry N2. The resulting hydrolysates were treated with 1 M NaHCO3 (20 µL) and 
L-FDAA (1-fluoro-2-4-dinitrophenyl-5-L-alanine amide, 1% solution in acetone, 40 µL) at 40 °C for 
1 h, after which the reactions were neutralised with 1 M HCl (20 µL), diluted with MeCN (100 µL) 
and filtered (0.45 µm PTFE) prior to HPLC-ESIMS analysis [Agilent Zorbax SB-C3 column, 5 μm, 
150 × 4.6 mm, 50 °C, 1 mL/min, 55 min gradient elution from 80:15:5 H2O:MeOH:MeCN to 35:60:5 
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H2O:MeOH:MeCN with an isocratic 0.05% v/v formic acid modifier]. Authentic samples of L-Phe 
were derivatized with either D-FDAA, or L-FDAA, and analysed by HPLC-DAD-ESIMS and UV 
(340 nm). 
5.10.6 Cytotoxicity (MTT) Assays 
The MTT assay was modified from that previously described89using adherent cell lines SW620 and 
NCIH460. SW620 and NCIH460 were cultured in RPMI medium 1640 90 as adherent mono-layer in 
flasks supplemented with 10% foetal bovine serum, 2 mM L-glutamine, 100 unit/mL penicillin and 
100 µg/mL streptomycin in a humidified 37°C incubator supplied with 5% CO2. Briefly, cells were 
harvested with trypsin and dispensed into 96-well microtiter assay plates at 2,000 cells/well for 
SW620, and 5,000 cells/well for NCIH460, then incubated for 18 h at 37 °C with 5% CO2 (to allow 
cells to attach). Testing compounds were dissolved in 5% DMSO in PBS (v/v) and aliquots (20 µL) 
tested over a series of final concentrations ranging from 10 nM to 30 μM. Control wells were treated 
with 5% aqueous DMSO. After 68 h incubation at 37 °C with 5% CO2 an aliquot (20 µL) of MTT in 
PBS (4 mg/mL) was added to each well (final concentration of 0.4 mg/mL), and the microtiter plates 
incubated for a further 4 h at 37 °C with 5% CO2. After this final incubation the medium was 
aspirated, and precipitated formazan crystals dissolved in DMSO (100 µL/well). The absorbance of 
each well was measured at 580 nm with a PowerWave XS Microplate Reader from Bio-Tek 
Instruments Inc. (Vinooski, VT). IC50 values were calculated using Prism 7.0 (GraphPad Software 
Inc., La Jolla, CA), as the concentration of analyte required for 50% inhibition of cancer cell growth 
(compared to negative controls). All experiments were performed in duplicate. Vinblastine (20 
µg/mL) and 1% DMSO served as positive and negative controls, respectively.
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Chapter 6 : Lincolnenins: New antibacterial biantharyl atropisomers isolated from 
Streptomyces lincolnensis ACM-4234 
The secondary metabolism in microbes can be modified qualitatively and quantitatively through the 
variation of culture conditions (as shown in chapter 5). A previous study within the Capon group 
showed that under certain conditions Streptomyces lincolnensis ACM-4234 could be induced to 
produce a new series of bianthracenes, leading to the isolation and structure elucidation of the natural 
products lincolnenins A and B (6.01 and 6.02), and two chlorinated artefacts, lincolnenins A1 and A2 
(6.03 and 6.04) (Figure 6.1). To continue this investigation, we set out to more exhaustively explore 
the production of these bianthracenes from ACM-4234. This chapter is focused on the impact of 
culture conditions, using an in house developed media (MATRIX) approach as applied to 
Streptomyces lincolnensis ACM-4234. In the course of these studies, particular emphasis was given 
to assigning the absolute configuration of bianthracene atropisomers, and on documenting the 
antibacterial and cytotoxicity properties. 
 
Figure 6.1. Previously isolated ACM-4234 bianthracenes (6.01–6.04) 
 
6.1 Taxonomy of Streptomyces lincolnensis ACM-4234  
Streptomyces lincolnensis ACM-4234 was obtained from the Australian Collection of 
Microorganisms (ACM) held by the Capon group. S. lincolnensis is a Gram-positive actinomycete, 
first isolated as part of NRRL culture collection at The National Center for Agricultural Utilization 
Research in Illinois, USA and described by Shirling and Gottlieb in 1969.133 Its taxonomic lineage 
is: Bacterial (Rank: superkingdom); Actinobacteria (Rank: phylum); Actinobacteria (Rank: class); 
Actinobacteridae (Rank: subclass); Actinomycetales (Rank: order); Streptomycineae (Rank: 
suborder); Streptomycetaceae (rank: family), Streptomyces (Rank: genus). 
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6.2 Analytical Cultivation and Chemical Analysis 
Streptomyces lincolnensis ACM-4234 was cultured in a panel of eleven different liquid media in a 
micro-bioreactor (MBR) (1.5 mL, each well) format, incubated under both static and shaking 
conditions, as well as on twelve solid media (2.5 g, each well) (Table 6.1). All cultures were 
incubated at 30 °C for 7 d, after which the MBR cultures were extracted with EtOAc (2 mL). All 
organic extracts were concentrated in vacuo, redissolved in MeOH (40 µL) and analysed by UHPLC-
DAD (Zorbax C8 RRHD column 1.8 µm 50 ´ 2.1 mm column, 2.50 min, 0.417 mL/min gradient 
elution from 90% H2O: MeCN to 100% MeCN with an isocratic 0.01% TFA modifier). Chemical 
analysis revealed high levels of production of the lincolnenins in only two out of thirty four culture 
conditions, namely ISP2 broth-shaken and oatmeal agar (Figure 6.2) with no production of 
monomeric precursors. 
 
Figure 6.2. Heat map of UHPLC-DAD (254 nm) chromatograms of Streptomyces lincolnensis ACM-4234 cultured in 
thirty four different culture conditions. black cells represent lincolnenin metabolites 
 
Table 6.1. List of different culture conditions of Streptomyces lincolnensis ACM-4234 
Number Medium Number Medium Number Medium 
1 M1 agar 13 M1 broth-static 24 M1 broth-shaken 
2 ISP2 agar 14 ISP2 broth-static 25 ISP2 broth-shaken 
3 ISP4 agar 15 PY broth-static 26 PY broth-shaken 
4 M2 agar 16 M2 broth-static 27 M2 broth-shaken 
5 PDA 17 PDB-static 28 PDB-shaken 
6 TSA 18 TSB-static 29 TSB-shaken 
7 SDA 19 SDB-static 30 SDB-shaken 
8 PYG agar 20 PYG-broth-static 31 PYG-broth-shaken 
9 Basal agar 21 Basal broth-static 32 Basal broth-shaken 
10 Czapek agar 22 Czapek broth-static 33 Czapek broth-shaken 
11 YES agar 23 YES broth-static 34 YES broth-shaken 
12 Oatmeal agar 
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An aliquot of the crude extract of an oatmeal agar culture analysed by HPLC-DAD-ESI(±)MS 
(Zorbax Eclipse XDB-C8 5 µm 150 ´ 4.6 mm column, 15 min, 1 mL/min gradient elution from 90% 
H2O/MeCN to 100% MeCN with a constant 0.05% HCO2H in MeCN modifier) revealed two 
lincolnenins at retention times of 11.6 (m/z 599 [M+H]+, 6.01), 11.8 (m/z 599 [M+H]+, 6.05), min 
(Figure 6.3). 
 
Figure 6.3. HPLC-DAD (254 nm) chromatogram of the crude extract and an image of Streptomyces lincolnensis ACM-
4234 cultured on oatmeal agar. 
 
The effect of cultivation time on the lincolnenins production was studied by cultivating ACM-4234 
on three oatmeal agar plates (20 g, each) at 30 oC with harvesting at 7, 14 and 21 days, respectively. 
After harvest, the agar was chopped (approx. 1.5 cm ´ 1.5 cm), transferred to Falcon tubes (50 mL) 
and extracted with EtOAc (16 mL) by shaking at 150 rpm for 4 hours. The decanted EtOAc extracts 
were evaporated under a stream of dry N2 at 40 oC, to yield crude extracts of 8, 11.2, and 24 mg, 
respectively. Crude extracts were dissolved in MeOH (3 mL) and an aliquot (5 µL) of each analysed 
by HPLC-DAD-ESI(±)MS (Zorbax Eclipse XDB-C8 5 µm 150 ´ 4.6 mm column, 15 min, 1 mL/min 
gradient elution from 90% H2O/MeCN to 100% MeCN with a constant 0.05% HCO2H in MeCN 
modifier). The morphology of cultures and HPLC-DAD-ESI(±)MS analysis showed a notable 
production of lincolnenins in 14 and 21 d cultures compared to 7 d culture (Figure 6.4). As a result, 
21 days was chosen as a suitable cultivation time for scale-up cultivation. 
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Figure 6.4. Images and HPLC-DAD (254 nm) chromatograms of crude extract of ACM-4234 oatmeal agar culture 
cultivated for (a) 7 days, (b) 14 days, and (c) 21 days  
 
6.1 Scale-up cultivation on oatmeal agar 
Streptomyces lincolnensis ACM-4234 was cultivated on oatmeal agar plates (´75), incubated at 30 
oC for 21 days. Following the incubation period, the agar was chopped (approximately 1.5 cm ´ 1.5 
cm), transferred to 2L flasks and extracted with EtOAc (4 ´  400 mL) by shaking at 150 rpm overnight. 
The decanted organic layer was concentrated in vacuo at 40 oC to yield a crude extract (3.94 g). The 
crude extract was partitioned between n-hexane (3 ´ 50 mL) and MeOH (50 mL), with two solvents 
concentrated in vacuo to yield fractions that were weighted and kept for further investigation (scheme 
6.1). An aliquot of each fraction was redissolved in MeOH and subjected to HPLC-DAD-MS 
analysis. Based on the chemical profiles the MeOH fraction was chosen for further purification, as it 
proved to be enriched with lincolnenins. 
The MeOH fraction was fractionated by gel chromatography (Sephadex LH-20, 2.5 ´ 86 cm column, 
isocratic elution with MeOH) to yield lincolnenin A (6.01), and two enriched lincolnenin fractions. 
The two enriched fractions were subjected to further chromatographic purification using semi-
preparative reversed phase HPLC (Zorbax Eclipse XDB-C8, 9.4 mm ´ 25 cm, 5 µm, 3 mL/min, 
isocratic elution with 55% H2O/MeCN for 35 min including 10% isocratic 0.01% TFA as modifier) 
to yield lincolnenin A (6.01) (tR = 26.3 min, 9.6 and 5 mg), lincolnenin C (6.05) (tR = 29.8 min, 3.8 
and 5.6 mg), lincolnenin D (6.06) (tR = 28.4 min, 1 and 4.4 mg), and lincolnenin E (6.07) (tR = 24.2 
min, 1.9 mg). 
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Scheme 6.1. Fractionation scheme for ACM-4234 oatmeal agar extract 
 
 
Figure 6.5. Semi-preparative HPLC (210 nm) chromatogram of fraction (F5) 
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6.2 Structure elucidation 
6.2.1 lincolnenin A (6.01) 
 
HRESI(+)MS data of 6.01 revealed a molecular ion ([M+Na]+) which corresponded to a pseudo 
molecular ion C34H30NaO10 (Dmmu 0.8) requiring 20 double bond equivalents (DBE). 6.01 was 
assumed to possess an element of symmetry since the number of carbon resonances recorded in the 
13C NMR (CDCl3) spectrum was half that required by the molecular formula. The 1H NMR, HSQC 
and COSY data confirmed that the monomeric unit included two 3o-methyls (dH 1.19, s, H3-13/13'; 
dH 1.58, s, H3-12/12'), an isolated diastereotopic methylene (dH 2.55, dd, J= 18.0 and 1.3 Hz, H-
3b/3'b; dH 3.19, d, J= 18.0 Hz, H-3a/3'a), an isolated deshielded methine (dH 3.70, s, H-1/1'), and a 
1,2,3-trisubstituted benzene moiety (dH 6.75, dd, J= 8.3 and 0.7 Hz, H-8/8'; dH 6.95, dd, J= 8.3 and 
0.7 Hz, H-6/6'; dH 7.39 dd, J= 8.3 and 8.3 Hz, H-7/7') and two chelated phenol moieties (dH 10.13, s, 
5/5'-OH; dH 16.79, s, 10/10'-OH).  
O OH OH
HO
O
OOHOH
OH
O
13
12
11
1
9a
9
8a
8
7
6
5
10a 4a
10
4
3
2
lincolnenin A (6.01)
 Chapter 6: Lincolnenins: biantharyl atropisomers from ACM-4234 
 
183 
 
Figure 6.6. 1H NMR (600 MHz, CDCl3) and UV-vis (HPLC-DAD, H2O/MeCN plus HCO2H) (inset) spectra for 
lincolnenin A (6.01)  
 
 
Figure 6.7. 13C NMR (150 MHz, CDCl3) spectrum for lincolnenin A (6.01) 
 
HMBC correlation from the 3o methyl (dH 1.58) to a ketone carbonyl (dC 207.0) prompted its 
assignment to an acetyl moiety. The structure elucidation of 6.01 was further supported by 2D NMR 
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(CDCl3) data as outlined in Table 6.2 and Figure 6.12. The relative stereochemistry of 6.01 was 
determined by a diagnostic ROESY correlation between H-1/1′ and H-13/13′, which required the 
acetyl group pendent to C-1/1′ and the methyl pendent to C-2/2′ be trans oriented to each other 
(Figure 6.9).  
In silico conformational energy analysis of 6.01 showed an energy barrier sufficient to hinder the 
rotation about the biaryl axis, giving rise to the potential for M vs P atropisomers. As the relative 
regio-stereochemistry of the chiral centres was elucidated, four stereoisomers (6.01a–6.01d) were 
proposed for 6.01. A diagnostic ROESY correlation between H-1/1′ and H-8/8′ excluded two 
possibilities of the four possible diastereomers (Figures 6.8 and 6.9). As a result, the absolute 
configuration of the metabolite (6.01) is either M, 1R, 2S, 1′R, 2′S (6.01a) or its enantiomer P, 1S, 
2R, 1′S, 2′R (6.01d). 
 
 
Figure 6.8. Possible stereoisomers of lincolnenin A (6.01). (6.01a) M, 1R, 2S, 1′R, 2′S, (6.01b) P, 1R, 2S, 1′R, 2′S, (6.01c), 
M, 1S, 2R, 1′S, 2′R, and (6.01d) P, 1S, 2R, 1′S, 2′R. 
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Figure 6.9. Expanded 2D NMR ROESY (CDCl3) spectrum for lincolnenin A (6.01) 
 
In order to determine the absolute stereochemistry of 6.01, ECD spectra were calculated for the two 
possible atropisomers, 6.01a and 6.01d, and compared with the measured CD spectrum of 6.01. The 
experimental CD spectrum of 6.01 was found to match with 6.01a indicating that it possessed M, 1R, 
2S, 1′R, 2′S configuration. 
 
Figure 6.10. Calculated ECD spectra of 6.01a and 6.01d 
 
Figure 6.11. Experimental CD spectrum of lincolnenin A (6.01) 
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Figure 6.12. Key 2D NMR (CDCl3) correlations for lincolnenin A (6.01) 
 
Table 6.2. NMR (600 MHz, CDCl3) data for lincolnenin A (6.01) 
Pos.  dH, mult (J in Hz)  dC  COSY  1H-13C HMBC ROESY 
1/1′ 3.70, s 59.0 3b/3′b, 12/12′ 2/2′, 3/3′, 4a/4′a, 9/9′, 
9a/9′a, 11/11′, 13/13′ 
8/8′, 12/12′, 13/13′ 
2/2′ --- 72.6 ---   
3a/3′a 3.19, d (18.0) 47.0 3b/3′b, 13/13′ 1/1′, 2/2′, 4/4′, 13/13′ --- 
3b/3′b 2.55, dd (18.0, 1.3) 47.0 1/1′, 3a/3′a 1/1′, 2/2′, 4/4′, 4a/4′a, 
13/13′ 
13/13′ 
4/4′ --- 204.2 ---  --- 
4a/4′a --- 109.7 ---  --- 
5/5′ --- 159.1 ---  --- 
6/6′ 6.95, dd (8.3, 0.7) 113.0 7/7′ 5/5′, 8/8′, 10a/10′a --- 
7/7′ 7.39, dd (8.3, 8.3) 133.7 6/6′, 8/8′ 5/5′, 6/6′, 8a/8′a, 10a/10′a 13/13′ 
8/8′ 6.75, dd (8.3, 0.7) 117.3 7/7′ 5/5′, 6/6′, 8a/8′a, 9/9′, 
10/10′, 10a/10′a 
1/1′, 13/13′ 
8a/8′a --- 138.6 --- --- --- 
9/9′ --- 124.9 --- --- --- 
9a/9′a --- 135.4 --- --- --- 
10/10′ --- 166.6 --- --- --- 
10a/10′a --- 113.6 --- --- --- 
11/11′ --- 207.0 --- --- --- 
12/12′ 1.58, s 34.7 1/1′ 1/1′, 11/11′ 1/1′ 
13/13′ 1.19, s 29.4 3a/3′a 1/1′, 2/2′, 3/3′ 1/1′, 3b/3′b , 7/7′, 
8/8′ 
5/5′-OH 10.13, s --- --- 5/5′, 6/6′, 10a/10′a --- 
10/10′-OH 16.79, s --- --- 4/4′, 4a/4′a, 10/10′, 
10a/10′a 
--- 
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6.2.2 lincolnenin C (6.05) 
 
HRESI(+)MS data for 6.05 revealed an adduct ion ([M+Na]+) corresponding to a pseudo molecular 
ion C34H30NaO10 (Dmmu 1.4) isomeric with 6.01. Analysis of the 1D NMR (CDCl3) data for 6.05 
indicated a lack of symmetry, revealing four 3o methyls (dH 1.21, s, H3-13'; dH 1.29, s, H3-12; dH 1.34, 
s, H3-13; dH 2.26, s, H3-12'), two isolated diastereotopic methylenes (dH 2.63, dd, J= 17.5 and 1.5 Hz, 
H-3b; dH 2.65, dd, J= 17.9 and 1.3 Hz, H-3'b;  dH 3.15, d, J= 17.5 Hz, H-3a;  dH 3.31, d, J= 17.9 Hz, 
H-3'a), two deshielded isolated methines (dH 3.88, s, H-1'; dH 4.06, s, H-1), a 1,2,3-trisubstituted 
benzene moiety (dH 6.42, dd, J= 8.1 and 1.0 Hz, H-8; dH 6.90, dd, J= 8.1 and 1.0 Hz, H-6; dH 7.29, 
dd, J= 8.1 and 8.1 Hz, H-7), an isolated aromatic proton (dH 6.08, s, H-9'), two ortho coupled aromatic 
protons (dH 7.08, d, J= 8.0, H-6'; dH 7.34, d, J= 8.0, H-7') and four chelated phenol protons (dH 10.06, 
br s, 5-OH and 5'-OH; dH 16.23, s, 10'-OH; dH 16.59, s, 10-OH). As with 6.01, the relative 
stereochemistry of 6.05 was determined by a diagnostic ROESY correlation between H-1 and H-13 
and between H-1′ and H-13′, which required the acetyl groups pendent to C-1 and C-1′ and the methyl 
pendent to C-2 and C-2′ be trans oriented (Figure 6.15). A diagnostic HMBC key correlation from 
H-9¢ to the quaternary C-8¢ confirmed a C-9 to C-8¢ linkage (Figure 6.16). 
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Figure 6.13. 1H NMR (600 MHz, CDCl3) and UV-vis (HPLC-DAD, H2O/MeCN plus HCO2H) (inset) spectra for 
lincolnenin C (6.05) 
 
 
Figure 6.14. 13C NMR (150 MHz, CDCl3) spectrum for lincolnenin C (6.05) 
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Figure 6.15. Expanded 2D NMR ROESY (CDCl3) spectrum for lincolnenin C (6.05) 
 
Figure 6.16. Expanded 2D NMR HMBC (CDCl3) spectrum for lincolnenin C (6.05) 
 
An in silico conformational energy analysis of 6.05 showed a sufficient energy barrier to hinder the 
rotation about the biaryl axis, giving rise to (M) and (P) atropisomers. As a result, four stereoisomers 
(6.05a–6.05d) were proposed for 6.05 (Figure 6.17). The diagnostic ROESY correlations between 
(i) H-1 and H-7′, (ii) H-7′ and H3-13 pendent to C-2, and (iii) H-9′ and H3-12 pendent to C-1, excluded 
two of the four possible diastereomers (Figure 6.18). As a result, the absolute configuration of 6.05 
was either M, 1R, 2S, 1′R, 2′S (6.05a) or P, 1S, 2R, 1′S, 2′R (6.05d). Previous studies of biosynthesis 
of similar compounds, setomimycin and julichromes (see structures on page 199), suggested that the 
monomeric subunits are formed first from a nonaketide, prior to dimerization.134 As the absolute 
stereochemistry of 6.01 monomeric units was confirmed to be 1R, 2S, 1′R, 2′S, the absolute 
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stereochemistry of 6.05 is proposed to be the same. However, the calculation of ECD spectra of the 
possible atropenantiomers (6.05a and 6.05d) is a future work to be done by our collaborators and the 
comparison with experimental CD spectrum will be done to confirm the absolute configuration. 
 
Figure 6.17. Possible stereoisomers of lincolnenin C (6.05). (6.05a) M, 1R, 2S, 1′R, 2′S, (6.05b) P, 1R, 2S, 1′R, 2′S, 
(6.05c) M, 1S, 2R, 1′S, 2′R, and (6.05d) P, 1S, 2R, 1′S, 2′R. 
 
Figure 6.18. Expanded 2D NMR ROESY (CDCl3) spectrum for lincolnenin C (6.05) 
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Figure 6.19. Key 2D NMR (CDCl3) correlations for lincolnenin C (6.05) 
 
Table 6.3. NMR (600 MHz, CDCl3) data for lincolnenin C (6.05) 
Pos.  dH, mult (J in Hz)  dC  COSY  1H-13C HMBC ROESY 
1 4.06, s 60.2 3b, 12 2, 3, 4a, 9, 9a, 11, 13 12, 13, 7′ 
2 --- 72.6B --- --- --- 
3a 3.15, d (17.5) 47.4 3b, 13 1, 2, 4, 13 --- 
3b 2.63, dd (17.5, 1.5)  1, 3a 1, 2, 4, 4a, 13 13 
4 --- 203.6 --- --- --- 
4a --- 109.1 --- --- --- 
5 --- 158.8 --- --- --- 
6 6.90, dd (8.1, 1.0) 112.3 7 5, 8, 10a 5-OH 
7 7.29, dd (8.1, 8.1) 133.3 6, 8 5, 8a --- 
8 6.42, dd (8.1, 1.0) 118.1 7 6, 9, 10a 7′ 
8a --- 139.8 --- --- --- 
9 --- 127.3 --- --- --- 
9a --- 133.8 --- --- --- 
10 --- 166.6 --- --- --- 
10a --- 113.3 --- --- --- 
11 --- 208.7 --- --- --- 
12 1.29, s 33.9 1 1, 11 1 
13 1.34, s 29.9 3a 1, 2, 3 1, 3b, 7′ 
5-OH 10.06, br sA --- --- --- 6, 10-OH 
10-OH 16.59, s --- --- 4, 4a, 10, 10a 5-OH 
1′ 3.88, s 61.5 3′b, 9′, 12′ 2′, 3′, 4′a, 9′, 9′a, 11′, 13′ 9′, 12′, 13′ 
2′ --- 72.6 B --- --- --- 
3′a 3.31, d (17.9) 48.2 3′b, 13′ 1′, 2′, 4′, 13′ --- 
3′b 2.65, dd (17.9, 1.3)  1′, 3′a 1′, 2′, 4′, 4′a, 13′ 13′ 
4′ --- 203.4 --- --- --- 
4′a --- 108.9 --- --- --- 
5′ --- 158.7 --- --- --- 
6′ 7.08, d (8.0) 112.5 7′ 5′, 8′, 10′a 5′-OH 
7′ 7.34, d (8.0) 135.4 6′ 5′, 8′a, 9 1, 8 
8′ --- 126.3 --- --- --- 
8′a --- 138.2 --- --- --- 
9′ 6.08, s 116.8 1′ 1′, 4′a, 8′, 8′a, 10′a 12, 1′, 12′ 
9′a --- 134.4 --- --- --- 
10′ --- 166.4 --- --- --- 
10′a --- 113.5 --- --- --- 
11′ --- 209.4 --- --- --- 
12′ 2.26, s 34.1 1′ 1′, 11′ 1′, 9′ 
13′ 1.21, s 29.2 3′a 1′, 2′, 3′ 1′, 3′b 
5′-OH 10.06, br sA --- --- --- 6′, 10′-OH 
10′-OH 16.23, s --- --- 4′, 4′a, 10′, 10′a 5′-OH 
A, B Assignments for overlapping resonances (same superscript) are interchangeable 
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6.2.1 lincolnenins D and E (6.06 and 6.07) 
 
HRESI(+)MS data for 6.06 and 6.07 revealed a pseudo molecular ion C34H30NaO10 (Dmmu 0.07 and 
–0.22) isomeric with 6.01. It’s noteworthy that 6.07 was sparingly soluble in CDCl3 so MeOH-d4 was 
used as a solvent to acquire NMR data. 1D NMR data revealed that 6.06 and 6.07 possess an element 
of symmetry and each monomer subunit included two 3o methyls, an isolated diastereotopic 
methylene, a deshielded methine, an isolated aromatic proton, and two ortho coupled aromatic 
protons (Figures 6.20-6.23). The regiochemistry for dimerization for both metabolites was 
determined to be a C-8 to C-8¢, based on the ortho disposition of H-6/6¢ and H-7/7¢, and an HMBC 
correlation from H-9/9¢ to C-8/8¢. 6.06 and 6.07 were stereoisomers. That was evident from 1H NMR 
data differences (Figure 6.24).  
Moreover, in silico conformational energy analysis of 6.06 showed a sufficient energy barrier, more 
than 23 kcalmol-1, to hinder the rotation about the biaryl axis. The previous findings suggested that 
6.06 and 6.07 were distinct atropisomers. 
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Figure 6.20. 1H NMR (600 MHz, CDCl3) and UV-vis (HPLC-DAD, H2O/MeCN plus HCO2H) (inset) spectra for 
lincolnenin D (6.06) 
 
 
Figure 6.21. 13C NMR (150 MHz, CDCl3) spectrum for lincolnenin D (6.06) 
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Figure 6.22. 1H NMR (600 MHz, MeOH-d4) and UV-vis (HPLC-DAD, H2O/MeCN plus HCO2H) (inset) spectra for 
lincolnenin E (6.07) 
 
 
Figure 6.23. 13C NMR (150 MHz, MeOH-d4) spectrum for lincolnenin E (6.07) 
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Figure 6.24. 1H NMR (600 MHz, MeOH-d4) spectra for lincolnenins D and E (6.06 and 6.07) 
 
Nevertheless, the opposite optical rotation sign and experimental CD spectra (Figure 6.25) of both 
metabolites supported this assumption. Further studies will be required to determine the absolute 
configuration through performing ECD spectral calculation for 6.06 and 6.07. 
 
 
Figure 6.25. Experimental CD spectra for lincolnenins D and E (6.06 and 6.07) 
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Figure 6.26. Possible stereoisomers of lincolnenins D and E (6.06 and 6.07). (6.06a/6.07a) M, 1R, 2S, 1′R, 2′S, 
(6.06b/6.07b) P, 1R, 2S, 1′R, 2′S 
 
Although in silico conformational energy analysis of 6.06 showed the presence of a sufficient energy 
barrier to hinder the rotation about the biaryl axis, it was low compared to lincolnenin A. This finding 
led us to check the thermal interconvertability of 6.06 and 6.07. A thermolability study was performed 
where aliquots (200 µg) of 6.06 and 6.07 dissolved in MeOH (250 µL) in a sealed vial and an aliquot 
(5 µL) of each solution was analysed by reversed phase HPLC (Zorbax Eclipse XDB-C8, 5 µm, 4.6 
mm ´ 15 cm, 1 mL/min, isocratic elution with 45% MeCN/H2O for 20 min including isocratic 0.05% 
formic acid as modifier). Other aliquots (100 µL) were subjected to heating at 50 oC for 5 hours and 
29 hours, respectively. An aliquot (5 µL) of each solution was subjected to HPLC analysis. HPLC 
chromatograms (Figure 6.27) showed the ability of each metabolite to convert to the other, 
confirming that they were atropisomers with a low barrier to rotation. 
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Figure 6.27. Thermolability study of 6.06 and 6.07. (a) effect of heat on 6.07, and (b) effect of heat on 6.06. 
 
The interconvertibility of lincolnenins D (6.06) and E (6.07) at 50 oC raised the prospect that one of 
atropisomers might be a handling artefact. As a result, a 3 week oat meal cultivation of ACM-4234 
was extracted with EtOAc and the fresh crude extract was dried under nitrogen at room temperature 
to avoid thermal epimerization of atropisomers. An aliquot (10 µL) of the crude extract was analysed 
by HPLC-DAD-ESIMS using the same chromatographic conditions as for the thermolability study. 
HPLC analysis showed the presence of both metabolites, proving that both were natural products 
(Figure 6.28). 
 
 
Figure 6.28. HPLC-DAD (268 nm) chromatogram of ACM-4234 oatmeal crude extract 
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Table 6.4. NMR (600 MHz, CDCl3) data for lincolnenin D (6.06) 
Pos.  dH, mult (J in Hz)  dC  COSY  1H-13C HMBC ROESY  
1/1′ 3.83, s 61.7 3b/3′b, 9/9′ 2/2′, 3/3′, 4a/4′a, 9/9′, 
9a/9′a, 11/11′, 13/13′ 
9/9′, 12/12′, 13/13′ 
2/2′ --- 72.1 --- ---  
3a/3′a 3.30, d (18.0) 48.8 3b/3′b, 13/13′ 1/1′, 2/2′, 4/4′, 13/13′ --- 
3b/3′b 2.69, dd (18.0, 1.2) 48.8 1/1′, 3a/3′a 1/1′, 2/2′, 4/4′, 13/13′ 13/13′ 
4/4′ --- 203.0 --- --- --- 
4a/4′a --- 108.6 --- --- --- 
5/5′ --- 158.5 --- --- --- 
6/6′ 6.38, d (8.0) 111.9 7/7′ 5/5′, 8/8′, 10a/10′a --- 
7/7′ 7.43, d (8.0) 135.6 6/6′ 5/5′, 8/8′, 8a/8′a --- 
8/8′ --- 128.1 --- --- --- 
8a/8′a --- 137.9 --- --- --- 
9/9′ 6.38, s 117.1 --- 1/1′, 4a/4′a, 8/8′, 10a/10′a 1/1′, 12/12′ 
9a/9′a --- 133.9 --- --- --- 
10/10′ --- 166.7 --- --- --- 
10a/10′a --- 113.4 --- --- --- 
11/11′ --- 209.4 --- --- --- 
12/12′ 1.58, s 32.8 --- 1/1′, 11/11′ 1/1′ 
13/13′ 1.19, s 28.8 3a/3′a 1/1′, 2/2′, 3/3′ 1/1′, 3b/3′b 
5/5′-OH 10.00, s --- --- 5/5′, 6/6′, 10a/10′a 10/10′-OH 
10/10′-OH 16.29, s --- --- 4a/4′a, 10/10′, 10a/10′a 5/5′-OH 
 
Table 6.5. NMR (600 MHz, MeOH-d4) data for lincolnenin E (6.07) 
Pos.  dH, mult (J in Hz)  dC  COSY  1H-13C HMBC ROESY  
1/1′ 4.00, s 63.9 3b/3′b, 9/9′, 
12/12′ 
2/2′, 3/3′, 4a/4′a, 9/9′, 
9a/9′a, 11/11′, 13/13′ 
9/9′, 12/12′, 13/13′ 
2/2′ --- 72.3 --- ---  
3a/3′a 3.20, d (17.9) 49.1* 3b/3′b, 13/13′ 1/1′, 2/2′, 4/4′, 13/13′ --- 
3b/3′b 2.66, br d (17.9) 49.1* 1/1′, 3a/3′a 1/1′, 2/2′, 4/4′, 4a/4′a, 
13/13′ 
13/13′ 
4/4′ --- 205.4 --- --- --- 
4a/4′a --- 110.2 --- --- --- 
5/5′ --- 159.3 --- --- --- 
6/6′ 6.98, d (8.0) 112.5 7/7′ 5/5′, 8/8′, 10a/10′a --- 
7/7′ 7.45, d (8.0) 136.4 6/6′ 5/5′, 8/8′, 8a/8′a 9/9′ 
8/8′ --- 129.6 --- --- --- 
8a/8′a --- 139.3 --- --- --- 
9/9′ 6.52, s 118.0 1/1′ 1/1′, 4a/4′a, 8/8′, 8a/8′a, 
10a/10′a 
1/1′, 7/7′, 12/12′ 
9a/9′a --- 136.0 --- --- --- 
10/10′ --- 166.4 --- --- --- 
10a/10′a --- 114.5 --- --- --- 
11/11′ --- 210.1 --- --- --- 
12/12′ 2.16, s 33.3 1/1′ 1/1′, 11/11′ 1/1′ 
13/13′ 1.21, s 29.4 3a/3′a 1/1′, 2/2′, 3/3′ 1/1′, 3b/3′b 
 
Reviewing the literature for structurally similar dimeric biantharyl metabolites led us to setomimycin 
(6.08), spectomycin B1 (6.09), and julichrome Q6-6 (6.10) (Figure 6.30). Setomimycin (6.08) was 
first isolated in 1978 from Streptomyces pseudovenezuelae by Omura et al, 135 and was reported to 
exhibit antibacterial activity against Gram-positive bacteria (MIC 5.39 µM) and Mycobacterium 
smegmatis (ATCC607) (MIC 2.69 µM), with no activity against Gram-negative bacteria. 
Interestingly, the absolute stereochemistry for the biaryl axis of setomimycin (6.08) was determined 
to be P (opposite to lincolnenin A) by Prag et al 134 by comparison of experimental CD spectrum with 
calculated ECD spectra. 
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Spectomycin B1 (6.09), isolated from Streptomyces spectabilis, showed moderate activity against 
Gram-positive bacteria Bacillus subtilis (MIC 2.8 µM), with no activity against Gram-negative 
bacteria).136 Julichrome Q6-6 (6.10) is a member of the julimycins family first isolated in 1971 by 
Tsuji and Nagashima from Streptomyces shiodaensis.137 
 
 
Figure 6.29. Structures of metabolites similar to lincolnenins 
 
6.3 Biological Assays  
The antibacterial activity of structurally similar biantharyl metabolites, setomimycin (6.08) and 
sepctomycin B1 (6.09), suggested that the lincolnenins A (6.01), C–D (6.05–6.07), might show 
similar activity. As a result, metabolites 6.01 and 6.05–6.07 were evaluated for antibacterial and 
cytotoxic properties 
6.3.1 Antibacterial assay against drug susceptible bacteria 
Metabolites 6.01 and 6.05–6.07 were evaluated for antibacterial activity against the Gram-positive 
bacteria, Staphylococcus aureus ATCC25923, and Staphylococcus epidermidis ATCC12228, and the 
Gram-negative bacteria Escherichia coli ATCC25922. The tested compounds displayed no activity 
against E. coli, while they showed variable activities against the Gram-positive bacteria, as shown in 
Figure 6.30. Lincolnenin A (6.01) and C (6.05) were the most active with IC50 range (1.3–4.1 µm) 
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Figure 6.30. Antibacterial activity of 6.01, and 6.05-6.07 against Gram-positive bacteria. (a) S. aureus ATCC25923, and 
(b) S. epidermidis ATCC12228 
 
6.3.2 Mycobacterium bovis (BCG) assay  
Evaluation of the antimycobacterial activity of isolated metabolites, 6.01 and 6.05–6.07 against 
Mycobacterium bovis, Bacille Calmette Guerin (BCG), showed good in vitro activity of lincolnenin 
A (6.01) with an IC50 2.86 µM and moderate activity of 6.05 with IC50 14.2 µM. 
 
Figure 6.31. Antibacterial activity of 6.01, and 6.05-6.07 against Mycobacterium bovis (BCG) 
 
6.3.3 Cytotoxicity (MTT) Assays  
Metabolites 6.01 and 6.05–6.07 were evaluated for cytotoxicity against human lung (NCIH460) and 
colon (SW620) cancer cells. The tested metabolites were non-cytotoxic at 30 µM. 
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Figure 6.32. Cytotoxic activity of 6.01, and 6.05-6.07. (a) NCIH460 and (b) SW620 
 
6.4 Conclusion 
This chapter highlights the capability of our in-house developed media MATRIX approach not only 
in inducing but also enhancing the production of microbial secondary metabolites. Cultivation of 
Streptomyces lincolnensis ACM-4234 under thirty four different culture conditions showed a 
remarkable production of biantharyl metabolites in only two culture conditions, namely ISP2 broth 
shake and oatmeal agar. Oatmeal agar cultivation showed optimal levels of production of these 
metabolites. 
Four new biantharyls from Streptomyces lincolnensis ACM-4234 were isolated and characterized on 
the basis of spectroscopic data. The absolute configuration of lincolnenin A (6.01) was found to be 
opposite to setomimycin (6.08), a known antibacterial metabolite.134 Lincolnenins A (6.01) and C 
(6.05) showed good antibacterial activity against Gram-positive bacteria (IC50 1.3-4.1 µM). 
6.5 Future directions 
ECD calculation of lincolnenins C–E (6.05–6.07) will be performed to determine their absolute 
configuration. 
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6.6 Experimental 
6.6.1 General experimental details 
Refer to Appendix 
6.6.2 Micro-bioreactor analytical cultivation and chemical analysis 
The spores of S. lincolnensis ACM-4234 were individually transferred from ISP2 agar culture to a 
sterile 24-well microbioractor, each well containing 1.5 mL broth media or 2.5 g solid media (Tables 
6.6 and 6.7), by using inoculation loops under sterile condition. The broth shaking plate was incubated 
on an orbital platform shaker at 190 rpm. All cultures were incubated at 30 °C for 7 days. After the 
incubation, ACM-4234 cultures were extracted with EtOAc (2 mL) in situ at 150 rpm for 30 min. 
The organic layer was filtered through 0.45 µm millipore sterile filter into 2 mL vials and dried under 
N2 at 40 °C. Crude extracts were dissolved in MeOH (40 µL). Aliquots (1 µL) of samples were 
analysed on UHPLC-DAD using the method described under general experimental details. All data 
were analysed using Agilent ChemStation Open Lab CDS Rev. C.0103 (37) software. The resulting 
chromatograms were overlaid and compared in the same scale. Heat map at 254 nm was drawn using 
Prism 7.0 (GraphPad Software Inc., La Jolla, CA) 
 
Table 6.6. Types and compositions of liquid-based media of media matrix 
Medium Composition (per Litre) 
M1  Peptone (2.0 g), yeast extract (4.0 g), and starch (10.0 g). pH 7.0 
ISP2 Yeast extract (4.0 g), malt extract (10.0 g), and dextrose (4.0 g). pH 7.2 
PY Peptone (10 g), and yeast Extract (5 g) 
M2  Mannitol (40.0 g), maltose (40.0 g), yeast extract (10.0 g), K2HPO4 (2.0 g), MgSO4.7H2O (0.5 g), and FeSO4.7H2O (0.01 g)  
PDB Potato extract (4.0 g), and dextrose (20.0 g). pH 5.6 
TSB Pancreatic digest of casein (15.0 g), papaic digest of soybean (5.0 g), and NaCl (5.0 g). pH 7.3 
SDB Peptic digest of animal tissue (5.0 g), pancreatic digest of casein (5.0 g), and dextrose (40.0 g). pH 5.6 
PYG Peptone (10 g), yeast Extract (5 g) and dextrose (20 g)  
Basel K2HPO4 (1.5 g), MgSO4.7H2O (0.025 g), CaCl2 (0.025 g), FeSO4.7H2O (0.015 g), and ZnSO4.7H2O (0.005). pH 7.8 
Czapek K2HPO4 (1.0 g), NaNO3 (0.3 g), KCl (0.005 g), MgSO4.7H2O (0.005 g), FeSO4 (0.0001 g), and sucrose (30 
g). pH 7.0 
YES Sucrose (150 g), yeast extract (20 g), MgSO4.7H2O (0.5 g), ZnSO4.7H2O (0.01 g), and CuSO4.5H2O (0.005 g) 
 
  
 Chapter 6: Lincolnenins: biantharyl atropisomers from ACM-4234 
 
203 
Table 6.7. Types and compositions of solid-based media of media matrix 
Medium Composition (per Litre) 
M1  Peptone (2.0 g), yeast extract (4.0 g), starch (10.0 g), and agar (18.0 g). pH 7.0 
ISP2 Yeast extract (4.0 g), malt extract (10.0 g), dextrose (4.0 g), and agar (20.0 g). pH 7.2 
ISP4 Soluble starch (10.0 g), CaCO3 (2.0 g), (NH4)2SO4 (2.0 g), K2HPO4 (1.0 g), MgSO4.7H2O (1.0 g), NaCl (1.0 
g), FeSO4.7H2O (1.0 mg), MnCl2.7H2O (1.0 mg), ZnSO4.7H2O (1.0 mg), and agar (20.0 g). pH 7.2 
M2  Mannitol (40.0 g), maltose (40.0 g), yeast extract (10.0 g), K2HPO4 (2.0 g), MgSO4.7H2O (0.5 g), 
FeSO4.7H2O (0.01 g), and agar (18.0 g) 
PDA Potato extract (4.0 g), dextrose (20.0 g), and agar (15.0 g). pH 5.6 
 
TSA Pancreatic digest of casein (15.0 g), papaic digest of soybean (5.0 g), NaCl (5.0 g), and agar (15.0 g).      pH 
7.3 
SDA Peptic digest of animal tissue (5.0 g), pancreatic digest of casein (5.0 g), dextrose (40.0 g), and agar (15.0 
g). pH 5.6 
PYG Peptone (10.0 g), yeast Extract (5.0 g) dextrose (20.0 g), and agar (20.0 g) 
Basel K2HPO4 (1.5 g), MgSO4.7H2O (0.025 g), CaCl2 (0.025 g), FeSO4.7H2O (0.015 g), and ZnSO4.7H2O (0.005), 
and agar (18.0 g). pH 7.8 
Czapek K2HPO4 (1.0 g), NaNO3 (0.3 g), KCl (0.005 g), MgSO4.7H2O (0.005 g), FeSO4 (0.0001 g), sucrose (30 g), 
and agar (18.0 g). pH 7.0 
YES Sucrose (150 g), yeast extract (20 g), MgSO4.7H2O (0.5 g), ZnSO4.7H2O (0.01 g), CuSO4.5H2O (0.005 g), 
and agar (18.0 g) 
Oatmeal agar Difco™ oatmeal Agar (72.5 g) 
6.6.3 HPLC-DAD-MS analysis of oatmeal agar culture 
S. lincolnensis ACM-4234 oatmeal crude extract was analysed by injecting an aliquot (5 µL) on 
Agilent 1100 series LC/MSD instrument (Zorbax Eclipse XDB-C8 column, 150 × 4.6 mm, 5 µm, 1.0 
mL/min, standard gradient from 90% H2O/MeCN to MeCN with isocratic 0.05% formic acid 
modifier over 15 min, then held at 100% MeCN for 5 min with UV-vis detection at 210, 254, 360 
and 400 nm) 
6.6.4 Scale-up cultivation and characterization of licolnenins 
The spores of S. lincolnensis ACM-4234 were transferred from ISP2 agar culture to oatmeal agar 
plates (´ 75, 20 g each) and incubated at 30 oC for 21 days. After the incubation period, the agar was 
chopped into pieces (approximately 1.5 cm ´ 1.5 cm), transferred to 2 L flasks, extracted with EtOAc 
(4 ´ 400 mL), shaken at 150 rpm overnight, filtered, and the organic layer concentrated to dryness in 
vacuo at 40 oC to yield a crude extract (3.94 g). The crude extract was partitioned between n-hexane 
(3 ´ 50 mL) and MeOH (50 mL). Both fractions were concentrated in vacuo to afford n-hexane (2.54 
g) and MeOH (1.38 g) fractions. The MeOH fraction was further purified by gel chromatography 
(Sephadex LH-20, 2.5 ´ 86 cm column, isocratic elution with MeOH, 0.6 mL/min). The two 
lincolnenins enriched fractions, F4 and F5, were subjected to further chromatographic purification 
using semi-preparative reversed phase HPLC (Zorbax Eclipse XDB-C8, 9.4 mm ´ 25 cm, 5 µm, 3 
mL/min, isocratic elution with 55% H2O/MeCN for 35 min including 10% isocratic 0.01% TFA as 
modifier) to yield lincolnenin A (6.01) (tR = 26.3 min, 9.6 and 5 mg), lincolnenin C (6.05) (tR = 29.8  
min, 3.8 and 5.6 mg), lincolnenin D (6.06) (tR = 28.4 min, 1 and 4.4 mg), and lincolnenin E (6.07) (tR 
= 24.2  min, 1.9 mg). 
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Lincolnenin A (6.01): yellow powder; [a]20.5D +466.3 (c 0.03, MeOH); UV-vis (MeOH) λmax (log ε) 
231.3 (4.61), 268.0 (4.69), 331.0 (3.78), 416.9 (4.10); CD (MeOH) lmax (De) 231.2 (-58.1), 261 
(+50.5), 293.4 (-16.0), 327.8 (+8.5), 397.2 (+9.9); 1D and 2D NMR (600 MHZ, CDCl3) see Table 
6.2 and Figures 6.6 and 6.7; HRESI(+)MS m/z 621.1739 [M+Na]+ (calculated for C34H30O10Na 
621.1731). 
 
Lincolnenin C (6.05): yellow powder; [a]20.5D −169.6 (c 0.03, MeOH); UV-vis (MeOH) λmax (log ε) 
227 (4.54), 271 (4.69), 328 (3.80), 412.9 (4.09); CD (MeOH) lmax (De) 204.8 (-19.3), 227.6 (-22.0), 
258.2 (+92.1), 273.4 (-84.6), 326.2 (+8.1); 1D and 2D  NMR (600 MHZ, CDCl3) see Table 6.3 and 
Figures 6.13 and 6.14; HRESI(+)MS m/z 621.1745 [M+Na]+ (calculated for C34H30O10Na 621.1731). 
 
Lincolnenin D (6.06): yellow powder; [a]20.5D −119.7 (c 0.03, MeOH); UV-vis (MeOH) λmax (log ε) 
230 (4.24), 275.1 (4.32), 330 (3.59), 420 (3.79); CD (MeOH) lmax (De) 208.2 (+7.1), 227.6 (-15.6), 
257.2 (+58.0), 276 (-63.1), 327.8 (+8.0); 1D and 2D  NMR (600 MHZ, CDCl3) see Table 6.4 and 
Figures 6.20 and 6.21; HRESI(+)MS m/z 621.1730 [M+Na]+ (calculated for C34H30O10Na 621.1731). 
 
Lincolnenin E (6.07): yellow powder; [a]20.5D +206.0 (c 0.03, MeOH); UV-vis (MeOH) λmax (log ε) 
228 (4.37), 274.9 (4.45), 335.1 (3.79), 416 (3.96); CD (MeOH) lmax (De) 207.2 (-8.6), 231.8 (-14.8), 
258.4 (-44.2), 276 (+61.5), 300.6 (-9.6), 328.2 (+12.0); 1D and 2D  NMR (600 MHZ, MeOD-d4) 
see Table 6.5 and Figures 6.22 and 6.23; HRESI(+)MS m/z 621.1733 [M+Na]+ (calculated for 
C34H30O10Na 621.1731). 
6.6.5 Circular Dichroism (CD) analysis  
Metabolites 6.01, and 6.05–6.07 were recorded in MeOH using a JASCO J-810 spectropolarimeter. 
Measurement parameters as follows: 0.1 cm path-length cell, room temperature, concentration 0.02 
%(w/v), measurement range 500–200 nm and band width 1 nm. 
6.6.6 Thermolability study of 6.07 and 6.08 
Aliquots (200 µg) of lincolnenins D (6.06) and E (6.07) were dissolved MeOH (250 µL). Both 
solutions were analysed by injecting an aliquot (5 µL) on Agilent 1100 series LC/MSD instrument 
(Zorbax Eclipse XDB-C8, 5 µm, 4.6 mm ´ 15 cm, 1 mL/min, isocratic elution with 45% MeCN/H2O 
for 20 min including isocratic 0.05% formic acid as modifier, with UV-vis detection at 210, 254, and 
268 nm). Both solutions were heated to 50 °C in seal vials. An aliquot (5 µL) of each solution was 
injected at 5 h and 29 h intervals post heating using the same HPLC conditions. 
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6.6.7 Biological Assays  
6.6.7.1 Antibacterial assay 
The bacterium to be tested was streaked onto a tryptic soy agar plate and was incubated at 37 °C for 
24 h. One colony was then transferred to fresh lysogeny broth (15 mL), and the cell density was 
adjusted to 104−105 cfu/mL. The tested metabolites were dissolved in DMSO and diluted with H2O 
to give 600 μM stock solutions (20% DMSO). The stock solutions were then serially diluted with 
20% DMSO to give final concentrations of 30 to 0.01 μM in 20% DMSO. An aliquot (10 μL) of each 
dilution was transferred to a 96-well microtiter plate, and freshly prepared microbial broth (190 μL) 
was added to each well. The plates were incubated at 37 °C for 24 h, and the optical density of each 
well was measured spectrophotometrically at 600 nm using a POLARstar Omega plate (BMG 
LABTECH, Offenburg, Germany). Each test compound was screened against the Gram-negative 
bacteria Escherichia coli ATCC25922 and the Gram-positive bacteria Staphylococcus aureus 
ATCC25923 and Staphylococcus epidermidis ATCC12228. Ampicillin was used as a positive control 
(30 μM in 20% DMSO). 
6.6.7.2 Mycobacterium bovis (BCG) assay 
Mycobacterium bovis, Bacille Calmette Guerin (BCG) was grown until early-mid log phase in 7H9 
liquid medium (Difco) containing 0.2% glycerol, 0.05% Tween80, 0.5% bovine serum albumin 
(BSA), 0.2% dextrose, and 0.085% sodium chloride. Single cell suspensions of independent cultures 
were prepared by centrifuging the bacterial cultures for 10 min, at room temperature, 130 ´ g and 
then diluted to an optical density (OD; 600 nm) of 0.02. Bacterial growth in the presence of 
lincolnenins A, C–E (6.01, 6.05–6.07) (200 µL aliquots) was monitored in 96 well plates by OD 
measurements. To analyze bacterial survival, serial dilutions of culture material were plated on 
Middlebrook 7H10 plates supplemented with 10% oleic acid/albumin/dextrose catalase (OADC; 
Middlebrook) and 0.5% glycerol. Plates were incubated at 37 °C for 3 weeks and colonies enumerated 
to calculate colony forming units (CFU). Isoniazid (INH) was used as a positive control (20 µg/ml in 
H2O). 
6.6.7.3 Cytotoxicity (MTT) Assays 
The MTT assay was modified from that previously described89 using adherent cell lines SW620 and 
NCIH460. SW620 and NCIH460 were cultured in RPMI medium 164090as adherent mono-layer in 
flasks supplemented with 10% foetal bovine serum, 2 mM L-glutamine, 100 unit/mL penicillin and 
100 µg/mL streptomycin in a humidified 37°C incubator supplied with 5% CO2. Briefly, cells were 
harvested with trypsin and dispensed into 96-well microtiter assay plates at 3,000 cells/well for 
SW620, and 5,000 cells/well for NCIH460, then incubated for 18 h at 37 °C with 5% CO2 (to allow 
cells to attach). Testing compounds were dissolved in 5% DMSO in PBS (v/v) and aliquots (20 µL) 
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tested over a series of final concentrations ranging from 10 nM to 30 μM. Control wells were treated 
with 5% aqueous DMSO. After 68 h incubation at 37 °C with 5% CO2 an aliquot (20 µL) of MTT in 
PBS (5 mg/mL) was added to each well (final concentration of 0.4 mg/mL), and the microtiter plates 
incubated for a further 4 h at 37 °C with 5% CO2. After this final incubation, the medium was 
aspirated, and precipitated formazan crystals dissolved in DMSO (100 µL/well). The absorbance of 
each well was measured at 580 nm with a PowerWave XS Microplate Reader from Bio-Tek 
Instruments Inc. (Vinooski, VT). IC50 values were calculated using Prism 7.0 (GraphPad Software 
Inc., La Jolla, CA), as the concentration of analyte required for 50% inhibition of cancer cell growth 
(compared to negative controls). All experiments were performed in duplicate.
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Appendix: General experimental details  
Materials  
All the solvents used for HPLC were HPLC grade and were filtered through an Alltech 0.45 µm 
polytetrafluoroethylene (PTFE) filter before use. Deionised water for HPLC was filtered through 
Elga PURELAB Ultra filtration system. The pre-prepared culture media were purchased from 
Difco/BBL. Most of the media components were purchased from Sigma-Aldrich. Other chemicals 
were purchased from Sigma-Aldrich and Merck. 
Equipment  
Specific optical rotations ([α]D) were measured on a JASCO P-1010 polarimeter in a 100 × 2 mm 
cell. NMR spectra were acquired on a Bruker Avance 600 MHz spectrometer in the solvents indicated 
and referenced to residual solvent proton and carbon signals of the deuterated solvents. Electrospray 
ionization mass spectra (ESI-MS) experiments were carried out on an Agilent 1100 series equipped 
with an agilent 1100 series LC/MSD detector in both positive and negative ion modes under the 
following conditions (Zorbax Eclipse XDB-C8 5 µm column, 150 ´ 4.6 mm, eluting with 1.0 mL/min 
90% H2O/MeCN to 100% MeCN (with isocratic 0.05% HCO2H modifier) over 15 min, at 210 and 
254 nm). Ultra high-performance liquid chromatographs (UHPLC) were obtained on an Agilent 1290 
infinity UHPLC system composed of 1290 infinity quaternary pump, thermostat, autosampler and 
diode array detector (Zorbax C8 RRHD 1.8 µm column, 50 ´ 2.1 mm, eluting with 0.417 mL/min 
90% H2O/MeCN to 100% MeCN (with isocratic 0.01% TFA modifier) over 2.50 min, with detection 
at 210, 254, 300 and 400 nm). High-resolution ESI-MS spectra were obtained on a Bruker micrOTOF 
mass spectrometer by direct infusion in MeCN at 3 µL/min using sodium formate clusters as an 
internal calibrant. Semi-preparative and preparative HPLC was performed using Agilent 1100 series 
LC instruments with corresponding detectors, fraction collectors and software inclusively. Pure 
compounds from semi-preparative HPLC were dried on Christ freeze dryer. Solvents were 
concentrated under reduced pressure by using Büchi Rotavapor R-114. Crude extracts, fractions and 
pure compounds were preserved at –30 °C in SANYO biomedical freezer.    
Faecal samples were all acquired in sterile 50 mL Falcon tubes. Microorganisms were isolated under 
sterile conditions using a Laftech class II biological safety cabinet and incubated in MMM Friocell 
incubator or Innova 42 incubator shaker with temperature set at 26.5°C or 30°C. Pure strains were 
cyro-preserved in 15% glycerol at -80°C in deep freezer. Twenty-four well micro-bioreactor, cover 
clamp and the sandwich covers were purchased from Applikon Biotechnology. 
 
 
